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A BST R A C T 
  
 Obesity has become an increasingly common health condition over the last 
several decades. It has been estimated that this largely preventable disease affects over 
one billion people worldwide and that its prevalence will have doubled by the year 2030. 
Currently, obesity is the leading cause of preventable deaths worldwide and is predicted 
to become the biggest public health problem of the century. For the treatment and 
management of obesity, traditional Chinese medicine (TCM) has become an increasingly 
attractive form of alternative/complementary medicine. This trend is also occurring in the 
face of a weight-loss product market largely typified by mediocre long-term efficacy and 
safety concerns, and an increasing global desire to seek out and develop safe and 
efficacious products from natural sources. This thesis aimed to assess the anti-obesity 
efficacy and mechanism of the traditional Chinese herbal formula, Liuwei Dihuang 
(LWDH), using both in vivo and in vitro approaches. 
 An in vivo study using obese-prone rats treated by twice-daily oral gavage with 
LWDH showed the body weight- and food intake-lowering efficacy of the product, which 
also favourably affected body fat composition. Subsequent biochemical analyses revealed 
the lipid-lowering, as well as leptin- and insulin-sensitizing efficacy of LWDH, in 
addition to its beneficial effects on biomarkers of inflammation and oxidative stress and 
adiponectin production. Liver function testing, assessed by measuring liver enzymes 
levels in the serum, revealed no adverse side effects of LWDH in rats under the 
experimental conditions of this thesis.  
! vi 
 The potential anti-obesity mechanisms of action subsequently investigated 
included regulation of appetite and/or fatty acid metabolism. Using collected ileal and 
hypothalamic tissues of LWDH-treated obese rats, and cell lines representative of the gut 
and brain treated with an ethanol extract of LWDH, gene expression results did not 
strongly support appetite regulation as a body weight-lowering mechanism of action of 
the product. Further investigation into this potential mechanism is, however, highly 
warranted. Both gene and protein expression results using liver and muscle tissues, and 
cells lines representative of the liver and muscle, supported the notion that beneficial 
effects on fatty acid oxidation/synthesis may represent a potential body weight-lowering 
mechanism of action of the product, especially in muscle tissue and cells.  
 Overall, results from this thesis demonstrated the potential of LWDH as a natural 
agent against obesity and several associated complications, particularly through 
beneficial effects on fatty acid metabolism.  
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C H APT E R 1: IN T R O DU C T I O N 
!
1.1. Overview 
 The present thesis consists of a series of in vivo and in vitro experiments 
conducted to elucidate the anti-obesity efficacy and potential mechanism(s) of action of a 
traditional Chinese herbal formula and its ethanol extract. 
 Obesity has become an increasingly common health condition over the last 
several decades (James 2008) and has been referred to by many as the epidemic of the 
21
st
 century (Greenberg and Obin 2006). A greater than 70% increased risk of developing 
a myriad of associated complications, such as irregularities in lipid and lipoprotein 
metabolism, leptin and insulin resistance, abnormal liver enzyme profiles, chronic low-
grade inflammation, systemic oxidative stress, and dysregulated production of various 
adipokines have been attributed to obesity (Rippe 1998; Haslam and James 2005). 
Notably, however, it has long been recognized that even modest weight loss can improve, 
or even abolish, the vast majority of obesity-associated complications (Goldstein 1992; 
Cordero-MacIntyre et al. 2000).  
 Currently available weight loss treatment strategies include lifestyle changes, such 
as diet and exercise, pharmacological intervention, and bariatric surgery (Adams et al. 
2007; Klonoff and Greenway 2008; Xiao and Yang 2012). For many persons suffering 
from obesity, lifestyle changes often represent an ineffective and/or inadequate anti-
obesity treatment strategy (Klonoff and Greenway 2008). However, well-structured 
interventions, such as pedometer-based physical activity (Chan et al. 2004) and the 
Diabetes Prevention Program (Knowler et al. 2009) have shown promising results. 
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Furthermore, most pharmacological interventions have been shown to be associated with 
limited long-term success and a variety of safety concerns (Kang and Park 2012). Despite 
its relative effectiveness in promoting (O'Brien et al. 2006) and maintaining (Christou 
and MacLean 2005) weight loss, bariatric surgery has also been rendered largely 
impractical as a viable anti-obesity strategy given its high cost, mortality rates, and 
relative invasiveness (Adams et al. 2007). Therefore, a strong demand remains to 
continue searching for both safe and efficacious products to combat the obesity epidemic.  
 Traditional Chinese medicine (TCM) has played a pivotal role in disease 
prevention and treatment, primarily in Asian countries (Li et al. 2008; Yin et al. 2008; 
Pan et al. 2010). More recently, TCM has represented a viable alternative treatment 
approach with enormous potential as a starting point for the development of anti-obesity 
products in Western countries as well (Perry et al. 2012). The ancient TCM formula, 
Liuwei Dihuang (LWDH), is widely produced in China and has traditionally been used 
for the treatment oh" fkugcugu" cuuqekcvgf" ykvj" Ðmkfpg{-{kp" fghkekgpe{Ñ, such as T2DM, 
hyperlipidemia, and hypertension (Xie et al. 2008). Its use worldwide has been for 
general health promotion (Ma et al. 2004). Limited studies have demonstrated its ability 
to reduce visceral fat deposition in rats (Xue et al. 2006) and inhibit rat preadipocyte 
differentiation (Xiao et al. 2007). Overall, however, very little to no investigation into its 
potential benefits in regard to energy homeostasis and weight management, or their 
associated mechanism of action, has been documented.  
 To investigate the efficacy of LWDH as a potential anti-obesity product in vivo, a 
rat model of obesity representative of the human condition of obesity (Jackman et al. 
2006) was employed. Chapters 2 and 3 of this thesis will outline results from this in vivo 
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study. To subsequently investigate the potential anti-obesity mechanism(s) of action of 
LWDH, a series of in vivo experiments using collected tissue samples from LWDH-
treated obese rats and in vitro experiments using representative cell lines treated with an 
ethanol extract of LWDH were conducted. Chapter 4 of this thesis will outline results 
from in vivo and in vitro analyses investigating the effect of LWDH and its ethanol 
extract on appetite regulation as a potential anti-obesity mechanism of action of the 
product. Chapter 5 will outline results investigating the effect of LWDH and its extract 
on key aspects of fatty acid metabolism. 
 
1.2. Definition of obesity 
 In the biological sense, obesity can be defined as an abnormal or excessive 
accumulation of fat in adipose tissue, to the extent that health is impaired (WHO 2000). 
In order to quantify weight changes across populations and estimate health and economic 
risks associated with obesity, simple anthropometric screening indices have included the 
body mass index (BMI) and measurements of waist circumference (WC) and skin fold 
thickness (Laurson et al. 2011). The most commonly used measurement has been the 
BMI (Janssen et al. 2012). The ease by which it can be calculated (weight in kilograms 
(kg) divided by the square of height in meters (m)), its defined risk categories (Figure 1-
1; most commonly reported as overweight, BMI œ"47"mi1o2 qt"qdgug."DOK"œ"52"mi1o2) 
(Prentice 2006), and its close correlation with body fat in the vast majority of people 
(Stein and Colditz 2004; Barlow 2007; Dietz et al. 2009) have collectively contributed to 
the common use of BMI for body weight quantification.   
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 F igure 1-1: Quantification of body weight using the body mass index. Adapted 
 from Janssen et al. (2012). "Prevalence and secular changes in abdominal obesity 
 in Canadian adolescents and adults, 1981 to 2007-2009." Obes Rev 12(6): 397-
 405. 
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1.3. Prevalence of obesity 
 Obesity has become an increasingly common health condition over the last 
several decades and its global prevalence only continues to escalate (Drewnowski and 
Popkin 1997; Wang et al. 2002; James 2008). In 2009, it was estimated that this largely 
preventable disease affects over one billion people worldwide and that its prevalence will 
have at least doubled by the year 2030 (Gnacinska et al. 2009). Currently, obesity is the 
leading cause of preventable deaths worldwide (Alfadda and Sallam 2012) and it is 
predicted to become the biggest public health problem of the century (Gnacinska et al. 
2009). Collectively, these reports have resulted in obesity as having been referred to as 
the epidemic of the 21
st
 century (Greenberg and Obin 2006).  
 Closer to home, the percentage of obese Canadians has also risen dramatically 
(Tremblay et al. 2002), with recent estimates of an approximately 25% obese population 
(Janssen et al. 2012). It has been well documented, however, that the obesity epidemic is 
not limited to only the most affluent countries, but has been spreading to many of the less 
affluent countries as well (Popkin 1998; Janssen et al. 2012). Over 20% of all adults in 
most European countries are obese (James 2008). The Middle East now has similar rates 
of obesity, in addition to the highest national prevalence of T2DM in the world (James 
2008). In less affluent Caribbean countries, Africa, and Asia, there has been an 
overwhelming rise in obesity-associated pre-mature deaths, as well as changes in diet and 
physical activity associated with obesity (James 2008). As the obesity epidemic continues 
to spread, so too have concerns about the staggering associated economic consequences. 
In fact, in terms of the economic burden of obesity, obese individuals have been 
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collectively documented to accrue upwards of 30% greater medical costs compared to 
their normal weight counterparts (Andreyeva et al. 2004; Lakdawalla et al. 2005).   
 
1.4. E tiology of obesity  
 The interaction of several factors, including behavioural, environmental, 
physiological, and hereditary has contributed to the ever increasing prevalence of obesity 
in recent years (Stein and Colditz 2004). Notably, the alarming rate at which the 
prevalence statistics have increased has been reported to be suggestive of a more 
significant contribution of a combination of behavioural and environmental factors 
toward the obesity epidemic (Stein and Colditz 2004). Collectively, increased energy 
intake and decreased energy expenditure have given rise to the marked increases in body 
weight in our society over the last several decades (Harnack et al. 2000). At least in part 
responsible for this shift towards a positive energy balance have been increases in fast 
food and soft drink consumption (Harnack et al. 2000; French et al. 2003), increasingly 
larger portion sizes (Smiciklas-Wright et al. 2003), and decreases in physical and 
increases in sedentary activities (Jeffery and Utter 2003; Haslam and James 2005). 
 
1.5. Obesity-associated risks/complications 
 Obesity has been reported to negatively affect physical functioning and the 
general quality of human life (Coakley et al. 1998; Fine et al. 1999), and has also been 
associated with a reduction in average life expectancy (Hu et al. 2001). Furthermore, 
even small increases in body weight have been documented to confer a significant 
negative impact on overall public health (Stein and Colditz 2004). Excess body weight 
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increases the risk of developing a myriad of serious chronic diseases, including, but not 
limited to, type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD), and certain 
forms of cancer (Mokdad et al. 2003). Furthermore, it has been reported that a BMI score 
of greater than 27 kg/m
2 
predisposes to a 70% greater risk of developing a suite of 
obesity-associated complications (Rippe 1998). Importantly, this risk can manifest not 
only in overweight and obese individuals, but also in those at the upper end of the normal 
body weight (20 kg/m
2 œ" DOK" œ" 47" mi1o2) range (Field et al. 2001). Noteworthy, 
however, is the evidence that even modest losses in body weight have long been 
documented to improve, or even reverse, the vast majority of obesity-associated 
complications (Goldstein 1992; Cordero-MacIntyre et al. 2000).  
 For the purpose of this thesis, the relationship between excess body weight and 
lipid and lipoprotein irregularities, leptin and insulin resistance, liver enzyme profile 
abnormalities, chronic low-grade inflammation, systemic oxidative stress, and 
dysregulated adipokine production will be discussed. Subsequent chapters of this thesis 
will provide evidence of the associated beneficial effects of body weight control by 
dietary supplementation of LWDH on these associated complications.  
 
1.5.1. Lipid and lipoprotein irregularities  
 Excess body weight has long been known to result in changes in circulating levels 
of lipids and lipoproteins (Larsson et al. 1984; Flock et al. 2011). Obesity has been 
reported to exacerbate various dyslipidemias, such as elevated total cholesterol (TC), 
triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) levels, as well as 
diminished high-density lipoprotein cholesterol (HDL-C) levels (Ferrannini et al. 1991; 
8 
!
Cordero-MacIntyre et al. 2000) (Figure 1-2). Furthermore, being overweight or obese, in 
addition to having a lipid irregularity, confers a greater risk of developing CVD (Sharma 
2003), which remains to be the leading cause of mortality in developed countries (Kung 
et al. 2008). Conversely, weight loss has been shown to improve irregularities in lipid and 
lipoprotein concentrations (Larsson 1991; Dattilo and Kris-Etherton 1992). Levels of TC, 
TG, and LDL-C have been shown to be reduced in response to weight loss (Despres et al. 
1989; Peeples et al. 1989; Weinsier et al. 1992), while HDL-C levels have been shown to 
be increased in response to the same effect (Dattilo and Kris-Etherton 1992). More 
recently, non-HDL-C, commonly calculated as TC minus HDL-C and accounting for 
LDL-C and other lipoprotein fractions, has been documented to better represent CVD 
risk than LDL-C alone, despite being recognized only as a secondary therapeutic target in 
persons with elevated TG levels (Hoenig 2008). Furthermore, non-HDL-C has even been 
documented as a superior CVD risk predictor than LDL-C alone, regardless of TG levels 
(Liu et al. 2006). Increased BMI scores have been shown to be associated with elevated 
non-HDL-C levels, which are also known to correlate inversely with HDL-C levels 
(Srinivasan et al. 2002). Notably, however, weight loss has been shown to be associated 
with improved non-HDL-C levels in obese individuals (Wong et al. 2011).  
 In addition to the above mentioned obesity-associated irregularities in blood lipids 
and lipoprotein fractions, circulating free fatty acid (FFA) levels are typically elevated in 
the obese state, in response to a combination of enlarged adipose tissue mass, increased 
FFA release, and/or reduced FFA clearance (Boden 2008). Elevated FFA levels in 
obesity are well documented to be associated with insulin resistance (Boden 1997; Kahn 
et al. 2006), making them a likely culprit in the development of T2DM (Wilding 2007).  
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 F igure 1-2: Relationship between weight gain and lipid and lipoprotein 
 irregularities. Adapted from Cordero-MacIntyre *4222+0"ÐYgkijv"nquu"ku"eqttgncvgf"
 ykvj" cp" kortqxgf" nkrqrtqvgkp" rtqhkng" kp" qdgug" rquvogpqrcwucn" yqogpÑ0" JACN 
 19(2): 275-284.  
 
 
 
Weight Gain 
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Weight loss, however, has been shown to be associated with a reduction in FFA levels 
and an improvement in insulin sensitivity (Goodpaster et al. 1999; Boden 2008). 
 
1.5.2. Leptin and insulin resistance 
 Leptin, secreted exclusively by white adipose tissue (WAT), represents one of the 
core components of the physiological control of body weight (Murphy and Bloom 2004). 
Leptin inhibits food intake, increases energy expenditure, and reduces lipid accumulation 
in tissues by stimulating fatty acid oxidation and inhibiting lipogenesis (Unger 2003). 
Leptin levels have been shown to be positively correlated with body fat mass (Kelesidis 
and Mantzoros 2006). However, in most cases of obesity, despite high circulating levels 
and intact receptors, there is a diminished response to the beneficial effect of leptin, 
suggestive of the development of leptin resistance in the obese state (Enriori et al. 2007). 
Notably, exercise-driven weight loss has been shown to largely prevent the obesity-
induced development of leptin resistance (Steinberg et al. 2004). Furthermore, both diet- 
and exercise-driven weight loss alike have been shown to improve leptin sensitivity 
(Steinberg and Dyck 2000). In addition, moderate weight loss of as little as 5% has been 
reported to lower leptin to near physiological levels, resulting in improved sensitivity to 
its beneficial effects (Mazzali et al. 2006) 
 Insulin resistance, a state in which a given amount of insulin produces a below 
average physiological response (Kahn 1978; Kahn et al. 2006), has been reported to 
strongly correlate with increased adiposity (Caprio 2002), and in particular, increased  
circulating levels of FFA (Kahn et al. 2006). More specifically, insulin resistance refers 
to the reduced ability of insulin to stimulate glucose use in the peripheral tissues and to 
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suppress glucose production in the liver (Matthaei et al. 2000). Indeed, insulin resistance 
has been documented as the most common obesity-associated metabolic complication 
(Weiss and Kaufman 2008). Furthermore, insulin resistance is considered to represent an 
important link between obesity and several associated metabolic complications, 
particularly T2DM (Alberti et al. 2004). Weight loss has been shown to improve insulin 
sensitivity in both healthy and diabetic individuals (Goodpaster et al. 1999). Furthermore, 
a significantly reduced risk of developing insulin resistance and T2DM has been shown 
in response to losses of body weight of as little as 5-7% (Tuomilehto et al. 2001). 
 
1.5.3. Liver enzyme profile abnormalities  
 Abnormal liver enzyme levels have been reported to be indicative of liver damage 
or alterations in bile flow (Giannini et al. 2005). Several common biomarkers of such 
pathologies include aspartate aminotransferase (AST), alanine aminotransferase (ALT), 
cnmcnkpg"rjqurjcvcug"*CNR+."cpf"け-glutamyl transferase (GGT). Studies have shown that 
increased circulating levels of these biomarkers are often associated with obesity (Dixon 
et al. 2001; Iacobellis et al. 2007) and increase the risk of developing obesity-associated 
complications, such as CVD and T2DM (Hanley et al. 2004; Stefan et al. 2008). A mild 
increase in aminotransferase (AST or ALT) enzyme levels and/or an AST/ALT ratio 
greater than one are the most commonly documented liver enzyme alterations (Giannini 
et al. 2005) and have been associated with excess body fat mass and obesity (Marchesini 
et al. 2001). An increase in ALP is typically indicative of cholestasis, or bile duct 
obstruction (Moss 1997), and has also been shown to be independently associated with 
obesity (Nannipieri et al. 2005). Similar to ALP, GGT is also commonly elevated in 
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response to bile duct damage or obstruction (Giannini et al. 2001), and increased levels 
have been linked to obesity, physical inactivity, dyslipidemia, and other obesity-
associated co-morbidities (Wannamethee et al. 1995). Due to its relative lack of 
specificity yet high sensitivity for liver damage, GGT is also often useful for further 
elucidation of altered ALP levels, or in combination with AST/ALT measurements, for 
more specifically diagnosing liver damage (Giannini et al. 2005). Lifestyle modifications, 
such as increased physical activity and decreased alcohol consumption, with 
corresponding weight loss have been shown to reduce circulating liver aminotransferase 
levels in obesity (Suzuki et al. 2005; Utzschneider and Kahn 2006). Similarly, weight 
reduction as a result of low-fat diet feeding in obese individuals has been shown to 
significantly lower serum levels of AST, ALT, and GGT (de Luis et al. 2010). A 
reduction in serum liver enzymes levels, most notably ALT, has also been largely 
attributed to weight loss in obese diabetic subjects (Krakoff et al. 2010). 
 
1.5.4. Chronic low-grade inflammation 
 Adipose tissue is no longer considered to be a passive storage depot for excess fat 
(Flier 1995), but rather, is now known to produce several inflammatory mediators 
(Browning et al. 2008). Indeed, obesity has been shown to be associated with a state of 
chronic low-grade inflammation (O'Rourke 2009) (Figure 1-3). Elevated levels of 
circulating inflammatory biomarkers common to obesity include the pro-inflammatory 
e{vqmkpg" vwoqwt"pgetquku" hcevqt" g" *VPH-g+." vjg" cewvg"rjcug"rtq-inflammatory cytokine 
interleukin-6 (IL-6), and the chronic inflammatory biomarker C-reactive protein (CRP) 
  
13 
!
 
 
 
  
 F igure 1-3: Association between obesity and circulating biomarkers of 
 inflammation. Adapted from Despres *4225+0" ÐKpuwnkp" tgukuvcpeg" cpf" cdfqokpcn"
 adiposity in young men with documented malnutrition during the first year of 
 nkhgÑ0"Int J Obes Metab Disord 27: 5224.  
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(Visser et al. 1999; Kern et al. 2001). In addition to being increased in the obese state, 
inflammation has been investigated as a possible contributor to several of the most 
serious obesity-related co-morbidities (O'Rourke 2009). It is evidenced that both diet- 
and surgery-induced weight loss have been shown to be effective in reducing obesity-
related inflammation (Laimer et al. 2002; Ziccardi et al. 2002) and improving several 
obesity-associated co-morbidities (Krebs et al. 2002).  
 The pro-inflammatory cytokine TNF-g" ku" eqpuvkvwvkxgn{" gzrtguugf" kp" cfkrqe{vgu 
(Hotamisligil et al. 1995). Its expression has been shown to be upregulated in response to 
obesity (Hotamisligil et al. 1995) and in proportion to the degree of adiposity (Bullo et al. 
2002). Furthermore, levels of TNF-g"kp"vjg"ektewncvkqp"jcxg"dggp"ujqyp"vq"dg"kpetgcugf"
in obese compared to lean individuals (Dandona et al. 1998). Adipose tissue expression 
of TNF-g" jcu." jqygxgt." dggp" ujqyp" vq" fgetgcug" kp" rtqrqtvkqp" vq" dqf{" ygkijv" nquu"
(Hotamisligil et al. 1995; Bullo et al. 2002). Circulating levels of TNF-g"jcxg"cnuq"dggp"
shown to decrease following weight loss and/or an increase in physical activity (Kern et 
al. 1995; Dandona et al. 1998).  
 Compared to lean individuals, adipose tissue of obese persons has been shown to 
elicit an increase in the expression of the acute phase pro-inflammatory cytokine IL-6, 
which has been shown to occur in proportion to body fat mass (Vozarova et al. 2001). In 
fact, adipose tissue IL-6 expression has been reported to be 10-fold higher in obese 
compared to lean individuals (Fried et al. 1998). Similarly, levels of IL-6 in the 
circulation have also been shown to increase with obesity and as much as 30% of which 
has been reported to be derived from adipose tissue (Mohamed-Ali et al. 1997). A 
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reduction in body fat mass has, however, been shown to result in both reduced adipose 
tissue expression and circulating levels of IL-6 (Kershaw and Flier 2004).  
 Reportedly the most extensively studied inflammatory biomarker, CRP is 
produced mainly by the liver, largely in response to obesity-induced inflammation 
(Nguyen et al. 2009). Given its stable half-life and lack of diurnal variation in the blood, 
CRP has been reported as the best characterized biomarker of chronic inflammation 
(Devaraj et al. 2010; Punyadeera et al. 2011). Changes in CRP have been shown to 
significantly correlate with changes in adiposity (Browning et al. 2008). Indeed, obese 
individuals have increased circulating levels of CRP as compared to their lean 
counterparts (Kopp et al. 2003). Furthermore, CRP is a strong predictor of obesity-
associated co-morbidities; even stronger than IL-6, the cytokine which stimulates its 
production (Pradhan et al. 2001). Significant reductions in CRP have, however, been 
shown in response to moderate weight loss and bariatric surgery (Vazquez et al. 2005; 
Selvin et al. 2007). 
 
1.5.5. Systemic oxidative stress  
 It has been shown that reactive oxygen species (ROS) are positively correlated 
with BMI (Keaney et al. 2003) and elevated in the obese state, resulting in increased 
oxidative stress in accumulated fat (Furukawa et al. 2004) (Figure 1-4). Furthermore, an 
increase in ROS from accumulated fat has been shown to lead to increased systemic 
oxidative stress and play a critical role in the onset of several obesity-associated co-
morbidities (Melissas et al. 2006). In the obese state, the main source of ROS production 
is believed to be NADPH oxidase, which catalyzes the reduction of oxygen to yield  
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 F igure 1-4: Association between obesity and systemic oxidative stress. Adapted 
 from Furukawa (2004). "Increased oxidative stress in obesity and its impact on 
 metabolic syndrome." J Clin Invest 114(12): 1752-61. 
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superoxide anions, with NADPH serving as the electron donor (Feillet-Coudray et al. 
2009). When produced at chronically high levels, ROS can have detrimental effects 
through irreversible oxidation of their primary targets, including lipids, proteins, and 
DNA (Valko et al. 2007). In addition to increased ROS production and resultant systemic 
oxidative stress, obesity has also been shown to be associated with a decline in 
antioxidant defences (Khan et al. 2006), including suppressed activity of the antioxidant 
enzyme superoxide dismutase (SOD) and lower levels of glutathione (GSH) (Furukawa 
et al. 2004). Furthermore, adipose tissue of obese subjects has been shown to produce 
increased levels of thiobarbituric acid reactive substances (TBARS), a marker of lipid 
peroxidation and oxidative damage (Furukawa et al. 2004). Caloric restriction and 
reduced adiposity have, however, been shown to be associated with improvements in 
circulating biomarkers of oxidative stress and antioxidant defences (Heilbronn et al. 
2006).  
 In order to protect against the potentially detrimental effects of ROS, cells are 
equipped with antioxidant defence systems (Feillet-Coudray et al. 2009). Superoxide 
dismutase is considered the first line of defence against oxidative stress (Johnson 2002) 
and plays a physiological antioxidative stress role by converting superoxide anions to 
hydrogen peroxide (H2O2), which can then be further detoxified through the action of 
glutathione peroxidase (GPx) (Fridlyand and Philipson 2005). Adiposity and increased 
caloric intake alike have been shown to result in decreased activity of SOD (Beltowski et 
al. 2000). Inversely, weight loss and exercise training have been shown to result in 
increased SOD activity and a resultant improvement in the first line of antioxidant 
defence (Selamoglu et al. 2000; Shih et al. 2006). 
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 Glutathione is a key antioxidant that plays a major role in maintaining redox 
balance by providing reduced ROS for GPx-catalyzed H2O2 reductions (Feillet-Coudray 
et al. 2009). Furthermore, the ratio between reduced (GSH) and oxidized (GSSG) 
glutathione is a strong and reliable biomarker of oxidative stress (Ashfaq et al. 2006). 
Levels of GSH have been shown to be significantly reduced in response to obesity 
(Feillet-Coudray et al. 2009). However, weight loss has been shown to largely reverse 
this effect (Uzun et al. 2007). 
 Lipids are among the main classes of molecules targeted by ROS (Joao Cabrera et 
al. 2010) and lipid peroxidation has been shown to be associated with increased adiposity 
(Noeman et al. 2011). Obesity-associated lipid peroxidation is believed to be caused by at 
least one of three mechanisms, including increased ROS production, cell injury as a result 
of increased body mass pressure, and/or consumption of a high fat diet (Olusi 2002). The 
major indicator of lipid peroxidation is malondialdehyde (MDA), levels of which can be 
determined by measuring thiobarbituric acid reactive substances (TBARS) (Uzun et al. 
2007). Obesity is associated with an increase in lipid peroxidation, evidenced in large 
part by increases in MDA and TBARS levels (Furukawa et al. 2004; Noeman et al. 2011). 
Fortunately, weight loss of as little as 5-10% through either caloric restriction or surgical 
intervention has been shown to lower MDA and TBARS levels in obese patients 
(Dandona et al. 2001; Mohn et al. 2005). 
 
1.5.6. Dysregulated adiponectin production 
 Adipose tissue is now regarded as an active endocrine organ which produces and 
secretes a variety of bioactive mediators termed adipokines (Rabe et al. 2008). 
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Adiponectin represents the most abundant circulating adipokine and is secreted 
exclusively from adipose tissue (Schraw et al. 2008). It is a 30kD molecule existing in at 
least 3 different complexes, including a high molecular weight (HMW) form (12-36 mer), 
a low molecular weight (LMW) form (hexamer), and a trimeric form (trimer) (Pajvani et 
al. 2003). Adiponectin exerts its effects via its specific receptors, AdipoR1 and AdipoR2, 
on insulin-sensitive cells in liver, muscle, and adipose tissues (Sattar and Sattar 2012). 
Circulating levels of adiponectin have been established as an important biomarker for 
several metabolic disorders (Lara-Castro et al. 2006), in addition to playing a role in the 
control of lipid and glucose metabolism (Berg et al. 2001). HMW adiponectin in 
particular has been linked to increased fat oxidation in muscle tissue and improved 
whole-body insulin sensitivity (Fruebis et al. 2001; Yamauchi et al. 2001). Unlike the 
vast majority of adipokines, circulating adiponectin levels are decreased in response to 
obesity (Kadowaki and Yamauchi 2005). A negative correlation between circulating 
adiponectin levels and obesity has been shown in both humans and rodent models (Arita 
et al. 1999; Hotta et al. 2001), with particularly strong correlations in response to visceral 
obesity (Cnop et al. 2003; Yatagai et al. 2003). Increases in circulating adiponectin levels 
have been shown in response to weight loss (Martos-Moreno et al. 2010) and bariatric 
surgery (Illan-Gomez et al. 2012). Exercise training has also been shown to beneficially 
affect adiponectin levels, independent of weight loss or gain (Lee et al. 2012). 
 
1.6. Obesity treatment/management 
 Given the interrelated combination of behavioural, environmental, physiological, 
and hereditary factors that contribute to obesity, prevention, treatment, and/or 
management of this complex disease has proven extremely difficult (Kushner and 
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Weinsier 2000). Currently available weight loss treatment strategies include lifestyle 
changes, such as dietary and exercise intervention, pharmacological intervention, and 
bariatric surgery (Xiao and Yang 2012). It is generally accepted that primary treatment of 
obesity should include lifestyle changes, with a focus on behavioural and environmental 
modification (Stafford and Radley 2003). Dietary and exercise changes have in large part 
focused on reducing calorie intake, such as by adhering to a low-fat diet (Samaha et al. 
2003; Vetter et al. 2010) and increasing the amount of daily physical activity (Jakicic et 
al. 1999; Jeffery and Utter 2003). Resistance training has also been shown to be 
beneficial for maintaining fat-free mass during weight loss (Jakicic et al. 1999). In obese 
patients presenting with associated co-morbidities, or in cases where there is minimal or 
no response to primary treatment, pharmacological intervention is often considered as a 
secondary treatment option (Greenberg et al. 1999; Snow et al. 2005). Lastly, in morbid 
qdgukv{"*DOK"œ"62"mi1o2), or in obesity (35.0 kg/m2 œ"DOK"œ"5;0;"mi1o2) accompanied 
by an associated co-morbidity, bariatric surgery has been shown to be a highly effective 
and relatively safe treatment strategy (Sjostrom et al. 2012). 
 
1.6.1. Primary treatment: lifestyle changes 
 Weight loss is essential for the prevention, treatment, and management of obesity 
(Renehan et al. 2008). Accordingly, it has been reported that diet- and exercise-driven 
primary anti-obesity intervention should be targeted at an approximate 10% loss in initial 
body weight (WHO 2000). For the majority of obese persons, short-term weight loss is 
achieved more readily through dietary intervention than through increased physical 
activity (Xiao and Yang 2012). In fact, many obese persons can achieve short-term 
weight loss through dietary intervention alone (Xiao and Yang 2012). Although 
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achieving long-term weight loss success is more difficult, managing food intake remains 
to be the focal point of first-line anti-obesity treatment (Xiao and Yang 2012). Physical 
activity is associated with a marked increase in energy expenditure (Bruce et al. 2006). 
Although exercise alone is generally not a sufficiently effective short-term weight loss 
strategy, when combined with dietary intervention, it represents an integral component of 
long-term weight loss success (Xiao and Yang 2012).  
 
 Upwards of twenty percent of overweight or obese persons show long-term 
weight loss success (Wing and Phelan 2005). Well-designed lifestyle interventions have 
been particularly effective. In Prince Edward Island, a pedometer-based physical activity 
intervention resulted in increased physical activity in sedentary workers (Chan et al. 
2004). Other major randomized trials, such as the Diabetes Prevention Program (Knowler 
et al. 2002; Knowler et al. 2009), the Finnish Diabetes Prevention study (Tuomilehto et al. 
2001), and the look AHEAD (Action for Health in Diabetes) (Pi-Sunyer et al. 2007) have 
shown promising results in response to intensive lifestyle intervention. In comparing 
results from lifestyle versus pharmacological intervention, 10-year follow-up results from 
the Diabetes Prevention Program Outcomes Study (Knowler et al. 2009) demonstrate that 
lifestyle intervention can be superior to pharmacological intervention in promoting and 
maintaining weight loss. However, in this particular study, modest weight loss in the 
long-term was achieved more readily by way of pharmacological intervention. 
Collectively, weight loss and weight maintenance by way of lifestyle changes are 
associated with a reduced risk for the development of the most serious obesity-associated 
co-morbidities and a general improvement in the overall quality of life (Thompson et al. 
1999; Caterson et al. 2012).  
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1.6.2. Secondary treatment: pharmacological intervention 
 For many persons suffering from obesity, lifestyle changes such as dietary habits 
and exercise often represent an ineffective and/or inadequate anti-obesity treatment 
strategy (Klonoff and Greenway 2008). For obese persons, or overweight persons also 
suffering from an obesity-associated complication, pharmacological intervention as a 
complement to lifestyle changes is often times a viable option for the induction, and 
furthermore, the maintenance of weight loss (Snow et al. 2005). Unfortunately, most 
pharmacological interventions are associated with poor adherence rates and limited long-
term success (Hemo et al. 2011), safety concerns (Ling et al. 2013), and in some cases, 
weight regain upon cessation of treatment (Kang and Park 2012). 
 
1.6.2.1. Current anti-obesity drug marketplace 
  Anti-obesity drugs are generally classified into one of three groups, 
depending on their mechanism of action, and include appetite suppressors, dietary fat 
absorption inhibitors, and energy expenditure stimulators (Li and Cheung 2009). Various 
drugs and drug combinations have been used to treat and/or manage obesity over the last 
couple of decades, however, most of them have been removed from the market due to 
reports of a variety of serious adverse side effects (Li and Cheung 2011). The three most 
widely prescribed anti-obesity drugs over the last couple of decades include phentermine, 
sibutramine, and orlistat (Klonoff and Greenway 2008). The following sections will 
outline the rise and fall over the last couple of decades of the most common anti-obesity 
therapeutics. 
  The appetite suppressor phentermine has been in clinical use for over 50 
years (Bays et al. 2007). In the past, phentermine has been prescribed as an anti-obesity 
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treatment in combination with other medications, most notably fenfluramine (Vetter et al. 
2010). However, due to associations with cardiac valvulopathy, fenfluramine was 
removed from the market in 1997 (Connolly et al. 1997). Phentermine, however, was not 
implicated in the cardiac risks associated with the drug combination and remains to be the 
most commonly prescribed anti-obesity pharmacological option for short-term use (Bays 
et al. 2007). Chemically related to amphetamine, phentermine is approved only for short-
term (up to twelve weeks) use, due in large part to its reported potential of abuse 
(Silverstone 1992). Other reported side effects include headache, insomnia, and mild 
increases of blood pressure and heart rate (Klonoff and Greenway 2008). 
  The noradrenaline and serotonin re-uptake inhibitor, sibutramine, was 
approved as a long-term anti-obesity treatment over a decade ago (Halford et al. 2007). 
This drug functions primarily by suppressing appetite and inducing satiety (Nisoli and 
Carruba 2000). Reported side effects include headache, nausea, and increased blood 
pressure (Klonoff and Greenway 2008). More recently, long-term use of sibutramine has 
been linked to severe cardiovascular risk, resulting in its withdrawal from the market in 
late 2010 (Li and Cheung 2011). 
  The gastrointestinal lipase inhibitor, orlistat, prevents lipolysis of TG into 
absorbable FFA, resulting in increased fecal excretion of undigested fat (Drew et al. 
2007) and a corresponding reduction in the absorption of dietary fat by up to 30% 
(Hauptman 2000). Due to its low bioavailability (< 1%), side effects of orlistat are less 
reported compared to other anti-obesity drugs and usually occur in the gastrointestinal 
tract (Drew et al. 2007). Some concerns have been reported that orlistat may lower 
absorption of fat soluble dietary vitamins (McDuffie et al. 2002). As a result, adequate 
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vitamin supplementation is a common requirement associated with the use of orlistat (Li 
and Cheung 2011). 
  Despite that three anti-obesity drugs have been approved and used 
short/long-term for the last 20 years, at present only orlistat is an approved 
pharmacological option for long-term use. In the summer of 2012, two new anti-obesity 
drugs were approved, including an appetite suppressing monotherapeutic and a drug 
combination. 
  The monothereapeutic appetite suppressing agent, lorcaserin (Belviq®), 
has been shown to induce modest, yet significant, weight loss compared to placebo 
control and appears to be additionally beneficial in regard to weight loss maintenance 
(Thomsen et al. 2008). A short-term study on lorcaserin in both men and women reported 
progressive weight losses over placebo control within as little as two weeks, even despite 
the lack of a concurrent caloric restriction regime or increase in physical activity (Smith 
et al. 2009). Furthermore, short-term lorcaserin-associated weight loss has been linked to 
decreases in several biomarkers of cardiovascular risk (Smith et al. 2009). Longer-term 
studies have reported significant reductions in body weight in lorcaserin-treated obese 
persons compared to placebo control, attributed in large part to decreased energy intake 
(Martin et al. 2011). The most commonly reported side effects have been minor, 
including headache, nausea, and dizziness (Smith et al. 2009; Smith et al. 2010). Unlike 
fenflurmine, which has a similar mechanism of action but lacks the selectivity of 
lorcaserin, deleterious drug-related effects on cardiac valvulophathy have not been 
anticipated (Jones 2009). In fact, lorcaserin treatment in obese persons for up to two years 
25 
!
has been reported without documented risk of harmful effects on heart valve function 
(Smith et al. 2010). 
  As a complement to lifestyle changes, Qsymia®, a combination of 
phentermine and the anticonvulsant agent topiramate, has also been found to induce 
significant weight loss and to promote the maintenance of weight loss (Vetter et al. 2010; 
Mercer 2011). Clinical trials have reported upwards of 9% placebo-adjusted weight 
losses over a one year period, of which 60% of participants lost greater than 10% of their 
initial body weight (Kennett and Clifton 2010). The precise mechanism of action of 
Qsymia® is currently under investigation, but has been anticipated to reflect the 
mechanisms of the individual components (Mercer 2011), primarily including 
phentermine-induced appetite suppression (Rothman and Baumann 2009). Although the 
body weight-lowering mechanism of action of topiramate is still unclear, it is known to 
have a satiating effect (Mercer 2011). Adverse side effects of Qsymia® reported during 
clinical trials include headache, dizziness, dry mouth, and constipation (Gadde and 
Allison 2009; Vetter et al. 2010). Other safety concerns, including rare psychiatric events, 
have been linked almost exclusively to the topiramate component of the combinatorial 
treatment (Kennett and Clifton 2010). 
  
1.6.3. Bariatric surgery 
 Most current weight loss approaches, including lifestyle changes and 
pharmacological intervention, have proven largely unsuccessful in cases of morbid (BMI 
œ"62"mi1o2) obesity (Ramsey-Stewart 1995). As a result, this has spurred investigation 
into and the development of several bariatric surgical techniques (Colquitt et al. 2009). In 
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the United States alone, there has been a 10-fold increase in the number of bariatric 
surgeries in the past decade (Tice et al. 2008). The surgery is generally done by either 
gastric restriction or biliopancreatic bypass, resulting in nutritional maldigestion or 
malabsoption, respectively (Marceau et al. 1998; Wolfe and Morton 2005). Evidence 
suggests that successful short- and long-term weight loss in morbidly obese subjects can 
be readily achieved by bariatric surgery (O'Brien et al. 2006; Colquitt et al. 2009). 
Furthermore, bariatric surgery can be more effective than dieting in producing sustained 
weight loss (Christou and MacLean 2005). In addition to morbid obesity, the surgery is 
often considered in obese (35.0 kg/m2 œ" DOK" œ" 5;0;" mi1o2) people suffering from a 
concurrent obesity-associated co-morbidity that may be improved through weight loss 
(Brolin 2002). Although there is evidence of substantial savings in prescription 
medication costs following bariatric surgery-assisted weight loss (Craig and Tseng 2002), 
access to the procedure continues to represent a major limitation. Recent statistics 
showed a mean investment of between $17,000 and $26,000 per operation (Cremieux et 
al. 2008). In addition, early and late mortality rates associated with bariatric surgery, 
although low, act as a deterrent for a sub-set of eligible candidates (Buchwald et al. 2007). 
Overall, bariatric surgery has been shown to significantly improve obesity and several 
associated co-morbidities, yet the substantial cost, surgery-associated mortality rates, and 
relative invasiveness associated with the procedure itself have rendered the approach 
largely impractical as a viable anti-obesity strategy (Adams et al. 2007).  
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1.7. T raditional Chinese medicine (T C M) 
 Although lifestyle changes continue to represent the primary intervention against 
obesity and its associated co-morbidities, mediocre long-term compliance has greatly 
challenged its effectiveness (Klonoff and Greenway 2008; Li and Cheung 2011). 
Furthermore, very few pharmacological interventions have been successful in the 
prevention or treatment of obesity and bariatric surgery is generally reserved for a subset 
of the morbidly obese population (Adams et al. 2007; Colquitt et al. 2009). Therefore, 
continued investigation into the development of both safe and efficacious anti-obesity 
products continues to be a top priority in nutritional and medical research.  
 Traditional Chinese medicine (TCM) has played a pivotal role in disease 
prevention and treatment in Asian countries, particularly China (Li et al. 2008), and now 
represents a viable complementary and alternative treatment approach. It is also 
considered to have enormous potential as an information source and starting point for the 
development of anti-obesity products (Perry et al. 2012). As such, a plethora of 
traditional Chinese herbs and their bioactive components have been, and will continue to 
be, investigated for their beneficial anti-obesity effects (Yin et al. 2008). Common 
examples of such Chinese herbal medicines include ginseng, which has been shown to 
have beneficial effects on glucose and lipid metabolism, as well as food intake regulation 
(Kim and Park 2003; Kim et al. 2005; Vuksan et al. 2008), and the plant alkaloid 
berberine, which has also been intensely investigated for its beneficial effects on glucose 
and lipid metabolism (Kong et al. 2004; Wang et al. 2011). 
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1.7.1. Liuwei Dihuang (LWD H) 
 One of the more common approaches to TCM is herbology, a Chinese art of 
combining various medicinal herbs into a single therapeutic prescription (Yin et al. 2008). 
Recently, a number of studies have been conducted to investigate the efficacy and 
mechanism of action of several medicinal herbs and herbal formulations on body weight 
and composition (Lenon et al. 2012; Sui et al. 2012). The TCM of interest for this thesis 
was the ancient herbal formula Liuwei Dihuang (LWDH). LWDH is prepared from a 
combination of six Chinese herbs (Table 1-1), including Radix Rehmanniae Preparata, 
Rhizoma Dioscoreae, Fructis Corni, Cortex Moutan, Rhizoma Alismatis, and Poria (Xie 
et al. 2008). It is widely produced in China and commonly used for the treatment of 
fkugcugu"cuuqekcvgf"ykvj"Ðmkfpg{-{kp"fghkekgpe{Ñ"(Ma et al. 2004). LWDH has been used 
worldwide for general health promotion (Ye et al. 2009) and its safety has been evaluated 
(Ha et al. 2011). Various studies have demonstrated its anti-aging, anti-T2DM, and 
radical-scavenging effects (Hsieh et al. 2003; Ye et al. 2009). Despite reports of its effect 
on reducing visceral fat deposition in rats and inhibiting rat preadipocyte differentiation 
(Xue et al. 2006; Xiao et al. 2007), few investigations into its potential anti-obesity 
effects have been documented. 
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 Table 1-1: Composition of Liuwei Dihuang herbal formula.  
 
 
 
 
 
 
 
 
 
 
 
 Adapted from Xie et al. (2008). ÐAn approach based on HPLC-fingerprint and 
 chemometrics to quality consistency evaluation of Liuwei Dihuang pills produced 
 by different manufacturersÑ. J Pharm Biomed Anal 48(4): 1261-1266. 
 
 
 
 
 
 
 
 
 
 
 
 
 
H erb 
 
Source 
 
Amount (g) 
 
 
Radix Rehmanniae Praeparata  
 
Root of  
R. glutiosa 
 
 
 
160 
Fructis Corni 
 
Fruit of  
C . officianalis 
 
 
60 
Cortex Moutan 
 
Root bark of  
P. suffruticosa 
 
 
60 
Rhizoma Dioscoreae 
 
Rhizome of 
D . opposita 
 
 
80 
Poria 
 
Sclerotia of 
P. cocos 
 
 
60 
Rhizoma Alismatis 
 
Rhizome of  
A. plantago-aquatica 
 
60 
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1.7.2. Liuwei Dihuang (LWD H) ethanol extract 
 As LWDH is a crude mixture of medicinal herbs, information on the bioactive 
components potentially responsible for its body weight-lowering effect is lacking. 
Furthermore, the potential mechanism of action of LWDH on obesity remains to be 
elucidated. In order to further investigate the potential body weight-lowering efficacy and 
mechanism of action of LWDH, an ethanol extract of the product was investigated using 
in vitro experimental designs. Unpublished data from the Wang lab has indicated that in 
vivo, the ethanol extract of LWDH reduces weight gain and visceral fat accumulation, as 
well as improves metabolic phenotypes such as lipid profiles and leptin levels. This same 
study also revealed beneficial effects of the ethanol extract on fat and carbohydrate 
oxidation, as well as energy expenditure.  
 
1.8. Appetite regulation and body weight control 
! The body has evolved mechanisms to control body weight over time, however, it 
tends to favour defending against starvation and are intuitively less robust in preventing 
obesity (Chaudhri et al. 2008). Furthermore, the sedentary lifestyle that has in part fuelled 
the now well recognized obesity epidemic, has turned this evolutionary advantage of 
storing excess energy as fat into an increased risk of morbidity or mortality (Roth and 
Reinehr 2010). Thus, harnessing of the physiological mechanism of appetite regulation 
has recently become an intensely investigated approach to body weight control and has 
been reported to involve a communication line from the gastrointestinal (GI) tract to the 
central nervous system (CNS) and resident centres of appetite regulation (Gardiner et al. 
2008). 
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1.8.1. The gut/brain axis 
 Increasing recognition of the intricate interplay between gut hormones and the 
CNS has resulted in enhanced understanding of the control of food intake and body 
weight through appetite regulation (Hameed et al. 2009). As such, this line of 
communication between the GI tract and the CNS, referred to as the gut-brain axis, has 
been recognized as a key component of a now well-established model of appetite 
regulation (Chaudhri et al. 2008). The gut-brain axis has both hormonal and neural 
components which relay information to key CNS centres, particularly the hypothalamus 
(Stanley et al. 2005) (Figure 1-5). The arcuate nucleus (Arc) represents the primary CNS 
region involved in the control of food intake (Valassi et al. 2008). Signals from regions 
along the gut-brain axis effect changes in the relative activity of two neuronal 
subpopulations. These signals include an orexigenic or appetite stimulating population 
co-expressing the neuropeptides neuropeptide Y (NPY) and agouti-related peptide 
(AgRP), and an anorexigenic or appetite suppressing population co-expressing the 
neuropeptides pro-opiomelanocortin (POMC) and cocaine- and amphetamine-regulated 
transcript (CART) (Chaudhri et al. 2008). Changes in the relative release of these 
neuropeptides strongly influence appetite regulation, and ultimately, body weight control.  
 
!
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 F igure 1-5: Central mechanisms in appetite regulation and body weight control: 
 the gut/brain axis. Adapted from Geraedts et al. (4233+0"ÐIcuvtqkpvguvkpcn" vctigvu"
 to mofwncvg"ucvkgv{"cpf"hqqf"kpvcmgÑ0"Obes Rev 12(6): 470-477. 
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1.8.2. Gut hormones and neuropeptides 
 The GI tract represents the largest endocrine organ in the body and plays an 
important role in appetite regulation and body weight control as a source of regulatory 
peptide hormones (Hameed et al. 2009). The synthesis and release of gut hormones from 
a suite of endocrine cells occurs in response to nutrient intake and are thought to play a 
critical role in meal initiation and termination (Pournaras and Le Roux 2009). Along the 
gut-brain axis, neuropeptides such as NPY have also been documented to strongly 
influence the physiological control of body weight through appetite modulation (Valassi 
et al. 2008). In this thesis, the gut hormones ghrelin and peptide tyrosine-tyrosine (PYY), 
and the neuropeptide NPY, were primarily investigated and will be discussed. Their 
relation to the beneficial effects of weight loss will be outlined in Chapter 4.  
 
1.8.2.1. Ghrelin and peptide tyrosine-tyrosine (PYY) 
  Ghrelin and peptide tyrosine-tyrosine (PYY) represent key gut hormones 
involved in the regulation of appetite and energy homeostasis, but have been shown to 
exert opposing effects (Kirchner et al. 2010).  
  Ghrelin is the only known orexigenic gut hormone and is produced 
primarily in the stomach (Kojima et al. 1999), and to a lesser degree, in regions of the 
small intestine (Date et al. 2000). Shortly after its discovery in 1999, the role of ghrelin in 
food intake regulation and body weight control was described (Tschop et al. 2000). 
Ghrelin has been demonstrated to be a potent food intake stimulator and meal initiator 
(Wren et al. 2001; Drazen et al. 2006). Appetite-stimulating effects in lean and obese 
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humans, including an approximately 30% increase in food intake at a buffet-style meal, 
have been documented (Murphy and Bloom 2004; Druce et al. 2005). 
  Peptide tyrosine-tyrosine (PYY) is an anorexigenic gut hormone produced 
and secreted mainly from the distal gut and ileum (Ekblad and Sundler 2002). Circulating 
levels of PYY are strongly influenced by meal composition and postprandial levels have 
been shown to become elevated within as little as one hour in humans (Adrian et al. 
1985). Decreases in appetite and a resultant negative energy balance have been 
demonstrated in response to PYY in both lean and obese humans (Batterham et al. 2003). 
This effect has largely been attributed to interaction with its Y2 receptor in the Arc, as 
targeted deletion of the Y2 receptor has been shown to abolish the inhibitory effect of 
PYY on food intake (Batterham et al. 2002). 
 
1.8.2.2. Neuropeptide Y (NPY) 
  Neuropeptide Y (NPY), whose expression predominates in the Arc, is the 
most potent activator of appetite in the CNS (Valassi et al. 2008). In addition, projections 
from NPY-expressing neurons to other CNS regions are capable of initiating appetite 
stimulating anabolic effects (Ramos et al. 2005). The anabolic effects of NPY have 
largely been attributed to interaction with its Y1 and Y5 receptors (Parker et al. 2002), two 
of the six NPY receptors which have been isolated and investigated to date. Modulation 
of NPY signaling in the Arc has been shown to influence energy balance in rats (Chao et 
al. 2011). Central injection of NPY into the hypothalamic Arc region has been shown to 
induce a marked feeding response and to stimulate food intake (Williams et al. 2004). 
Furthermore, chronic administration has been shown to lead to obesity (Zarjevski et al. 
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1993). Conversely, down regulation of NPY expression has been shown to reduce fat 
deposition and to improve high-fat diet-induced hyperphagia and obesity (Chao et al. 
2011). 
 
1.8.3. E ffect of body weight on gut hormones and neuropeptides  
 Although the gut-brain axis represents an effective mechanism of body weight 
control through appetite regulation, long-term nutrient excess and resultant obesity have 
been shown to alter key components of this pathway, and in cases, to increase the 
difficulty by which the body can self-regulate the control of appetite and body weight 
(Roth and Reinehr 2010). The majority of the changes in gut hormones and other key 
components of the gut-brain axis seen in response to obesity have, however, been shown 
to be largely reversible in response to weight loss (Roth and Reinehr 2010). 
 Postprandial decreases in circulating ghrelin levels are attenuated, or even absent 
in the obese, suggestive of a role of ghrelin in the pathophysiology of obesity (le Roux et 
al. 2005). Conversely, circulating ghrelin levels have been reported as being significantly 
reduced in response to both diet- and bariatric surgery-induced weight loss (Cummings et 
al. 2002). Circulating PYY levels are often lower in the obese state, suggestive of a 
possible causative role of diminished PYY levels in the development of obesity (le Roux 
et al. 2006). Furthermore, postprandial increases in PYY levels typically seen in normal 
weight individuals are generally much lower, or even absent, in the obese state (Stock et 
al. 2005). In response to weight loss, however, significant increases in circulating PYY 
levels have been reported (Korner et al. 2005). Alterations in NPY levels have been 
shown to be associated with changes in energy balance (Sousa-Ferreira et al. 2011), 
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including evidence of a significant increase in NPY expression in response to obesity 
(Dryden et al. 1995) and decreased intake of high fat diets in response to central knockout 
of NPY (Sindelar et al. 2005).  
 
1.9. Fatty acid oxidation and synthesis 
 The marked increase in the prevalence of obesity in recent years suggests that 
environmental and behavioural factors, such as increased intake of dietary fat and 
decreased physical activity, increase the likelihood of developing obesity, and have 
contributed substantially towards the classification of the disease as a worldwide 
epidemic (Bray et al. 2004; Greenberg and Obin 2006). Circulating fatty acids, which are 
well documented as a risk factor for several obesity-associated co-morbidities, are 
generally either oxidized for energy production or re-esterified from the circulation for 
storage as TG (Teusink et al. 2003). As such, promotion of fatty acid uptake and 
oxidation, rather than storage as TG, has become an increasingly attractive potential anti-
obesity strategy (Niu et al. 2012). 
 In response to intake of dietary fat, oxidation of fatty acids has been shown to 
increase until its rate matches that of fat intake (Schrauwen et al. 1997). In the absence of 
a sufficiently compensatory increase in energy expenditure, however, the result has long 
been known to be an increase in fat mass (Flatt 1987). In metabolically healthy 
individuals, increased fat intake is matched with an increase in fatty acid oxidation 
(Boyle et al. 2011; Bergouignan et al. 2012). Conversely, a reduced capacity to oxidize 
fat predisposes to weight gain (Zurlo et al. 1990). In response to excessive dietary fat 
intake and obesity, the ability to adjust fat oxidation to fat intake is impaired (Schutz et al. 
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1989) and endogenous fatty acid oxidation capacity is reduced (Ceddia 2005). Further to 
the documented alterations in fatty acid oxidation in response to obesity, increased 
weight gain is associated with elevated hepatic lipogenesis, resulting in large part from 
stimulated expression of the lipogenic enzyme fatty acid synthase (FAS) (Diraison et al. 
2002). Collectively, these obesity-associated abnormalities in fatty acid oxidation and 
synthesis alike have been reported to lead to increased circulating levels and 
accumulation of fatty acids and an increased risk of obesity-associated morbidity and 
mortality (Tanaka et al. 2005).  
 
1.9.1. AMP-activated protein kinase (AMPK)-mediated fatty acid oxidation 
 Activation of metabolic pathways which promote fatty acid oxidation has been 
shown to prevent fatty acid accumulation in various tissues (Kahn et al. 2005). 
Conversely, a reduction in the capacity to oxidize fat predisposes to weight gain (Zurlo et 
al. 1990). It was once believed that transport of fatty acids across the plasma membrane 
for oxidation occurred by way of passive diffusion (Kiens and Roepstorff 2003). More 
recent evidence, however, has indicated that this process occurs in a protein-mediated 
fashion (Bonen et al. 2007). One such protein cascade that has been garnering significant 
attention as a mediator of cellular lipid homeostasis and fatty acid oxidation is driven by 
the heterotrimeric enzyme, AMP-activated protein kinase (AMPK)  (Ceddia 2005; Niu et 
al. 2012) (Figure 1-6). When activated, AMPK has been shown to inhibit anabolic 
pathways and promote catabolism (Carling 2005). As such, activation of AMPK has been 
emerging as a potential strategy for the treatment of obesity (Kahn et al. 2005). Activated 
(phosphorylated) AMPK has been shown to phosphorylate (and inactivate) the  
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 F igure 1-6: AMP-activated protein kinase-mediated fatty acid oxidation. Adapted 
 from Hopkins et al. *4225+0" ÐAMP-activated protein kinase regulation of fatty 
 acid oxidationÑ. Biochem Soc Trans 31: 207-212. 
 
 
 
 
 
 
!
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downstream target, acetyl-CoA carboxylase (ACC), in effect blocking the production of 
malonyl-CoA (Harwood et al. 2003). Malonyl-CoA is an inhibitor of carnitine 
palmitoyltransferase-1 (CPT1), the rate-limiting enzyme responsible for the transport of 
fatty acids into the mitochondrion for beta-oxidation (McGarry 2002). Reduced malonyl-
CoA production has been shown to result not only in a disinhibition of CPT1 activity, 
promoting the transfer of fatty acids into the mitochondrion for beta-oxidation, but also in 
a concomitant suppression of fatty acid synthesis (Kahn et al. 2005). By increasing fatty 
acid oxidation, the AMPK cascade has been reported to play an important role in 
protecting against obesity and several of its associated co-morbidities (Ceddia 2005). In 
line with this, however, the presence of excessive circulating or accumulated fatty acids 
has been reported to impair activation of the AMPK cascade (Taylor et al. 2005). 
Noteworthy is the recognition that obesity is associated with significantly elevated fatty 
acid levels, potentially compromising the oxidative response of the AMPK cascade 
(Roden 2004). A reduced capacity to oxidize fatty acids has been shown to be associated 
with excessive fatty acid accumulation, onset obesity, and an increased risk of obesity-
associated morbidity and mortality (Tanaka et al. 2005; Holloway et al. 2009). As such, 
obese individuals stand to benefit from an enhancement in fatty acid oxidation capacity. 
Furthermore, an attenuation in the phosphorylation of AMPK (activation) and ACC 
(deactivation) have both been linked to obesity and several of its associated co- 
morbidities (Tanaka et al. 2005). Conversely, increased physical activity and decreased 
high-fat dietary intake have been shown to increase fatty acid oxidation, with resultant 
improvements in obesity and several of its associated co-morbidities (Bruce et al. 2006). 
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1.9.1.1. AMP-activated protein kinase (AMPK) 
  The heterotrimeric enzyme AMPK has been described as a key cellular 
energy sensor (King et al. 2006). Activation of AMPK occurs through phosphorylation of 
a threonine (threonine-394+" tgukfwg" ykvjkp" kvu" ecvcn{vke" g-subunit, either 
pharmacologically, by upstream kinases, or in response to increased cellular AMP levels 
(Kemp et al. 2003; Woods et al. 2003; King et al. 2006). AMPK is the physiological 
kinase of ACC, serves as an upstream regulator of CPT1, and is recognized as a key 
enzyme involved in the beta-oxidation of fatty acids and whole body lipid homeostasis 
(Munday 2002; Long and Zierath 2006; Ix and Sharma 2010). In addition, activation of 
AMPK has been shown to concomitantly inhibit fatty acid synthesis by way of 
decreasing FAS expression, as well as by way of its downstream effect on malonyl-CoA 
production (Woods et al. 2003; Guo et al. 2012). 
  Further to the noted beneficial effects of AMPK activation on fatty acid 
oxidation and synthesis, AMPK has also been emerging as a regulator of appetite at both 
the cell and whole-body levels (Kola 2008). In the brain, AMPK is widely expressed in 
areas linked to the control of food intake, such as the hypothalamus (Turnley et al. 1999). 
Therein, the activity of AMPK increases in the fasted state and decreases upon re-feeding 
(Minokoshi et al. 2004). Similar to the case in peripheral tissues, the downstream targets 
of AMPK in the hypothalamus are believed to include the ACC-malonyl-CoA-CPT1 
pathway (Kola 2008).  
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1.9.1.2. Acetyl-CoA carboxylase (ACC) 
  In its active (dephosphorylated) form, ACC catalyzes the conversion of 
acetyl-CoA to malonyl-CoA for the endogenous synthesis of fatty acids by FAS (Wakil 
and Abu-Elheiga 2009). Conversely, in its inactive (phosphorylated) form, ACC has been 
shown to effectively decrease malonyl-CoA production, resulting in disinhibition of 
CPT1, increased shuttling of fatty acids into the mitochondrion, and a resultant increase 
in fatty acid oxidation potential (McGarry 2002). 
 
1.9.1.3. Carnitine palmitoyltransferase-1 (CPT1) 
  Carnitine palmitoyltransferase-1 has been shown to play a major role in 
the regulation of fatty acid metabolism by orchestrating the rate-limiting step of fatty acid 
transport into the mitochondrion for beta-oxidation (McGarry 2002). Under conditions of 
elevated circulating fatty acid levels, such as in obesity, it has been shown that cells elicit 
a diminished capacity, through decreased activation of CPT1, to oxidize fatty acids 
(Pimenta et al. 2008). Conversely, exercise- and diet-induced weight loss have both been 
shown to increase CPT1 activity, and over expression of CPT1 in the presence of 
excessive circulating fatty acids has been shown to sufficiently enhance fatty acid 
oxidation (Bruce et al. 2006; Bruce et al. 2009). 
 
1.9.2. F atty acid synthase (F AS)  
 In addition to impaired fatty acid oxidation, obesity has been shown to be 
associated with dysregulated fatty acid synthesis (Diraison et al. 2002). Obesity-
associated impairments in fatty acid synthesis have been reported to be due, in large part, 
to increased stimulation of FAS, a ubiquitously expressed lipogenic enzyme that 
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catalyzes the first committed step in the fatty acid biosynthesis pathway (Semenkovich 
1997; Wang et al. 2004). In fact, dysregulated expression of FAS has been reported in 
obesity (Boizard et al. 1998) and increased FAS expression in adipose tissue of human 
subjects has been linked to excessive visceral fat accumulation (Berndt et al. 2007). 
Conversely, positive correlations between diet-induced weight loss and decreased 
expression of FAS have been documented (Tian et al. 2004). 
 
1.10. Models of obesity   
1.10.1. In vivo models of obesity 
 Variability has been shown to exist in the predisposition of certain individuals to 
gain weight in response to excessive dietary fat intake, while others appear to be resistant 
to the same effect (Cornier et al. 2009). Individuals prone to the development of obesity 
in response to high-fat diet feeding have been reported to have a decreased capacity to 
sense the energy value of high-fat dietary intake and/or have a blunted adaptive response 
to defend against weight gain (Schwartz et al. 2003). Conversely, individuals resistant to 
the development of obesity in response to high-fat dietary intake have been reported to 
have an increased capacity to more accurately sense energy balance and to respond 
adaptively to counteract the physiological tendency towards weight gain (Jackman et al. 
2010).  
 For this thesis, the in vivo model chosen for investigation into the efficacy and 
subsequent mechanism of action of LWDH was the obesity-resistant (OR)/obesity-prone 
(OP)-CD rat model. 
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1.10.1.1. Obesity-resistant (OR)/obesity-prone (OP)-CD rat model 
  While most rats gain weight in response to high-fat diet feeding, some 
strains have been found to be more or less resistant to the same effect (Jackman et al. 
2006). An in vivo model of obesity with a predisposition for the development of obesity, 
in large part due to environmental conditions such as increased dietary fat intake, was 
developed in 1997 (Levin et al. 1997). By using variability in weight gain in response to 
high-fat diet feeding as a selective breeding tool, the design for this model yielded two 
strains of Sprague-Dawley rats which have a similar phenotype when fed a low-fat diet, 
but diverge into either susceptible or resistant phenotypes when fed a high-fat diet (Levin 
et al. 1997). Similar to the condition of obesity in humans, these two phenotypes 
represent the crossroads of nature and nurture, that is, the interface between genetic 
background and environmental factors (Levin and Keesey 1998). As a result, the obesity-
resistant (OR)/obesity-prone (OP)-CD rat model is now widely acknowledged as a 
representative model of the human condition of obesity (Jackman et al. 2006; Jackman et 
al. 2010). 
  Rats prone to high-fat diet-induced weight gain (OP) are generally larger 
than those resistant (OR) to the same effect, however, when fed a low-fat diet, body 
composition between the strains has been shown to remain very similar (Levin and 
Keesey 1998). Conversely, when fed a high-fat diet, OP rats become obese and develop 
several obesity-associated co-morbidities, including leptin and insulin resistance (Wang 
et al. 2001). Furthermore, OP rats have a greater tendency to store dietary fat, while OR 
rats have been shown to elicit a greater capacity to oxidize dietary fat (Jackman et al. 
2006). Resistance to high-fat diet-induced weight gain in OR rats has been suggested to 
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be due, in large part, to an increase in energy expenditure and a shift towards the use of 
stored fat as an energy source (Jackman et al. 2010). Furthermore, resistance to obesity in 
these same rats has been attributed in large part to more tightly regulated control of food 
intake (Jackman et al. 2010).! Overall, OR rats have been reported to sense and adapt to 
high-fat diet overfeeding more acutely and accurately than their OP counterparts 
(Jackman et al. 2010). 
 
1.10.2. In vitro models of obesity 
 In order to investigate the corresponding mechanism of action responsible for the 
efficacy of potential anti-obesity products, extracts of the product are commonly tested 
using physiologically-relevant in vitro models (Novakofski 2004). For this thesis, and as 
will be presented in subsequent chapters, two potential body weight-lowering 
mechanisms of action of LWDH and its ethanol extract were investigated. These included 
appetite regulation and increased fatty acid oxidation/decreased fatty acid synthesis. 
Appetite regulation as a potential mechanism of action was tested by measuring 
alterations in key components of the gut-brain axis in response to LWDH and its ethanol 
extract. As a representative in vitro model of the GI tract, the human intestinal CaCo-2 
cell line was employed. The neuroblastoma SH-SY5Y cell line was employed as a 
representative model of the CNS. Increased fatty acid oxidation/decreased fatty acid 
synthesis as a potential mechanism of action was tested by measuring alterations in key 
components of the AMPK-mediated fatty acid oxidation cascade and the lipogenic 
enzymes FAS in response to LWDH and its ethanol extract. As in vitro models of the 
liver and muscle tissue, respectively, human HepG2 hepatocytes and rat L6 skeletal 
muscle myotubes were employed.  
45 
!
1.10.2.1. Appetite regulation: CaCo-2 and SH-SY5Y cells 
  Harnessing of the physiological mechanism of appetite regulation has 
become an intensely investigated approach to body weight control and has been reported 
to involve a communication line from the gut to appetite regulating regions in the CNS 
(Gardiner et al. 2008). For this thesis, two gut hormones with opposing appetite-
suppressing and appetite-stimulating roles (PYY and ghrelin, respectively), and one 
appetite-stimulating neuropeptide (NPY) along the gut-brain axis, were investigated. 
  Peptide tyrosine-tyrosine (PYY) is a potent appetite-suppressing gut 
hormone secreted mainly from the ileum (Ekblad and Sundler 2002). Ghrelin, the only 
known appetite-stimulating gut hormone, is produced mainly in the stomach, and to a 
lesser degree, in regions of the small intestine (Date et al. 2000). As such, the human 
intestinal CaCo-2 cell line, which has been reported to express several morphological and 
biochemical characteristics of small intestinal enterocytes (Sambuy et al. 2005), was 
chosen for use as a representative in vitro model. These cells grow in monolayer, have 
tight junctions between adjacent cells, and express small intestinal hydrolase enzyme 
activities more similar to fetal than adult ileal enterocytes (Sambuy et al. 2005). 
Furthermore, previous studies have employed CaCo-2 cells for investigating PYY and 
ghrelin expression (Sonoyama et al. 2000; Yeung et al. 2006) and its use has grown 
significantly in recent years (Sambuy et al. 2005). Neuropeptide Y, whose expression 
predominates in the hypothalamic Arc, is reportedly the most potent activator of appetite 
in the CNS, and modulation of its signaling has been shown to significantly influence 
energy balance (Valassi et al. 2008; Chao et al. 2011). The SH-SY5Y cell line has been 
ykfgn{"wugf"cu"c"pgwtqpcn"oqfgn"ukpeg"vjg"3;:2Óu."cu"vjgug"egnnu"gnkekv"ugxgtcn"hwpevkqpcn"
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and biochemical characteristics of neurons (Xie et al. 2010). Such characteristics include, 
among others, expression of neurofilament proteins, nerve growth factor receptors, and 
neuronal enzyme activity (Ciccarone et al. 1989). In addition, SH-SY5Y cells can 
proliferate in culture for long periods of time without contamination (Xie et al. 2010). 
The most commonly reported use of SH-SY5Y cells has been as an in vitro model of 
RctmkpuqpÓu"fkugcug"(PD) (Xie et al. 2010). However, there has also been precedent in the 
literature for the expression of NPY in SH-SY5Y cells (Wernersson et al. 1998; Magni et 
al. 2000). Undifferentiated SH-SY5Y cells are commonly used as a model in 
neurotoxicity and neuroprotection studies (Xie et al. 2010). Certain limitations of 
undifferentiated SH-SY5Y cells reported in the literature have included the notion that 
when undifferentiated, the cell line is continuously dividing and that there is a certain 
degree of unreliability as to whether the cell line will elicit the typically expected markers 
of mature neurons (Datki et al. 2003; Xie et al. 2010). To investigate the efficacy of 
LWDH and its ethanol extract on NPY expression in this thesis, the human 
neuroblastoma SH-SY5Y cell line was chosen for use as a representative in vitro model. 
 
 
1.10.2.2. Fatty acid oxidation and synthesis: HepG2 cells and L6 myotubes 
  Obesity has been shown to be associated with impaired fatty acid 
oxidation, as well as dysregulated fatty acid synthesis (Diraison et al. 2002; Ceddia 2005). 
As such, promotion of fatty acid uptake and oxidation and/or inhibition of  fatty acid 
synthesis, have become increasingly attractive potential anti-obesity strategies (Berndt et 
al. 2007; Niu et al. 2012). Correspondingly, activation of metabolic pathways which 
promote fatty acid oxidation, such as the AMPK-mediated fatty acid oxidation cascade 
and inhibition of the lipogenic enzyme FAS, have both been emerging as potential anti-
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obesity targets (Diraison et al. 2002; Niu et al. 2012). As representative in vitro models of 
fatty acid metabolism in the liver and muscle tissue, human HepG2 hepatocytes (Lin et al. 
2007; Guo et al. 2012) and rat L6 skeletal muscle myotubes (Watt et al. 2006; Kelly et al. 
2010) were employed. HepG2 cells are a widely used human hepatocellular carcinoma 
cell line, which is highly differentiated and elicits several genotypic characteristics of 
normal liver cells (Sassa et al. 1987; Gerets et al. 2012). Their most common used has 
been in toxicity screening, but use of this cell line for investigating the effects of natural 
products on lipid metabolism have also been widely reported (Lin et al. 2007; Guo et al. 
2012; Niu et al. 2012). One of the major limitations of the HepG2 cell line is its low 
metabolic capacity relative to primary hepatocytes (Xu et al. 2004), often times leading to 
limited detection of changes in gene expression patterns. The myogenic L6 cell line, 
developed in 1968 (Yaffe 1968), elicits several characteristics of skeletal muscle cells, 
such as contractility, acetylcholine receptors, and insulin-sensitive glucose transport 
capabilities (Elsner et al. 1998). Certain myogenic characteristics reported to be lacking 
in the L6 cell line include high glycogen levels and low glucose levels (Meyer 1989; 
Nakatani et al. 1997). A common use for the L6 cell line in recent years has been the 
investigation of treatment effects on FFA-induced insulin resistance (Chen et al. 2009) 
and themechanism of action through fatty acid oxidation (Watt et al. 2006; Kelly et al. 
2010). 
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1.11. Project hypotheses and objectives 
 The present thesis consists of a series of in vivo and in vitro experiments designed 
to elucidate the anti-obesity efficacy and potential mechanism(s) of action of the 
traditional Chinese herbal formula, LWDH, and its ethanol extract. 
 The hypotheses were:   
  1. L iuwei Dihuang will lower body weight and improve body  
   composition, blood lipids, and leptin and insulin resistance.  
  2.  L iuwei Dihuang will improve biomarkers of inflammation,  
   oxidative stress, and adiponectin production.  
  3. L iuwei Dihuang and its ethanol extract will lower body weight  
   through regulation of appetite by modulating key components  
   of the gut-brain axis. 
  4. L iuwei Dihuang and its ethanol extract will lower body weight  
   through regulation of fatty acid oxidation and synthesis by  
   modulating key components of the A MP K-driven fatty acid  
   oxidation cascade and the lipogenic enzyme F AS. 
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 These hypotheses were tested by setting the following four main objectives: 
  1. To determine the efficacy of L W D H on body weight and  
   composition, food intake, blood lipids, and leptin and insulin  
   resistance using a rat model of obesity. 
  2. To determine the efficacy of L W D H on inflammatory and  
   oxidative stress biomarkers and adiponectin production using  
   a rat model of obesity. 
  3. To determine the efficacy of L W D H and its ethanol extract on  
   appetite regulation as a potential body weight-lowering   
   mechanism of action in vivo and in vitro. 
  4. To determine the efficacy of L W D H and its ethanol extract on  
   fatty acid oxidation and synthesis as a potential body weight- 
   lowering mechanism of action in vivo and in vitro. 
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 C H APT E R 2: E F F I C A C Y O F L IU W E I DI H U A N G PI L L O N B O D Y W E I G H T 
A ND C O MPOSI T I O N , F O O D IN T A K E , B L O O D L IPIDS, A ND L EPT IN A ND 
INSU L IN R ESIST A N C E IN O B ESE R A TS  
 
A version of this chapter has been published with modification as: 
Perry, B., J. Zhang, C. Sun, T. Saleh, Y. Wang (2012). "Liuwei dihuang lowers body 
weight and improves insulin and leptin sensitivity in obese rats." Evid Based 
Complement Alternat Med 2012: 847167. 
 
2.1. Abstract 
! The present study investigated the efficacy of a Chinese herbal formula, Liuwei 
Dihuang (LWDH), as a potential natural weight-lowering product. Twelve obesity-
resistant (OR-CD) and 48 obesity prone (OP-CD) rats were used. Following a 2 week 
acclimation period, the OP-CD rats were divided into 4 groups (n = 12 each). One group 
served as a positive control for obesity (OP), while the other 3 were challenged twice-
daily by oral gavage with total daily dosages of 500, 1500, or 3500 mg/kg body weight 
(BW) LWDH, respectively, for 9 weeks. The OR-CD rats served as the normal control 
group and were gavaged with the vehicle. All rats were fed an AIN-93G diet modified to 
contain 60% energy from fat. The highest LWDH dose led to a significant reduction in 
body weight during the last 4 weeks of treatment. Food intake was also reduced from the 
second to the last week of treatment. The high LWDH dose lowered serum triglyceride 
(TG) and free fatty acid (FFA) levels, as well as body fat. Both the high and medium 
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doses lowered serum leptin and insulin levels. Liver function testing, assessed by 
measuring serum liver enzyme levels, revealed no adverse side effects of LWDH in rats 
under the current experimental conditions. The results of the present study suggest that 
LWDH has potential as a safe and effective preventive or therapeutic natural weight-
lowering product. 
 
2.2. Introduction 
 The obesity epidemic is no longer limited to the developed countries, but has long 
been known to be rapidly spreading to developing countries as well (Drewnowski and 
Popkin 1997; Popkin 1998). Associated with overweight and obesity is an increased risk 
for the development of a series of chronic diseases including, but not limited to, type 2 
diabetes mellitus (T2DM), cardiovascular disease (CVD), dyslipidemias, and certain 
forms of cancer (Must et al. 1999; Mokdad et al. 2003). The rapidly increasing 
prevalence of obesity has also been reported to negatively influence the general quality of 
human life and to impose an enormous burden on the health care system (Fine et al. 
1999; Lakdawalla et al. 2005). Thus, control of body weight has now become one of the 
top priorities in nutritional and medical research (Perry et al. 2012). Studies have shown 
that a reduction of as little as 5-10% body weight is sufficient to significantly improve 
many of the known obesity-associated co-morbidities (Fujioka et al. 1991; Goldstein 
1992), such as dyslipidemia, increased circulating free fatty acid (FFA) levels, leptin and 
insulin resistance, and alterations in serum liver enzymes levels (Wood et al. 1988; 
Fujioka et al. 1991; Dattilo and Kris-Etherton 1992; Goldstein 1992).  
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 Leptin and insulin play a critical role in energy homeostasis (Carlson et al. 2009). 
These hormones have been shown to effectively relay information about peripheral fat 
stores to the brain by acting on specific neurons in the hypothalamus and modulating 
eating behaviour and energy expenditure (Kaiyala et al. 1995; Abizaid and Horvath 2008). 
A common feature of obesity is the development of leptin and insulin resistance (Enriori 
et al. 2007; Weiss and Kaufman 2008), resulting in an elevation of the circulating levels 
of these hormones as a consequence of compensatory physiological responses to leptin 
and insulin insensitivity (Shulman 2000; Schwartz and Niswender 2004). With the onset 
of leptin and insulin resistance, several obesity-related blood biomarkers change, such as 
an increase in FFA and triglyceride (TG) levels in the circulation, as well as in the liver 
and muscle tissues (Stefan et al. 2002). Furthermore, decreased insulin sensitivity is 
strongly correlated with the onset of T2DM (Colagiuri 2010). 
 To date, lifestyle changes including dietary habits and exercise remain the 
primary intervention for weight loss or control (Stafford and Radley 2003; Caterson et al. 
2012). Collectively, weight loss and weight maintenance by way of lifestyle changes 
have been reported to be associated with a reduced risk of developing the most serious 
obesity-associated co-morbidities, as well as a general improvement in the overall quality 
of life (Thompson et al. 1999; Caterson et al. 2012). However, mediocre long-term 
compliance has continued to significantly challenge its effectiveness (Klonoff and 
Greenway 2008). Few dietary supplements or drugs have been successful in the 
prevention or treatment of obesity (Klonoff and Greenway 2008). Furthermore, most 
available pharmacological treatment strategies have been reported to have limited long-
term success, a plethora of safety concerns, and are also often accompanied by weight 
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regain upon cessation of treatment (Li and Cheung 2011; Kang and Park 2012). Only 
bariatric surgery has been reported to effectively lead to substantial weight loss 
accompanied by long-term sustainability (Murphy et al. 2006), but its high cost and rate 
of mortality have rendered it largely impractical as a viable anti-obesity intervention 
(Adams et al. 2007). As a result, there exists a strong demand to continue searching for 
safe and efficacious products to combat this emerging health epidemic.  
 
! Traditional Chinese medicine (TCM) and the use of herbs and herbal formulations 
have been considered to have potential as an information source and starting point for the 
development of anti-obesity products (Perry et al. 2012). The ancient TCM Liuwei 
Dihuang (LWDH), prepared from a basic formula of 6 Chinese herbs (Radix Rehmannide 
Preparata, RRP; Rhizoma Dioscoreae, RD; Fructus Corni, FC; Cortex Moutan, CM; 
Rhizoma Alismatis, RA; and Poria) (Zhao et al. 2007; Xie et al. 2008), is widely 
produced in China in accordance with the China Pharmacopoeia standard of quality 
control (Fu et al. 2009). Despite its use worldwide for general health promotion (Ye et al. 
2009), little is known about its potential benefits in regard to overall energy homeostasis 
and weight management. Furthermore, aside from limited reports of its effect on reducing 
visceral fat deposition in rats and inhibiting rat preadipocyte differentiation (Xue et al. 
2006; Xiao et al. 2007), little to no investigation into its potential anti-obesity efficacy 
and mechanism(s) of action has been documented. 
! The aim of the present study was to investigate the anti-obesity efficacy of 
LWDH by measuring body weight and composition, food intake, blood lipid profiles, and 
the hormones leptin and insulin using a rat model of obesity. In order to evaluate any 
potential adverse side effects of LWDH, liver function tests were conducted by 
54 
!
measuring serum levels of a series of liver enzymes, including aspartate aminotransferase 
*CUV+." cncpkpg" cokpqvtcpuhgtcug" *CNV+." cnmcnkpg" rjqurjcvcug" *CNR+" cpf." け-
glutamyltransferase (GGT).  
 
2.3. Materials and methods 
2.3.1. Animals and diet 
 Sixty male rats were purchased from Charles River Laboratories (Montréal, QC, 
Canada). Twelve of these animals were of the obesity-resistant strain (OR-CD) and 48 
were of the obesity-prone strain (OP-CD). All animals were housed individually in cages 
in a temperature-controlled room with a 12 hour light:dark cycle and acclimated for 2 
weeks with free access to regular rodent chow and water. The OR-CD rats served as the 
normal control group (OR) and the OP-CD rats were randomly divided into 4 groups (n = 
12 each) prior to the commencement of treatment. Randomization of the OP-CD rats was 
accomplished by ordering the rats based on initial body weight from lightest to heaviest 
and assigning rats sequentially to 1 of 4 groups. These groups included an obesity control 
(OP) and  3 treatments (T1A, T1B, and T1C). The T1A, T1B, and T1C groups were 
treated for 9 weeks by twice-daily oral gavage with total daily dosages of 500, 1500, or 
3500 mg/kg body weight (BW) of the concentrated LWDH pills (Wanxi Pharmaceuticals 
Co. Ltd., Henan, China) suspended in water, respectively. The OR and OP control groups 
received water via oral gavage as the control vehicle. Treatment administration was 
performed during the light cycle; once in the morning and again 6 hours later. Although 
rats are generally more active and thus exert more energy during the dark period (Zucker 
1971), unpublished data from the Wang lab shows that LWDH enhances energy 
expenditure at a larger magnitude during the light period. Throughout the treatment 
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period, all rats were fed an AIN-93G diet (Research Diets Inc., New Brunswick, NJ, 
USA), modified to contain 60% energy from fat (lard:sunflower oil, 96:4 weight/weight; 
purchased locally) (Table 2-1). Body weight and food intake were recorded daily. Daily 
food intake was calculated by subtracting the total food plus dish weight from that of the 
previous day. At the end of the study, all animals were fasted overnight and anaesthetized 
using Isoflurane (Abraxis BioScience, Richmond Hill, ON, Canada). Blood samples were 
collected via left ventricular cardiac puncture, placed on ice, and allowed to clot. After 
centrifugation at 2,500 g at 4ºC for 15 minutes, serum was collected, aliquoted, and 
stored at -80°C until analysis of each biomarker was conducted. Testicular, perirenal, and 
visceral fat depots were excised and rinsed briefly in 1 X phosphate buffered saline (PBS; 
Sigma). The depots were then weighed, recorded, and the total body fat mass of the 3 
portions was calculated. The animal use and experimental protocols were approved by 
the Joint Animal Care and Research Ethics Committee of the National Research Council 
Canada and the University of Prince Edward Island. The study was conducted in 
accordance with the guidelines of the Canadian Council on Animal Care. 
 
 
 
 
 
 
Table 2-1: AIN-93G diet composition.  
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*Modified to contain 60% energy from fat (lard:sunflower oil; 96:4 w/w). 
̆
Composition of mineral and vitamin mixes are presented in APPENDIX A. 
  
 
2.3.2. Preparation and dose determination of LWD H pill 
 
Ingredient 
 
Amount (g) 
 
 
% of diet (g) 
 
Casein 
 
266 
 
19.73 
 
Corn starch 
 
159 
 
11.79 
 
Sucrose 
 
72 
 
5.34 
 
Fat* 
 
348 
 
25.81 
 
Lard (96% of Fat) 
 
334 
 
24.77 
 
Sunflower oil (4% of Fat) 
 
14 
 
1.04 
 
Cellulose 
 
66 
 
4.90 
 
DL-methionine 
 
4 
 
0.30 
 
Mineral mix
̆"
 
 
46 
 
3.41 
 
Vitamin mix
̆
  
 
13 
 
0.96 
 
Choline bitartrate 
 
3 
 
0.22 
 
Butylated hydroxytoluene 
 
0.3 
 
0.022 
 
Cholesterol 
 
20 
 
1.48 
 
Cholic acid  
 
Total  
 
 
3 
 
1348.3 
 
0.22 
 
100 
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 The LWDH concentrated pills used in the present study were manufactured by 
Henan Wanxi Pharmaceuticals Ltd. Co. (Nanyang, Henan, China) using the 6 previously 
described Chinese herbs at a composition of 160 g RRP, 80 g RD, 80 g FC, 60 g CM, 60 
g RA, and 60 g Poria. To ensure homogeneity, the pills were produced in accordance 
with the China Pharmacopoeia standard of quality control (Fu et al. 2009). Following 
extraction with 95% ethanol, the residue of CM was mixed with all RRP, RA, and Poria, 
and part of FC (27 g), followed by extraction with hot water (twice, 2 hours each). The 
water extract was then concentrated to form a paste, followed by mixing with powdered       
RD, FC (53 g), and the ethanol extract of CM to form the final product. Based on the 
recommended daily dosage of 24 pills (approximately 4.5 g/day) in humans and the 
previously reported dosage of 2.4 g/kg/day in rats (Xue et al. 2005), 3 dosages of 500, 
1500, and 3500 mg/kg BW were chosen for the present study. The daily stomach gavage 
capacity of the rats used in the present study was determined to be approximately 6 mL 
(University Veterinarian, personal communication). Thus, daily treatments were prepared 
in a vehicle volume of 6 mL, administered twice-daily (approximately 3 mL per gavage 
session), and adjusted based on daily body weight recordings.  
 
2.3.3. Measurement of serum lipids 
 Lipid levels in the serum, including total cholesterol (T-C), TG, and HDL-
cholesterol (HDL-C) were measured in duplicate using a TC Matrix Biochemistry 
Analyzer (Teco Diagnostics, Anaheim, CA, USA) and supplied reagents. Non-HDL-C 
levels were calculated by subtracting HDL-C from T-C, as previously reported (Wang et 
al. 2010). 
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2.3.4. Measurement of serum free fatty acids 
 Serum FFA levels were measured in duplicate using commercial kits (BioVision 
Research Products, Mountain View, CA, USA) and in accordance with the kit 
instructions. Standards were prepared at a series of concentrations and run in parallel with 
the samples. The levels of FFA in the samples were calculated in reference to the 
corresponding standard curves and expressed as mmol/L.  
 
2.3.5. Measurement of serum leptin and insulin 
 Serum leptin and insulin levels were measured in duplicate using commercial 
enzyme-linmgf"koowpquqtdgpv"cuuc{"*GNKUC+"mkvu"*Et{uvcn"Ejgo"Kpe0."FqypgtÓu"Itqxg."
IL, USA) and in accordance with the kit instructions. Standards were prepared at a series 
of concentrations and run in parallel with the samples. The leptin and insulin levels in the 
samples were calculated in reference to the corresponding standard curves and expressed 
as ng/mL.  
 
 
2.3.6. Measurement of serum liver enzymes 
 Liver enzyme levels in the serum, including AST, ALT, ALP, and GGT were 
measured in duplicate using enzymatic methods on a TC Matrix Biochemistry Analyzer 
(Teco Diagnostics) and supplied reagents. Levels are presented as units/L (U/L).  
 
2.3.7. Statistical analyses 
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 Data analyses were performed by one-way ANOVA using SAS 9.2 statistical 
software (SAS Institute, Cary, NC, USA). Body weight and accumulative food intake 
were calculated weekly and analyzed using ANOVA with repeated measures. Differences 
between treatment means were determined by pair-wise comparisons using the least 
squares means test, with P < 0.05 indicating statistical significance. Results are presented 
as mean values with their standard errors. 
 
2.4. Results 
2.4.1. E ffect of LWD H pill on body weight in obese rats 
 Throughout the 9 week treatment period, rats in the T1C treatment group had 
lower body weights, compared to the obesity control OP rats (Figure 2-1). This effect 
reached statistical significance in weeks 6, 7, 8, and 9 (P = 0.03, 0.02, 0.01, and 0.01, 
respectively). This was further highlighted by a total body weight reduction of 8% 
compared to the OP rats, beginning at week 8, and persisting until the end of the study. 
Under the current experimental conditions, the T1B and T1C treatments did not elicit 
significant body weight-lowering effects.  
 
2.4.2. E ffect of LWD H pill on body fat composition in obese rats 
 To determine the effect of LWDH on body fat composition, testicular, perirenal, 
and visceral fat depots were excised and weighed at the time of sacrifice. After the 9 
week treatment period, rats in the T1C treatment group showed significantly less fat mass 
in the testicular, perirenal, and visceral regions (P = 0.01, 0.04, and 0.04, respectively),  
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 F igure 2-1: Effect of LWDH pill on body weight in obese rats. OR: obese-
 resistant normal control; OP: obese-prone positive control; T1A, T1B, and T1C 
 represent the 3 OP groups treated twice a day by oral gavage with total daily 
 doses of 500, 1500, or 3500 mg/kg BW LWDH suspended in water, respectively. 
 All animals were fed a high-fat diet (AIN-93G diet modified to contain 60% 
 energy from fat). Data were analyzed by one-way ANOVA with repeated 
 measures. Differences between treatment means were determined by pair-wise 
 comparisons using the least squares means test, with P < 0.05 indicating statistical 
 significance. Data are expressed as mean values with their standard errors (n = 
 12). 
*
Mean values were significantly different from OP control. 
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 F igure 2-2: Effect of LWDH pill on body fat composition in obese rats. OR: 
 obese-resistant normal control; OP: obese-prone positive control; T1A, T1B, and 
 T1C represent the 3 OP groups treated twice a day by oral gavage with total daily 
 doses of 500, 1500, or 3500 mg/kg BW LWDH suspended in water, respectively. 
 All animals were fed a high-fat diet (AIN-93G diet modified to contain 60% 
 energy from fat). Data were analyzed by one-way ANOVA. Differences between 
 treatment means were determined by pair-wise comparisons using the least 
 squares means test, with P < 0.05 indicating statistical significance. Data are 
 expressed as mean values with their standard errors (n = 12). 
*
Mean values were 
 significantly different from OP control.  
 
 
 
 
compared to the OP control rats (Figure 2-2). This observation was also noted in the total 
fat mass of the 3 regions (P = 0.006). 
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2.4.3. E ffect of LWD H pill on food intake in obese rats 
 The effect of LWDH on weekly food intake is presented in Table 2-2. During the 
first week of treatment, food intake was not affected.  During weeks 1 through 9, rats in 
the T1C treatment group had reduced food intake (P = 0.007, 0.0006, 0.002, 0.02, 0.0005, 
0.0003, 0.02, 0.004, and 0.04, respectively), compared to the OP controls. Rats in the 
T1B treatment group had significantly reduced food intake during weeks 2 and 3 (P = 
0.01 and 0.03, respectively), compared to the OP control. The T1A treatment did not 
show any significant effect. Feed efficiency data, calculated as weekly food intake 
divided by weekly weight gain, are presented in APPENDIX B.  
 
2.4.4. E ffect of LWD H pill on serum lipids in obese rats 
 At the end of the study, serum T-C levels in the T1C treatment group were 
reduced by 11% compared to the OP control but did not reach statistical significance (P = 
0.13) due to large variations observed within the group (Figure 2-3). Serum TG levels in 
the T1C treatment group were significantly reduced by 28% (P = 0.01), compared to the 
OP control.  The serum levels of HDL-C and non-HDL-C in each of the LWDH 
treatment groups did not differ when compared to the OP control. 
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Table 2-2: Effect of LWDH pill on weekly food intake in obese rats"! OR: obese-resistant normal control; OP: obese-prone positive 
control; T1A, T1B, and T1C represent the 3 OP groups treated twice a day by oral gavage with total daily doses of 500, 1500, or 3500 
mg/kg BW LWDH suspended in water, respectively.  
 
    Control G roups                   L W D H-treated G roups 
             O R      OP    T1A       T1B                      T1C 
   
Week 0 (g)         13.88 ± 0.79         14.57 ± 0.62      15.42 ± 0.62         15.39 ± 0.44         15.17 ± 0.40 
Week 1 (g)         14.43 ± 0.61         15.34 ± 1.88      15.13 ± 0.36         14.14 ± 0.35         13.08 ± 0.61* 
Week 2 (g)         12.91 ± 0.63         14.41 ± 0.55      15.07 ± 0.44         12.55 ± 0.54*       11.92 ± 0.52* 
Week 3 (g)         13.35 ± 0.71         15.68 ± 0.89      15.03 ± 0.51         13.68 ± 0.62*       13.11 ± 0.36*  
Week 4 (g)    13.67 ± 0.49         17.07 ± 0.38      16.31 ± 0.55         15.11 ± 0.89         15.93 ± 0.54* 
Week 5 (g)    14.39 ± 0.64         14.36 ± 0.64      14.31 ± 0.73         13.75 ± 0.45         13.40 ± 0.42* 
Week 6 (g)    14.76 ± 0.65         15.81 ± 0.78      15.78 ± 0.96         14.68 ± 0.85         13.58 ± 0.51* 
Week 7 (g)    12.46 ± 0.86         14.16 ± 0.90      13.59 ± 0.52         13.14 ± 0.51         12.29 ± 0.51* 
Week 8 (g)    12.86 ± 1.02         13.68 ± 0.65      14.48 ± 0.64         13.12 ± 0.76         13.25 ± 0.63* 
Week 9 (g)         12.96 ± 0.84         14.42 ± 0.73      14.15 ± 0.58         15.10 ± 0.77         13.72 ± 0.65*  
 
Data were analyzed by one-way ANOVA with repeated measures. Differences between treatment means were determined by pair-
wise comparisons using the least squares means test, with P < 0.05 indicating statistical significance. Data are expressed as mean 
values with their standard errors (n = 12). 
*
Mean values were significantly different from OP control.  
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 F igure 2-3: Effect of LWDH pill on serum lipids in obese rats. OR: obese-
 resistant normal control; OP: obese-prone positive control; T1A, T1B, and T1C 
 represent the 3 OP groups treated twice a day by oral gavage with total daily 
 doses of 500, 1500, or 3500 mg/kg BW LWDH suspended in water, respectively. 
 All animals were fed a high-fat diet (AIN-93G diet modified to contain 60% 
 energy from fat). Data were analyzed by one-way ANOVA. Differences between 
 treatment means were determined by pair-wise comparisons using the least 
 squares means test, with P < 0.05 indicating statistical significance. Data are 
 expressed as mean values with their standard errors (n = 12). 
*
Mean values were 
 significantly different from OP control.  
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2.4.5. E ffect of LWD H pill on serum F F A in obese rats 
 Compared to the OP control, rats in the T1C treatment group had significantly 
lower (P = 0.04) FFA levels (Figure 2-4). In addition, serum FFA levels in the T1B 
treatment group were reduced by 21% compared to the OP control, but did not reach 
statistical significance (P = 0.09).  
 
 
2.4.6. E ffect of LWD H pill on serum leptin and insulin in obese rats 
 Serum levels of leptin and insulin were measured at the end of the treatment 
period and are presented in Figure 2-5. Rats in both the T1B and T1C treatment groups 
had significantly lower serum leptin (P = 0.03 and 0.02, respectively) and insulin (P = 
0.03 and 0.02, respectively) levels, compared to the OP control. The T1A treatment did 
not show any effect.  
 
 
2.4.7. E ffect of LWD H pill on serum liver enzymes in obese rats 
 To investigate the safety of the LWDH pill in the present study, serum levels of a 
suite of liver enzymes, including AST, ALT, ALP, and GGT were measured. The results 
indicated that none of the 3 LWDH doses altered the serum levels of AST, ALT, or GGT 
(Table 2-3). Notably, serum ALP levels were significantly reduced (P = 0.02) in the T1C 
treatment group, compared to the OP control. 
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 F igure 2-4: Effect of LWDH pill on serum free fatty acids in obese rats. OR: 
 obese-resistant normal control; OP: obese-prone positive control; T1A, T1B, and 
 T1C represent the 3 OP groups treated twice a day by oral gavage with total daily 
 doses of 500, 1500, or 3500 mg/kg BW LWDH suspended in water, respectively. 
 All animals were fed a high-fat diet (AIN-93G diet modified to contain 60% 
 energy from fat). Data were analyzed by one-way ANOVA. Differences between 
 treatment means were determined by pair-wise comparisons using the least 
 squares means test, with P < 0.05 indicating statistical significance. Data are  
 expressed as mean values with their standard errors  (n = 12). 
*
Mean values were 
 significantly different from OP control.  
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 F igure 2-5: Effect of LWDH pill on serum leptin and insulin in obese rats. OR: 
 obese-resistant normal control; OP: obese-prone positive control; T1A, T1B, and 
 T1C represent the 3 OP groups treated twice a day by oral gavage with total daily 
 doses of 500, 1500, or 3500 mg/kg BW LWDH suspended in water, respectively. 
 All animals were fed a high-fat diet (AIN-93G diet modified to contain 60% 
 energy from fat). Data were analyzed by one-way ANOVA. Differences between 
 treatment means were determined by pair-wise comparisons using the least 
 squares means test, with P < 0.05 indicating statistical significance. Data are 
 expressed as mean values with their standard errors  (n = 12). 
*
Mean values were 
 significantly different from OP control. 
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Table 2-3: Effect of LWDH pill on serum liver enzyme profile in obese rats. OR: obese-resistant normal control; OP: obese-prone 
positive control; T1A, T1B, and T1C represent the 3 OP groups treated twice a day by oral gavage with total daily doses of 500, 1500, 
or 3500 mg/kg BW LWDH suspended in water, respectively. U/L: units/L. All animals were fed a high-fat diet (AIN-93G diet 
modified to contain 60% energy from fat). 
 
 
 
 
Control G roups                   L W D H-treated G roups 
   O R         OP   T1A             T1B          T1C 
 
AST (U/L) 197.54 ± 25.14         178.79 ± 9.67         180.46 ± 12.09        187.25 ± 13.53         199.46 ± 12.77 
ALT (U/L)   38.00 ± 1.83             46.04 ± 1.95         44.88 ± 1.51            41.88 ± 1.16       44.45 ± 2.06 
ALP (U/L) 168.21 ± 13.15         295.75 ± 1.69       269.38 ± 6.16           271.29 ± 15.58         252.63 ± 11.68* 
GGT (U/L)     8.71 ± 0.14              9.12 ± 0.25           8.83 ± 0.33          9.25 ± 0.23         8.77 ± 0.42 
 
 
Data were analyzed by one-way ANOVA. Differences between treatment means were determined by pair-wise comparisons using the 
least squares means test, with P < 0.05 indicating statistical significance. Data are expressed as mean values with their standard errors 
(n = 12). 
*
Mean were values significantly different from OP control.  
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2.5. Discussion and conclusions 
 The results of the present study have highlighted the potential anti-obesity 
efficacy and safety of the herbal formula, LWDH. When rats were treated with the high 
dose of LWDH, body weights were lowered significantly after 6 weeks of treatment and 
this effect persisted throughout the remainder of the treatment period. In line with the  
observed body weight reductions, testicular, perirenal, and visceral fat depots were also 
significantly lowered, demonstrating the beneficial effects of LWDH on body fat mass.  
 Overweight and obesity continue to grow as new threats to the general quality of 
human life and even small increases in weight have been documented to confer a 
significant negative impact on overall public health (Stein and Colditz 2004). 
Accumulating evidence, however, suggests that even a modest reduction in body weight 
of as little as 5-10% is sufficient to improve, or even abolish, several obesity-related 
complications (Goldstein 1992; Renehan et al. 2008). In addition to reducing body weight 
and improving body fat composition, high dose LWDH treatment also significantly 
reduced serum TG and FFA levels. Furthermore, both the medium and high doses of 
LWDH lowered serum leptin and insulin levels in a significant and dose-dependent 
manner. These parameters are all highly related to obesity and a reduction in any one is, 
in turn, beneficial to weight control and the mitigation of obesity-related complications 
(Boden 1998; Gao et al. 2007; Yuan et al. 2007). 
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 In the present study, LWDH reduced body weight in obese rats by over 8% after 6 
weeks of treatment when provided at a high dose of 3500 mg/kg/day. A similar and dose-
dependent reduction was observed in regard to food intake, suggesting that the observed 
body weight reductions following LWDH treatment might, at least in part, be a result of 
decreased energy consumption. As such, Chapter 4 of this thesis will highlight 
investigations into appetite regulation as a potential body weight-lowering mechanism of 
action of the product. 
 
! A partially-refined concentrated pill form of LWDH was administered by oral 
gavage in the present study. In addition to its major bioactive components (Xie et al. 
2008), the product has been reported to contain a high level of saccharides (Sangha et al. 
2012), with very little to no bioactivity. Thus, the doses administered in the present study 
may appear to be higher than expected. The high dose LWDH treatment in the present 
study was, however, similar to that reported in a diabetes study in rats (Xue et al. 2005) 
and higher than the human dosage reported for general health promotion (Hu et al. 2005). 
The optimal dosage for weight management in humans has yet to be documented. The 
doses of LWDH used in the present study have potential to be significantly reduced when 
administered in the form of an extract or fraction and following dosage optimization. In 
addition, with respect to translation into the potential for anti-obesity use in humans, 
twice-daily (BID) oral dosing regimens have been shown to be equal (Insull et al. 1994), 
or superior (Ross et al. 2001), to once-daily regimes in terms of efficacy and safety.  
 
 Hyperlipidemia and increased circulating FFA levels are generally associated 
with obesity (Boden 2008). Furthermore, increased FFA levels in obesity are well 
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documented to be associated with the onset of insulin resistance (Boden 1997; Kahn et al. 
2006), making them a likely culprit in the development of the most prevalent obesity-
associated co-morbidity, T2DM (Wilding 2007). Metabolically, circulating FFA and TG 
are interrelated and their blood levels change in proportion to one another (Cusi 2010). In 
the present study, the high LWDH dose treatment significantly lowered blood TG and 
FFA levels, in line with the observed body weight reductions. Blood T-C levels were not  
significantly affected. It is well known that in addition to elevated circulating T-C levels, 
increased blood TG levels are an independent risk factor for the development of CVD 
(Yuan et al. 2007), the leading cause of mortality in developed countries (Kung et al. 
2008). In the fasted state, circulating FFA arise primarily from within the adipose tissue, 
as a result of the hydrolysis of TG (Karpe et al. 2011). Following ingestion of a high-fat 
meal, circulating FFA are further produced, as a result of TG hydrolysis by adipose tissue 
lipoprotein lipase (Karpe et al. 2011). In addition, when FFA in the adipose tissue are 
taken up in adipocytes for storage, a portion escapes and joins the circulating FFA pool 
(Evans et al. 2002). This latter process, referred to as spillover, may in fact constitute 
upwards of fifty percent of the total circulating FFA pool in the postprandial period 
(McQuaid et al. 2011). Elevated circulating levels of TG and FFA as a result of increased 
adipose tissue mass and fat mobilization are commonly observed in obese individuals 
(Kahn et al. 2006; Karpe et al. 2011). The process of fatty acid mobilization from adipose 
tissue is normally suppressed by insulin (Karpe et al. 2011). In addition to its essential 
role in the control of body weight through suppression of food intake and stimulation of 
fatty acid oxidation, leptin enhances insulin sensitivity (Hedbacker et al. 2010; Koch et al. 
2010). Thus, insulin and leptin play complementary roles in the regulation of nutrient 
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consumption, uptake, and oxidation (Morrison et al. 2009). Obesity is associated with 
resistance to the actions of both insulin and leptin , which can result in further elevations 
in circulating FFA (McLaughlin et al. 2001; Koch et al. 2010). For instance, in obesity, it 
has been reported that the mobilization of FFA from adipose tissue itself becomes insulin 
resistant, further increasing lipolysis (Karpe et al. 2011).An improvement in leptin and/or 
insulin sensitivity has been shown to stimulate fatty acid oxidation, correspondingly 
resulting in a reduction in circulating TG and FFA levels (Gil-Campos et al. 2004). The 
reductions in circulating TG and FFA levels observed in the present study might be a 
consequence of the observed body weight-lowering effects of LWDH, resulting in 
improved leptin and insulin sensitivity and thus fatty acid oxidation, in addition to 
reduced fat mobilization from adipose tissue and a consequential decrease in circulating 
FFA levels following weight loss. As such, Chapter 5 of this thesis will highlight 
investigations into increased fatty acid oxidation/decreased fatty acid synthesis as a 
potential body weight-lowering mechanism of action of the product. 
 
 Energy homeostasis requires a highly integrated control system involving neural, 
as well as both long- and short-term hormonal components (Stanley et al. 2005). Leptin 
and insulin, which are secreted in direct proportion to adipose tissue mass (Gil-Campos et 
al. 2004), have long been known to act as long-term signals of overall energy 
homeostasis (Kaiyala et al. 1995). In the obese state, an increase in adipose tissue mass 
leads to increased secretion of leptin and insulin into the circulation (Matsubara et al. 
2002), often resulting in the development of hyperleptinemia and hyperinsulinemia, 
respectively (Fried et al. 2000; Matyskova et al. 2010). Normally, these hormones can 
relay information about peripheral fat stores to the brain and effectively modulate food 
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intake and energy expenditure (Frederich et al. 1995; Halaas et al. 1995) through 
inhibition and activation of anabolic and catabolic pathways, respectively (Fried et al. 
2000). In the obese state, however, decreased sensitivity to the anti-obesity effects of 
these regulatory hormones often develops (Carlsson et al. 1997; Schwartz and Niswender 
2004). In the present study, both the medium and high LWDH dose treatments 
significantly lowered serum leptin and insulin levels. The reduced levels of both 
hormones in the serum could be attributed to the observed body weight-lowering effect of 
LWDH, or by direct effects of LWDH on leptin and insulin sensitivity, independent of 
weight changes.  
 
 As LWDH is a herbal formula, it was also of interest to determine if any toxic 
effects may be linked to the administration of this specific product. Rats were monitored 
on a daily basis and no abnormal behaviours or activities were noted throughout the 
entire study period. In addition, liver function tests which are used routinely to detect the 
potential toxicity of a product (Nannipieri et al. 2005) were conducted. Analysis of 4 liver 
enzymes which are commonly used in the clinical toxicological testing did not reveal any 
toxic effects of LWDH under the current experimental conditions. Furthermore, serum 
levels of the analyzed liver enzymes have been reported as being indicative of a tendency 
towards the development of obesity (Messier et al. 2010). Decreased levels of these 
enzymes in obese individuals can reflect improved insulin sensitivity and reduced fat 
accumulation in the liver (Messier et al. 2010), whereas elevated levels reportedly 
represent an increased risk for the development of T2DM and CVD (Hanley et al. 2005; 
Thamer et al. 2005). The observed reductions in serum ALP levels in response to the high 
dose LWDH treatment might be indicative of improved insulin sensitivity, in line with 
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the reduction in blood insulin levels, in addition to the potential improvement of liver 
function following weight loss.  
 
 In conclusion, the present study has demonstrated the body weight-lowering 
efficacy of LWDH in obese rats, without any toxic effects observed during the treatment 
period by conducting liver function testing at the study's conclusion. Moreover, LWDH 
improved serum lipid profiles, including FFA levels, and lowered serum levels of leptin 
and insulin, which may be indicative of an improvement in leptin and insulin sensitivity. 
The results presented herein have shed light on the potential for the development of 
LWDH as a natural product for the management of obesity and several of its related 
complications. These findings could be related to the regulation of LWDH on appetite 
and/or fatty acid oxidation/synthesis, which have been further explored and reported in 
the subsequent chapters of this thesis. 
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3.1. Abstract 
 The present study was conducted to evaluate the efficacy of Liuwei Dihuang 
(LWDH) on obesity-associated biomarkers of inflammation, oxidative stress, and 
adiponectin production in obese rats, and to assess the suitability of the obese-prone CD 
(OP-CD) rat model for the study of these parameters. Following a 2 week acclimation 
period with free access to regular rodent chow and water, OP-CD rats were fed an AIN-
93G diet modified to contain 60% energy from fat. Treatment occurred twice-daily by 
gavage feeding with doses of 500, 1500, or 3500 mg/kg body weight (BW) LWDH 
suspended in water (n = 12 rats per group). Twelve obese-resistant CD (OR-CD) rats 
served as the normal control. Biomarkers of inflammation, oxidative stress, and levels of 
the adipokine adiponectin were measured post-sacrifice. After 9 weeks of treatment, 
LWDH lowered serum C-reactive protein (CRP) and tumour necrosis factor-g" *VPH-g+"
levels. Serum interleukin-6 (IL-6) levels were not affected. The activity of superoxide 
dismutase (SOD) in the liver was increased by all 3 doses of LWDH, while the levels of 
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reduced (GSH) and oxidized (GSSG) glutathione (and their ratio), and thiobarbituric acid 
reactive substances (TBARS) were unchanged. Serum adiponectin levels were increased 
by both the 500 and 1500 mg/kg BW LWDH doses. The results of the present study show, 
for the first time, the anti-inflammatory, anti-oxidative stress, and adiponectin-
ameliorating efficacy of LWDH in obese-prone rats.  
 
3.2. Introduction!
 Evidence accumulated over the last number of decades has demonstrated that 
obesity is strongly associated with chronic inflammation and systemic oxidative stress 
(Dandona et al. 2004). For example, the pro-inflammatory cytokine, tumour necrosis 
factor-g" (TNF-g), has long been known to be constitutively expressed in adipocytes 
(Hotamisligil et al. 1993) and to be elevated in both the adipose tissue and blood of obese 
humans and some animal models of obesity (Kern et al. 1995; Dandona et al. 1998). The 
chronic inflammatory biomarker, C-reactive protein (CRP), and the acute phase pro-
inflammatory cytokine, interleukin-6 (IL-6), have also been reported to be increased in 
obesity (Mohamed-Ali et al. 1997; Yudkin et al. 1999). In the obese state, adipose tissue 
has been reported to become a major source of circulating reactive oxygen species (ROS) 
(Furukawa et al. 2004), which at chronically high levels, can have deleterious effects on 
their targets, such as lipids, proteins, and DNA (Valko et al. 2007). In addition, increased 
circulating levels of ROS have been linked to the development of insulin resistance 
(Urakawa et al. 2003). Adipose tissue of obese subjects has also been shown to have 
suppressed activity of the antioxidant enzyme superoxide dismutase (SOD), decreased 
levels of glutathione (GSH), and increased levels of thiobarbituric acid reactive 
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substances (TBARS), a marker of lipid peroxidation and oxidative damage (Furukawa et 
al. 2004). In addition, oxidative stress and elevated circulating ROS from adipose tissue 
are involved in the dysregulated production of various adipokines, including the insulin-
sensitizer adiponectin (Yamauchi et al. 2001). Collectively, increased levels of systemic 
biomarkers of inflammation and oxidative stress, along with dysregulated adiponectin 
production, represent some of the underlying causes of obesity and/or its associated co-
morbidities, especially insulin resistance. 
 
! At the forefront of complementary and alternative treatment strategies against the 
ever increasing health threats of obesity and its associated co-morbidities, is traditional 
Chinese medicine (TCM) and the combination of different medicinal herbs into a single 
therapeutic formula (Day 2007; Yin et al. 2008). Such treatment strategies have been 
used as an integrative approach along with Western medicine, not only in China and 
other Asian countries, but increasingly more often in North America and Europe (Yin et 
al. 2008). Liuwei Dihuang (LWDH) is a classic Chinese herbal formula that has 
traditionally been used to restore functional insufficiency of the kidney, liver, and spleen 
(Ye et al. 2009). It is comprised of 6 Chinese herbs, including Radix Rehmanniae 
Praeparata (RRP; prepared root of Rehmannial glutiosa), Rhizoma Dioscoreae (RD; 
rhizome of Dioscorea opposita), Fructus Corni (FC; fruit of Cornus officinalis), Cortex 
Moutan (CM; root bark of Paeonia suffruticosa), Rhizoma Alismatis (RA; rhizome of 
Alisma plantago-aquatica), and Poria (scleorotia of Poria cocos) (Xie et al. 2008). This 
formula has recently been reported to have potential as a therapeutic natural product 
against obesity and to improve insulin sensitivity (Perry et al. 2012). In the present study, 
we report for the first time, the effect of LWDH on obesity-associated biomarkers of 
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inflammation and oxidative stress, and adiponectin production in obese-prone rats, and 
the possible causal link between obesity and associated insulin resistance.  
 
 
3.3. Materials and methods 
3.3.1. Animals and diet 
 The animals and experimental diet used in the present study were as previously 
reported in Chapter 2. Sixty male rats were purchased from Charles River Laboratories 
(Montréal, QC, Canada). Twelve of these animals were of the obesity-resistant strain 
(OR-CD) and 48 were of the obesity-prone strain (OP-CD). All animals were housed 
individually in cages in a temperature-controlled room with a 12 hour light:dark cycle 
and acclimated for 2 weeks with free access to regular rodent chow and water. The OR-
CD rats served as the normal control group (OR) and the OP-CD rats were randomly 
divided into 4 groups (n = 12 each) prior to the commencement of treatment. 
Randomization of the OP-CD rats was accomplished by ordering the rats based on initial 
body weight from lightest to heaviest and assigning rats sequentially to 1 of 4 groups. 
These groups included an obesity control (OP) and  3 treatments (T1A, T1B, and T1C). 
The T1A, T1B, and T1C groups were treated for 9 weeks by twice-daily oral gavage with 
total daily dosages of 500, 1500, or 3500 mg/kg BW of the concentrated LWDH pills 
(Wanxi Pharmaceuticals Co. Ltd., Henan, China) suspended in water, respectively. The 
OR and OP control groups received water via oral gavage as the control vehicle. 
Treatment administration was performed during the light cycle; once in the morning and 
again 6 hours later. Although rats are generally more active and thus exert more energy 
during the dark period (Zucker 1971), unpublished data from the Wang lab shows that 
LWDH enhances energy expenditure at a larger magnitude during the light period. 
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Throughout the treatment period, all rats were fed an AIN-93G diet (Research Diets Inc., 
New Brunswick, NJ, USA), modified to contain 60% energy from fat (lard:sunflower oil, 
96:4 w/w). Body weight and food intake were recorded on a daily basis. Daily food 
intake was calculated by subtracting the total food plus dish weight from that of the 
previous day. At the end of the study, all animals were anaesthetized using Isoflurane 
(Abraxis BioScience, Richmond Hill, ON, Canada) following an overnight fast. Blood 
samples were collected via left ventricular cardiac puncture, placed on ice, and allowed to 
clot. After centrifugation at 2,500 g at 4ºC for 15 minutes, serum was collected, aliquoted, 
and stored at -80°C until analysis of each biomarker was conducted. Liver tissue samples 
were excised and rinsed briefly in 1 X phosphate buffered saline (PBS; Sigma). Samples 
were then weighed, recorded, transferred to pre-labelled aluminum foil packets, and 
placed in liquid nitrogen for short-term storage. Post-sacrifice storage occurred at -80°C 
until analysis of each biomarker. The animal use and experimental protocols were 
approved by the Joint Animal Care and Research Ethics Committee of the National 
Research Council Canada and the University of Prince Edward Island. The study was 
conducted in accordance with the guidelines of the Canadian Council on Animal Care. 
 
3.3.2. Preparation and dose determination of LWD H pill  
 The LWDH concentrated pills used in the present study were manufactured by 
Henan Wanxi Pharmaceuticals Ltd. Co. (Nanyang, Henan, China) using the 6 previously 
described Chinese herbs at a composition of 160 g RRP, 80 g RD, 80 g FC, 60 g CM, 60 
g RA, and 60 g Poria. To ensure homogeneity, the pills were produced in accordance 
with the China Pharmacopoeia standard of quality control (Fu et al. 2009). Briefly, 
following extraction with 95% ethanol, the residue of CM was mixed with all RRP, RA, 
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and Poria, and part of FC (27 g), followed by extraction with hot water (twice, 2 hours 
each). The water extract was then concentrated to form a paste, followed by mixing with 
powdered RD, FC (53 g), and the ethanol extract of CM to form the final product. Based 
on the recommended daily dosage of 24 pills (approximately 4.5 g/day) in humans and 
the previously reported dosage of 2.4 g/kg/day in rats (Xue et al. 2005), 3 dosages of 500, 
1500, and 3500 mg/kg BW were chosen for the present study. The daily stomach gavage 
capacity of the rats used in the present study was determined to be approximately 6 mL 
(University Veterinarian, personal communication). Thus, daily treatments were prepared 
in a vehicle volume of 6 mL, administered twice-daily (approximately 3 mL per gavage 
session), and adjusted based on daily body weight recordings.  
 
3.3.3. Measurement of serum C-reactive protein (CRP) 
 Serum C-reactive protein (CRP) was measured in duplicate using a commercial 
enzyme-linked immunosorbent assay (ELISA) kit (Kamiya Biomedical Company, Seattle, 
WA, USA) in accordance with the kit instructions. Standards were prepared at a series of 
concentrations and run in parallel with the samples. The levels of CRP in the serum were 
calculated in reference to the corresponding standard curves and expressed as µg/mL. 
 
3.3.4. Measurement of serum tumour necrosis factor-g (TN F-g) 
 Serum tumour necrosis factor-g (TNF-g) was measured in duplicate using a 
commercial ELISA kit (Hycult Biotech Inc., Plymouth Meeting, PA, USA) in accordance 
with the kit instructions. Standards were prepared at a series of concentrations and run in 
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parallel with the samples. The levels of TNF-g in the serum were calculated in reference 
to the corresponding standard curves and expressed as pg/mL. 
 
3.3.5. Measurement of serum interleukin-6 (IL-6) 
 Serum interleukin-6 (IL-6) was measured in duplicate using a commercial ELISA 
kit (Bioscience, San Diego, CA, USA) in accordance with the kit instructions. Standards 
were prepared at a series of concentrations and run in parallel with the samples. The 
levels of IL-6 in the serum were calculated in reference to the corresponding standard 
curves and expressed as pg/mL. 
 
3.3.6. Measurement of liver superoxide dismutase (SOD) activity 
 The activity of superoxide dismutase (SOD) in the liver was measured in 
duplicate using a commercial kit (Cayman Chemical) in accordance with the kit 
instructions. Frozen liver tissue was weighed and 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) buffer (1:10; Sigma) was added. Following tissue 
homogenization using a PowerGen 125 homogenizer (Fisher Scientific, Ottawa, ON, 
Canada) and centrifugation at 10,000 g at 4ºC for 10 minutes, the supernatant was 
removed and stored at -80°C until the analyses were performed. Standards were prepared 
at a series of concentrations and run in parallel with the samples. The activity of SOD in 
the liver was calculated in reference to the corresponding standard curve and expressed as 
U/g tissue.  
 
3.3.7. Measurement of liver reduced (GSH) and oxidized (GSSG) glutathione 
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 The levels of reduced (GSH) and oxidized (GSSG) glutathione in the liver were 
measured in duplicate using commercial kits (Cayman Chemical) in accordance with the 
kit instructions. Frozen liver tissue was weighed and 2-(N-morpholino)ethanesulfonic 
acid (MES) buffer (1:10; Sigma) was added. Following tissue homogenization and 
centrifugation at 10,000 g at 4ºC for 10 minutes, the supernatant was removed and stored 
at -80°C until further analysis. Standards were prepared at a series of concentrations and 
run in parallel with the samples. The levels of GSH and GSSG in the liver were 
calculated in reference to the corresponding standard curves and expressed as µmol/g 
tissue. The reduced (GSH) to oxidized (GSSG) glutathione ratio was calculated as 
reported previously (Park et al. 2011). 
 
3.3.8. Measurement of liver thiobarbituric acid reactive substances (TBARS) 
 The level of thiobarbituric acid reactive substances (TBARS) in the liver were 
measured in duplicate using a commercial kit (Cayman Chemical, Ann Arbor, MI, USA) 
in accordance with the kit instructions. Frozen liver tissue was weighed and 
radioimmunioprecipitation assay (RIPA) buffer (1:100; Sigma) was added. Following 
tissue homogenization and centrifugation at 10,000 g at 4ºC for 10 minutes, the 
supernatant was removed and stored at -80°C until further analysis. Standards were 
prepared at a series of concentrations and run in parallel with the samples. The levels of 
TBARS in the liver were calculated in reference to the corresponding standard curves and 
expressed as nmol/g tissue. 
 
3.3.9. Measurement of serum adiponectin 
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 Serum adiponectin was measured in duplicate using a commercial ELISA kit 
(Millipore Corporation, MA, USA) in accordance with the kit instructions. Standards 
were prepared at a series of concentrations and run in parallel with the samples. Serum 
adiponectin levels were quantitated in reference to the corresponding standard curves and 
expressed as ng/mL. 
 
3.3.10. Statistical analyses   
 Data analyses were performed by one-way ANOVA using SAS 9.2 statistical 
software (SAS Institute, Cary, NC, USA). Differences between treatment means were 
determined by pair-wise comparisons using the least squares means test, with P < 0.05 
indicating statistical significance. Results are presented as mean values with their 
standard errors. 
 
3.4. Results  
3.4.1. E ffect of LWD H pill on serum CRP in obese rats 
 The effect of LWDH on serum CRP levels in obese rats was assessed after the 9 
week treatment period and is presented in Table 3-1. Serum CRP was significantly 
reduced in rats treated with the 500, 1500, and 3500 mg/kg BW LWDH doses (P = 0.04, 
0.005, and 0.0004, respectively), compared to the obese control. Furthermore, the 
reductions in CRP levels in response to LWDH treatment occurred in a dose-dependent 
manner (16.5, 25.6, and 34.3 %, respectively). 
 
3.4.2. E ffect of LWD H pill on serum TN F-g in obese rats 
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 The effect of LWDH on serum TNF-g levels in obese rats is presented in Table 3-
1. Compared to the obese control, serum levels of TNF-g"ygtg"ukipkhkecpvn{"tgfwegf"kp"
rats treated with LWDH doses of 500 (55.9 %), 1500 (40.7 %), and 3500 (39.7 %) mg/kg 
BW (P = 0.009, 0.01, and 0.03, respectively).  
 
3.4.3. E ffect of LWD H pill on serum IL-6 in obese rats 
 The effect of LWDH on serum IL-6 levels in obese rats is presented in Table 3-1. 
Rats treated with the doses of 500, 1500, and 3500 mg/kg BW LWDH had reduced serum 
IL-6 levels but these changes were not statistically significant. 
 
3.4.4. E ffect of LWD H pill on liver SOD activity in obese rats 
 The effect of LWDH on liver SOD activity in obese rats was assessed after the 9 
week treatment period and is presented in Table 3-2. The activity of SOD in the liver was 
significantly increased in rats treated with the LWDH doses of 500 (20.7 %), 1500 
(16.7 %), and 3500 (13.9 %) mg/kg BW, compared to the obese control (P = 0.005, 0.02, 
and 0.04, respectively).  
 
3.4.5. E ffect of LWD H pill on liver GSH and GSSG in obese rats 
 The effect of LWDH on liver GSH and GSSG levels is presented in Table 3-2. 
Compared to the obese control, liver levels of GSH and GSSG (or their ratio) were 
unaffected by any of the LWDH doses under the current experimental conditions. 
 
3.4.6. E ffect of LWD H pill on liver TBARS in obese rats 
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 Similar to the effect of LWDH on liver glutathione levels, liver levels of TBARS 
were unaffected by LWDH in the present study (Table 3-2). 
 
3.4.7. E ffect of LWD H pill on serum adiponectin in obese rats 
 The effect of LWDH on serum adiponetin levels in obese rats is presented in 
Figure 3-1. In response to treatment with the doses of 500 and 1500 mg/kg BW LWDH, 
serum adiponectin levels were significantly increased (P = 0.03 and 0.04, respectively), 
compared to the obese control. The serum adiponectin levels in rats treated with the 3500 
mg/kg BW LWDH dose did not differ from the control (P = 0.08).  
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 Table 3-1: Effect of LWDH pill on serum inflammatory biomarkers in obese rats. OR: obese-resistant rats; OP: obese-prone 
 rats; T1A, T1B, and T1C represent the 3 groups of OP rats treated by twice-daily oral gavage with total daily dosages of 500, 
 1500, or 3500 mg/kg BW of LWDH suspended in water, respectively. CRP: C-reactive protein; TNF-g<" vwoqwt" pgetquku"
 factor-g="KN-6: interleukin-6. 
!
!
!
!
!
 
 
 Data are expressed as mean values with their standard errors (n = 12). Mean values not sharing a common superscript letter are 
 significantly different (P < 0.05).
 
 OR OP T1A T1B T1C 
 
CRP (µg/mL) 186.7 ± 14.1
a
 166.7 ± 10.3
a 
139.2 ± 8.9
b 
124.1 ± 7.5
b 
109.6 ± 4.9
b 
TNF-g (pg/mL) 599.6 ± 89.4a 507.0 ± 69.8a 223.8 ± 29.8b 300.6 ± 81.2b 305.6 ± 40.2b 
IL-6 (pg/mL) 528.4 ± 36.6
a
 
 
444.4 ± 43.7
b
 423.2 ± 34.8
b
 410.9 ± 47.7
b
 360.4 ± 52.7
b
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 Table 3-2: Effect of LWDH pill on liver oxidative stress biomarkers in obese rats. OR: obese-resistant rats; OP: obese-prone 
 rats; T1A, T1B, and T1C represent the 3 groups of OP rats treated by twice-daily oral gavage with total daily dosages of 500, 
 1500, or 3500 mg/kg BW of LWDH suspended in water, respectively. SOD: superoxide dismutase; GSH: reduced glutathione; 
 GSSG: oxidized glutathione; GSH:GSSG: reduced:oxidized glutathione ratio; TBARS: thiobarbituric acid reactive substances. 
 
 
 
!
 
 
 
 
 
 
 
 
 Data are expressed as mean values with their standard errors (n = 12). Mean values not sharing a common superscript letter are 
 significantly different (P < 0.05). Liver weights between groups did not differ. 
 
 
 
OR 
 
OP T1A T1B T1C 
 
SOD (U/g tissue)       9347.1 ± 336.2
a
 7675.2 ± 355.1
b
 9262.4 ± 523.6
a
 8960.1 ± 259.4
a
 8745.3 ± 329.6
a
 
GSH (µmol/g tissue) 1.7 ± 0.1
a
 1.6 ± 0.1
a
 1.6 ± 0.1
a
 1.5 ± 0.04
a
 1.40 ± 0.08
a
 
GSSG (µmol/g tissue)   1.7 ± 0.1
a
 1.5 ± 0.09
a
 1.5 ± 0.1
a
 1.4 ± 0.04
a
 1.43 ± 0.08
a
 
GSH:GSSG  1.0 ± 0.05
a
 1.0 ± 0.01
a
 1.0 ± 0.006
a
 1.0 ± 0.03
a
 0.98 ± 0.01
a
 
TBARS (nmol/g tissue) 55.4 ± 2.5
a
 58.0 ± 3.2
a
 60.2 ± 2.7
a
 58.8 ± 2.9
a
 60.97 ± 2.1
a
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F igure 3-1: Effect of LWDH pill on serum adiponectin in obese rats. OR: obese-resistant 
rats; OP: obese-prone rats; T1A, T1B, and T1C represent the 3 groups of  OP rats treated 
by twice-daily oral gavage with total daily dosages of 500, 1500,  or 3500 mg/kg BW of 
LWDH suspended in water, respectively. Data are  expressed as mean values with their 
standard errors (n = 12). Mean values not sharing a common superscript letter are 
significantly different (P < 0.05).
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3.5. Discussion and conclusions  
 It is well known that obesity is associated with a state of chronic low-grade 
inflammation (O'Rourke 2009), which has been shown to impair insulin signalling and 
has provided a molecular link between inflammation and insulin resistance (Andersson et 
al. 2008; Fiorentino et al. 2010). The pro-inflammatory cytokine TNF-g is constitutively 
expressed in adipocytes and its expression has long been known to be upregulated in 
response to increased adiposity (Hotamisligil et al. 1993). As such, elevated circulating 
levels of TNF-g are often observed in obese humans and consistently in some obese 
animal models, including rats (Hotamisligil et al. 1993; Kern et al. 1995). Conversely, 
weight loss has been shown to lead to a reduction in circulating TNF-g levels (Kern et al. 
1995). Similar to TNF-g, circulating levels of the systemic inflammatory biomarkers, 
CRP and IL-6, are elevated in response to overweight and obesity (Mora and Pessin 
2002; Tsuriya et al. 2011). These inflammatory biomarkers have also been shown to be 
associated with the onset of insulin resistance (Pradhan et al. 2001; Lalli et al. 2008) and 
to decrease following weight loss (Dandona et al. 2004). In the present study, treatment 
with LWDH in obese rats resulted in significant reductions in circulating levels of CRP 
and TNF-g, but did not affect IL-6 levels. These observations are in line with the recently 
documented weight-lowering and insulin-sensitizing effects of LWDH in the same 
animal model (Perry et al. 2012) and may provide insight into the mechanisms of action 
of this herbal formula.  
 In addition to increased inflammation, oxidative stress is believed to be a possible 
culprit in the development of insulin resistance (Bloch-Damti and Bashan 2005), 
evidenced in part by reports of increased oxidative stress in insulin resistant humans 
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(Martinez-Hervas et al. 2008). In the obese state, adipose tissue is known to become a 
prominent source of circulating ROS (Furukawa et al. 2004). To protect against the 
potentially deleterious effects of ROS, cells are equipped with antioxidant systems, 
including SOD, which converts superoxide anions to hydrogen peroxide (H2O2) for rapid 
removal by detoxifying enzymes, such as glutathione peroxidase (GPx) (Feillet-Coudray 
et al. 2009). Likewise, GSH can provide reduced ROS for GPx-catalyzed H2O2 reductions 
(Feillet-Coudray et al. 2009). Often associated with increased adiposity is a suppression 
of SOD activity, resulting in a reduction in GSH levels and an increase in TBARS 
(Furukawa et al. 2004). Accordingly, reductions of adiposity are generally associated 
with an improvement in oxidative stress biomarkers and antioxidant defence systems 
(Heilbronn et al. 2006). In the present study, LWDH significantly increased liver SOD 
activity in obese rats. Despite observing a lack of effect on liver GSH, GSSG (or their 
ratio), or TBARS, similar effects have been reported in several tissues of high-fat diet-fed 
rats (Feillet-Coudray et al. 2009). Although not performed in the present study, analysis 
of GPx may be useful in future studies, in order to elucidate whether the LWDH-mediated 
increase in liver SOD activity was accompanied by further downstream ROS detoxifying 
effects. Determining the starting source of ROS production may also be useful in further 
assessing the effect of LWDH on oxidative stress biomarkers. For instance, elevated ROS 
production from accumulated fat has been shown to lead to increased systemic oxidative 
stress and to mediate the obesity-associated development of insulin resistance.(Furukawa 
et al. 2004). Increased activity of nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase, which catalyzes the reduction of oxygen to generate superoxide radicals (Feillet-
Coudray et al. 2009), is a major starting source of ROS (Valko et al. 2007) and its 
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expression has been shown to be increased in the adipose tissue of obese rodents 
(Furukawa et al. 2004). The present study was limited to the analysis of antioxidants 
(SOD and GSH) and oxidation products (TBARS) in the liver. Studies wherein analyses 
of SOD, GSH, TBARS, and other biomarkers were analyzed in multiple tissues, 
including blood, liver, muscle, and heart (Feillet-Coudray et al. 2009), have shown 
differential effects, depending on the tissue studied. Thus, in addition to the liver, the 
effect of LWDH on oxidative stress biomarkers may need to be evaluated in other tissues, 
such as various fat depots, particularly from the visceral region.  
 
 Obesity is known to be associated with dysregulated production of various 
adipokines (Furukawa et al. 2004), such as the insulin-sensitizer adiponectin (Yamauchi 
et al. 2001). It has been reported that adiponectin correlates inversely with adiposity, 
inflammation, oxidative stress, and insulin resistance (Arita et al. 1999; Furukawa et al. 
2004). Despite gaps in the full elucidation of the mechanism by which increased 
adiposity leads to dysregulated production of adipokines, a decrease in the circulating 
level of adiponectin has been linked to the development of obesity-associated insulin 
resistance (Furukawa et al. 2004). The increase in adiponectin levels in obese rats 
following LWDH treatment in the present study may, in part, be attributable to the noted 
improvements in oxidative stress and/or suppression of chronic inflammation. This 
observation may also help explain our recent report of the insulin-sensitizing effect of 
LWDH in the same animal model (Perry et al. 2012), as discussed in Chapter 2 of this 
thesis.  
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 In conclusion, the present study has demonstrated the beneficial effects of LWDH 
on biomarkers of inflammation and oxidative stress, and adiponectin production in obese 
rats. In addition, the present study has provided further evidence in support of the 
therapeutic potential of this herbal formula as a natural agent to prevent and/or treat 
insulin resistance.  
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C H APT E R 4: E F F I C A C Y O F L IU W E I DI H U A N G PI L L A ND E X T R A C T O N 
APPE T I T E R E G U L A T I O N IN VIVO A ND IN VITRO 
 
A version of this chapter has been published (as a review paper) with modification as: 
 
Rgtt{." D0." [0" Ycpi" *4234+0" ÐCrrgvkvg" tgiwncvkqp" cpf" ygkijv" eqpvtqn<" vjg" tqng" qh" iwv"
jqtoqpgu0Ñ"Nutr Diabetes 2(1): 1-7. 
 
4.1. Abstract 
 The present study investigated the appetite-regulating efficacy of Liuwei Dihuang 
(LWDH) as a potential body weight-lowering mechanism of action of the product. The 
herbal formula and its ethanol extract were tested on key components of the gut-brain 
axis in vivo and in vitro, respectively, by quantitative real-time polymerase chain reaction 
(qPCR). Ileal mRNA levels of peptide tyrosine-tyrosine (PYY) were unchanged and 
ghrelin mRNA levels were decreased in high dose LWDH-treated (3500 mg/kg BW; 
T1C) rats, compared to obese control (OP) rats. In the hypothalamus, neuropeptide Y 
(NPY) mRNA levels were unaffected in T1C rats, compared to OP rats. In CaCo-2 cells, 
representative of the gut, PYY mRNA levels were dose-dependently increased, reaching 
statistical significance in response to high concentration (100 µg/mL) LWDH ethanol 
extract treatment. Ghrelin mRNA levels were unchanged in the same cell line. In SH-
SY5Y cells, representative of the CNS, NPY mRNA levels were unchanged. The results 
show that despite significant reductions in food intake as highlighted in Chapter 2 of this 
thesis, LWDH or its ethanol extract did not affect key components of the gut-brain axis at 
the gene expression level under the current experimental conditions. Thus, appetite 
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regulation does not appear to be responsible for the body weight-lowering mechanism of 
action of LWDH or its ethanol extract.  
 
 
4.2. Introduction 
 The overwhelming increase in the prevalence of overweight and obesity in recent 
years has been associated with increased rates of morbidity and mortality, in addition to 
well documented personal, societal, and economic consequences (Hedley et al. 2004; 
Murphy and Bloom 2004). Even modest weight loss achieved through currently 
employed approaches can dramatically reduce the likelihood and severity of these 
consequences, yet bariatric surgery represents the only treatment offering sustainable 
weight loss results (Colquitt et al. 2009). Notably, post-bariatric surgery results have, in 
large part, been attributed to alterations in the physiology of circulating gut hormones and 
their appetite-regulating capabilities (Small and Bloom 2004). In tandem with the 
realization of the devastating global obesity epidemic and its associated co-morbidities in 
recent years, has been an increase in the recognition and understanding of the intricate 
interplay between gut hormones and the CNS (Woods and D'Alessio 2008), and the 
regulation of food intake and body weight through appetite modulation (Hameed et al. 
2009). Several of these circulating appetite modulators, including ghrelin, the only known 
orexigenic gut hormone (Tschop et al. 2001), and a suite of anorexigenic gut hormones, 
such as peptide tyrosine-tyrosine (PYY), have been shown to influence appetite, and 
ultimately, body weight control (Batterham et al. 2003).  
 The gastrointestinal (GI) tract is the largest endocrine organ in the body and is 
believed to play an important appetite-regulating role as a source of various regulatory 
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peptide hormones (Chaudhri et al. 2008; Hameed et al. 2009). Postprandial satiety is 
believed to be regulated by a sensory system that communicates between the gut and 
appetite-regulating centers in the brain, with the hypothalamus being responsible for 
nutrient and energy sensing and corresponding adjustments in food intake (Murphy and 
Bloom 2004). In the gut, there exists a suite of endocrine cells which synthesize and 
release various hormones in response to nutrient and energy intake (Murphy and Bloom 
2004) and it has been demonstrated that these hormones strongly influence appetite when 
administered at physiological levels (Batterham et al. 2002; Batterham et al. 2003).  
 Since its discovery in 1999 (Kojima et al. 1999), ghrelin has been proposed to act 
as a meal initiator, in large part due to its potent appetite-stimulating effects in free-
feeding rats (Tschop et al. 2000). Although its signalling mechanisms remain to be 
completely understood, a particularly important role for the hypothalamic arcuate nucleus 
(Arc) has been suggested (Wren et al. 2001). Ghrelin has also been shown to stimulate 
appetite in both lean and obese humans (Wren et al. 2001; Druce et al. 2005), and 
administration (i.v.) in healthy individuals has been shown to increase appetite and food 
intake at a buffet-style meal by almost 30% (Murphy and Bloom 2004). The typically 
expected postprandial fall in circulating ghrelin levels is also attenuated, or even absent in 
the obese (English et al. 2002), suggestive of a role of ghrelin in the pathophysiology of 
obesity (le Roux et al. 2005). 
 Circulating levels of PYY are influenced by meal composition and calorie content, 
and postprandial levels have long been known to become elevated within as little as one 
hour in humans (Adrian et al. 1985; Murphy and Bloom 2004). In a trial consisting of 
both lean and obese humans, PYY administration (i.v.) was shown to lead to a decrease in 
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appetite and an almost 30% reduction in caloric intake in both groups (Batterham et al. 
2003). With the anorexigenic capabilities of exogenous PYY being fully intact in the 
obese, resistance is not thought to manifest in the obese state. This has encouraged 
longer-term weight loss studies involving chronic administration. However, since 
circulating PYY levels are often lower in the obese state, it has been suggested that this 
characteristic may in fact play a causative role in the development of obesity (le Roux et 
al. 2006). 
 The regulation of feeding, energy intake and expenditure, and body weight is a 
homeostatic process (Wilding 2002). Information regarding general health is 
communicated predominantly via long-term hormonal signals, while meal initiation and 
termination are believed to be regulated via short-term signals, such as neural signals 
from the brain and hormonal signals from the gut (Kaiyala et al. 1995). The receipt and 
integration of these signals occur mainly in the hypothalamus and are largely regulated 
by the hypothalamic Arc (Murphy and Bloom 2004). Within the Arc, there exists two 
distinct populations of neurons responsible for appetite regulation, including the pro-
opiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART) 
appetite-inhibiting co-expressing neurons, and the neuropeptide Y (NPY) and agouti-
related peptide (AgRP) appetite-stimulating co-expressing neurons (Cone et al. 2001; 
Williams et al. 2001). Signals from the periphery result in changes in the relative activity 
of these two neuronal sub-populations and the release of their respective neuropeptides, 
subsequently influencing feeding behaviour and energy expenditure (Chaudhri et al. 
2008). As a result of these collective reports, there has been increasing momentum aimed 
at turning this evidence-based knowledge into practical anti-obesity intervention. 
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 The aim of the present study was to investigate the appetite-regulating efficacy of 
LWDH and its ethanol extract as a potential body weight-lowering mechanism of action 
of the product by measuring gene expression levels of key targets along the gut-brain axis.  
 
4.3. Materials and methods  
4.3.1. In vivo study  
4.3.1.1. Animals and diet 
   The animals and experimental diet used in the present study were as 
described in Chapter 2. Sixty male rats were purchased from Charles River Laboratories 
(Montréal, QC, Canada). Twelve of these animals were of the obesity-resistant strain 
(OR-CD) and 48 were of the obesity-prone strain (OP-CD). All animals were housed 
individually in cages in a temperature-controlled room with a 12 hour light:dark cycle 
and acclimated for 2 weeks with free access to regular rodent chow and water. The OR-
CD rats served as the normal control group (OR) and the OP-CD rats were randomly 
divided into 4 groups (n = 12 each) prior to the commencement of treatment. 
Randomization of the OP-CD rats was accomplished by ordering the rats based on initial 
body weight from lightest to heaviest and assigning rats sequentially to 1 of 4 groups. 
These groups included an obesity control (OP) and  3 treatments (T1A, T1B, and T1C). 
The T1A, T1B, and T1C groups were treated for 9 weeks by twice-daily oral gavage with 
total daily dosages of 500, 1500, or 3500 mg/kg body weight (BW) of LWDH 
(concentrated pills; Wanxi Pharmaceuticals Co. Ltd., Henan, China) suspended in water, 
respectively. The OR and OP control groups received water via oral gavage as the control 
vehicle. Treatment administration was performed during the light cycle; once in the 
morning and again 6 hours later. Although rats are generally more active and thus exert 
98 
more energy during the dark period (Zucker 1971), unpublished data from the Wang lab 
shows that LWDH enhances energy expenditure at a larger magnitude during the light 
period. Throughout the treatment period, all rats were fed an AIN-93G diet (Research 
Diets Inc., New Brunswick, NJ, USA) modified to contain 60% energy from fat 
(lard:sunflower oil, 96:4 w/w; purchased locally). Body weight and food intake were 
recorded on a daily basis. Daily food intake was calculated by subtracting the total food 
plus dish weight from that of the previous day. At the end of the study, all animals were 
fasted overnight and anaesthetized using Isoflurane (Abraxis BioScience, Richmond Hill, 
ON, Canada). Blood samples were collected via left ventricular cardiac puncture, placed 
on ice, and allowed to clot. After centrifugation at 2,500 g at 4ºC for 15 minutes, serum 
was collected, aliquoted, and stored at -80°C until analysis of each biomarker was 
performed. Ileal and hypothalamic tissue samples were excised and rinsed briefly in 1 X 
phosphate buffered saline (PBS; Sigma). Samples were then weighed, recorded, 
transferred to pre-labelled aluminum foil packets, and placed in liquid nitrogen for short-
term storage. Post-sacrifice storage occurred at -80°C until analysis of each biomarker. 
The animal use and experimental protocols were approved by the Joint Animal Care and 
Research Ethics Committee of the National Research Council Canada and the University 
of Prince Edward Island. The study was conducted in accordance with the guidelines of 
the Canadian Council on Animal Care. 
 
 
4.3.1.2. Preparation and dose determination of LWDH pill 
  The LWDH concentrated pills used in the present study were 
manufactured by Henan Wanxi Pharmaceuticals Ltd. Co. (Nanyang, Henan, China) using 
the 6 Chinese herbs described in Chapter 2 of this thesis, at a composition of 160 g RRP, 
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80 g RD, 80 g FC, 60 g CM, 60 g RA, and 60 g Poria. To ensure homogeneity, the pills 
were produced in accordance with the China Pharmacopoeia standard of quality control 
(Fu et al. 2009). Briefly, following extraction with 95% ethanol, the residue of CM was 
mixed with all RRP, RA, and Poria, and part of FC (27 g), followed by extraction with 
hot water (twice, 2 hours each). The water extract was then concentrated to form a paste, 
followed by mixing with powdered RD, FC (53 g), and the ethanol extract of CM to form 
the final product. Based on the recommended daily dosage of 24 pills (approximately 4.5 
g/day) in humans and the previously reported dosage of 2.4 g/kg/day in rats (Xue et al. 
2005), 3 dosages of 500, 1500, and 3500 mg/kg BW were chosen for the present study. 
The daily stomach gavage capacity of the rats used in the present study was determined 
to be approximately 6 mL (University Veterinarian, personal communication). Thus, 
daily treatments were prepared in a vehicle volume of 6 mL, administered twice-daily 
(approximately 3 mL per gavage session), and adjusted based on daily body weight 
recordings.  
 
4.3.1.3. Rat ileal and hypothalamic tissue gene expression 
  In vivo expression of genes controlling appetite was conducted by way of 
quantitative real-time polymerase chain reaction (qPCR) using ileal and hypothalamic 
tissues of OP control and T1C rats. 
 
4.3.1.3.1. Rat ileal and hypothalamic tissue RNA isolation  
     Isolation of RNA from rat ileal and hypothalamic tissues was performed 
by way of homogenization using the Trizol method, as previously reported (Rio et al. 
2010). In brief, 1 mL Trizol reagent (Sigma-Aldrich Ltd., Oakville, ON, Canada) was 
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added per 100 mg frozen tissue to a 2 mL round-bottom tube (Sigma) and homogenized 
thoroughly using a PowerGen 125 homogenizer (Fisher Scientific, Ottawa, ON, Canada). 
Once homogenized, approximately 200 uL chloroform (Sigma; 1/5 the Trizol reagent 
volume) was added and the tubes were mixed vigorously using a bench top Mini 
Vortexer (Analytical Instruments, Golden Valley, MN, USA). Following incubation at 
room temperature and centrifugation at 10,000 g at 4ºC for 10 minutes using a bench top 
Mini Spin centrifuge (Eppendorf, Mississauga, ON, Canada), the aqueous phase was 
transferred to a clean 1.7 mL tube (Sigma). After addition of approximately 500 uL 
isopropanol (Sigma; 1/2 the Trizol reagent volume), vigorous vortexing, incubation at 
room temperature, and centrifugation at 12,000 g at 4ºC for 10 minutes, the isopropanol 
was removed. The remaining pelletized RNA was washed with 1 mL 75% EtOH (diluted 
in diethylpyrocarbonate (DEPC) H2O; Merck, Darmstadt, Germany), vortexed briefly, 
and centrifuged at 10,000 g at 4ºC for 10 minutes. After removal of the 75% EtOH, the 
pelletized RNA was allowed to dry at room temperature. The dried pellet was then 
dissolved in DEPC H2O. The samples were stored at -20ºC or processed immediately for 
measurement of concentration and purity. 
 
4.3.1.3.2. Rat ileal and hypothalamic tissue RNA concentration and purity  
     Measurement of RNA concentration and purity from rat ileal and 
hypothalamic tissues was performed using a NanoDrop ND-1000 spectrophotometer 
(Thermo Scientific, Wilmington, DE, USA). Rat ileal and hypothalamic pelletized RNA 
samples dissolved in DEPC H2O were used at a volume of 2 µL for the measurement of 
RNA concentration (µg/mL) and purity (A260/A280). The cut-off for RNA purity was 1.8. 
Blank measurements were performed using 2 µL DEPC H2O.  
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4.3.1.3.3. Synthesis of complementary DNA (cDNA) 
     For the synthesis of cDNA, enough RNA sample to obtain 2 µg cDNA, 4 
µL qScript cDNA SuperMix (Quanta BioSciences Inc., Gaithersburg, MD, USA), and 
enough DEPC H2O to reach a final volume of 20 µL were added to 200 µL reaction tubes 
(Sigma), vortexed, and centrifuged briefly. Reverse transcription to cDNA was 
performed using a thermocycler (Thermo Scientific) and under the following reaction 
conditions: 5 minutes at 25ºC, 30 minutes at 42ºC, 5 minutes at 85ºC, and a hold period at 
4ºC. Following reverse transcription, the cDNA samples were diluted using DEPC H2O. 
If not used immediately following reverse transcription and dilution, the samples were 
stored temporarily at -20ºC. 
 
4.3.1.3.4. Quantitative real-time polymerase chain reaction (qPCR) 
     Quantitative real-time polymerase chain reaction was performed using 3 
µL diluted cDNA and 12 µL qPCR MasterMix (7.5 µL SYBR Green SuperMix (Quanta 
BioSciences), 2.5 µL DEPC H2O, 1 µL forward primer, and 1 µL reverse primer). The 
MasterMix was vortexed and centrifuged briefly prior to adding to the diluted cDNA 
samples. The qPCR reaction was carried out in strip PCR tubes (Roche Applied Science, 
Indianapolis, IN, USA) using a Corbett Rotor-Gene 6000 real-time rotary analyzer 
(Corbett Life Science, Concorde, NSW, Australia) under the following conditions, 
slightly modified from those previously reported (Reja et al. 2002): initial denature at 
94ºC for 180 seconds followed by 40 cycles at 94ºC for 15 seconds, 57ºC for 20 seconds, 
and 72ºC for 25 seconds. Fold changes of target gene expression in response to treatment 
were calculated using the deltadelta CT method, as previously reported (Livak and 
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Schmittgen 2001)."cpf"pqtocnk¦gf"vq"vjg"kpvgtpcn"eqpvtqn"*く"cevkp+0"Vjg"rtkogt"ugswgpegu"
of the internal control and genes of interest (ghrelin, PYY, and NPY) were obtained from 
the literature (Lindqvist et al. 2008; Ferrer-Lorente et al. 2009), blasted to determine the 
sequence homology between species, and purchased from Sigma Genosys (Oakville, ON, 
Canada). The forward and reverse sequences for each primer are presented in 
APPENDIX A. Raw data are presented in APPENDIX C. 
 
4.3.1. In vitro study  
4.3.2.1. Preparation and concentration determination of LWDH ethanol extract 
  The ethanol extract of LWDH used in the present study was prepared from 
the standardized commercial concentrated LWDH pill described and used in vivo 
throughout this thesis, and as previously reported (Sangha et al. 2012): dry unpolished 
pills were milled and extracted twice with 95% ethanol (30 minutes each). Removal of 
the solvent under reduced pressure and drying at 70°C yielded the ethanol extract of 
LWDH used in the present study. Chemical profiling of the prepared ethanol extract of 
LWDH using various analytical techniques has recently been published (Sangha et al. 
2012). The major compounds elucidated in the extract can be found in APPENDIX D. 
Data from the Wang lab currently under consideration for publication in Frontiers in Life 
Science show that in OP-CD rats fed a high-fat diet, the ethanol extract of LWDH 
reduces weight gain and visceral fat deposition. Furthermore, the extract decreases serum 
T-C, non-HDL-C, TG, FFA, and leptin levels. 
  Cell viability in response to various concentrations of the ethanol extract 
of LWDH in both CaCo-2 and SH-SY5Y cells was determined by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Life Technologies, Inc.) 
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assay. A LWDH ethanol extract stock solution was made by dissolving the dried extract 
in dimethyl sulfoxide (DMSO; Sigma) and treatments ranging from 0-200 µg/mL were 
prepared in the cell type-specific complete medium. The concentration of DMSO in each 
treatment concentration was adjusted to 0.05%. Next, cells cultured to differentiation 
(CaCo-2) or confluency (SH-SY5Y) in 96-well plates (BD Biosciences, Mississauga, ON, 
Canada) were aspirated and treated with 200 µL of the prepared LWDH ethanol extract 
concentrations. After an overnight (24 hours) incubation at 37ºC, 20 µL of MTT stock 
solution (5 µg/mL) was added to each well and incubated for 4 hours at 37ºC. Following 
incubation, the wells were aspirated and 200 µL DMSO was added. The plate was then 
covered and shaken for 5 minutes on a plate rocker (Thermo Scientific) and the 
absorbance was read at 570 nm using a Varioskan Flash multimode reader (Thermo 
Scientific). 
 
4.3.2.2. CaCo-2 and SH-SY5Y cell gene expression 
  In vitro expression of genes controlling appetite regulation was conducted 
by qPCR in CaCo-2 and SH-SY5Y cells. 
 
4.3.2.2.1. Culture of CaCo-2 cells 
  Cells were cultured at 37ºC with 5% CO2 in complete CaCo-2 growth 
ogfkc" eqpukuvkpi" qh" GcingÓu" Okpkowo" Guugpvkcn" Ogfkwo" *GOGO=" American Type 
Culture Collection, Manassas, VA, USA) supplemented with 20% heat-inactivated fetal 
bovine serum (FBS; Life Technologies Inc., Burlington, ON, Canada) and 1% antibiotic 
(Penicillin/Streptomycin; Life Technologies, Inc.). Media was changed every 2-3 days.  
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4.3.2.2.2. Treatment of CaCo-2 cells with LWDH ethanol extract 
  Cells were grown in 75 cm
2
 flasks (BD Biosciences). Upon reaching 
~80% confluency, the media was removed and the cells were washed with 1 X PBS 
(Sigma). Trypsin (Cellgro, Manassas, VA, USA) was then added to detach the cells. 
When the cells were detached, fresh media was added to inactivate the trypsin. The flask 
contents were then transferred to 50 mL conical tubes (BD Biosciences). Following 
centrifugation at 10,000 g at 4ºC for 5 minutes, the media was removed and the  cells 
were re-suspended in fresh media. The cells were counted using a hemocytometer 
(Hausser Scientific, Horsham, PA, USA) and diluted to a density of 3 x 10
5 
cells/mL. An 
aliquot of 2 mL was added to each well to achieve the desired cell density of 6 x 10
5
 
cells/well. The media was changed every 2-3 days until the cells were differentiated (~11 
days). Once differentiated, the cells were treated overnight (24 hours) at 37ºC with 
LWDH ethanol extract concentrations ranging from 0-200 µg/mL.  
 
4.3.2.2.3. Culture of SH-SY5Y cells 
  Cells were cultured at 37ºC with 5% CO2 in complete growth media 
eqpukuvkpi" qh" FwndgeeqÓu" Oqfkhkgf" Gcing" Ogfkwo" *FOEM; Life Technologies, Inc.) 
supplemented with 10% heat-inactivated FBS (Life Technologies) and 1% antibiotic 
(Life Technologies, Inc.).!Media was changed every 2-3 days and cells were treated upon 
reaching 70-80% confluency. 
 
4.3.2.2.4. Treatment of SH-SY5Y cells with LWDH ethanol extract 
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     Cell culture conditions and treatment regimes were the same as for CaCo-
2 cells, with minor modifications: SH-SY5Y cells were seeded (8 x 10
5
 cells/well) and 
allowed to reach confluency prior to treatment. 
 
4.3.2.2.5. CaCo-2 and SH-SY5Y cell RNA isolation 
     Isolation of RNA from CaCo-2 and SH-SY5Y cells was performed using 
the Trizol method (Rio et al. 2010). In brief, after aspiration of the media, 1 mL Trizol 
reagent (Sigma) was added to each well and the plates were kept at room temperature for 
10 minutes. The well contents were then transferred to 1.7 mL tubes (Sigma), followed 
by addition of 200 µL chloroform (Sigma). The tubes were vortexed vigorously, 
incubated at room temperature for 10 minutes, and centrifuged at 12,000 g at 4ºC for 10 
minutes. The top aqueous phase was then transferred to a new 1.7 mL tube (Sigma) and 
500 µL isopropanol (Sigma) was added. The tubes were again vortexed vigorously, kept 
at room temperature for 10 minutes, and centrifuged at 12,000 g at 4ºC for 10 minutes. 
Following removal of the isopropanol, the RNA pellet was washed with 1 mL DEPC 
H2O-diluted EtOH (75%), vortexed, and centrifuged at 10,000 g at 4ºC for 10 minutes. 
After removal of the 75% EtOH, the pelletized RNA was allowed to dry at room 
temperature and then re-dissolved in DEPC H2O. The samples were stored at -20ºC or 
processed immediately for the measurement of concentration and purity.  
 
4.3.2.2.6. CaCo-2 and SH-SY5Y cell RNA concentration and purity 
  Measurement of RNA concentration and purity from CaCo-2 and SH-
SY5Y cells was performed as previously described for rat ileal and hypothalamic tissues. 
4.3.2.2.7. Synthesis of complementary DNA (cDNA) 
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     Synthesis of cDNA from CaCo-2 and SH-SY5Y RNA was performed as 
previously described for rat ileal and hypothalamic tissues. 
 
4.3.2.2.8. Quantitative real-time polymerase chain reaction (qPCR) 
     Quantitative real-time polymerase chain reaction using CaCo-2 and SH-
SY5Y cell cDNA was performed as previously described for rat ileal and hypothalamic 
tissues. The primer sequences (Sigma Genosys) used for the internal control (く"cevkp) and 
genes of interest (ghrelin, PYY, and NPY) are presented in APPENDIX C. Raw data are 
presented in APPENDIX E. 
 
4.3.3. Statistical analyses 
 UvwfgpvÓu" v-tests were used to compare results between the OP and T1C-treated 
groups in the in vivo analysis of the appetite-regulating efficacy of LWDH. The in vitro 
efficacy of the ethanol extract of LWDH was analysed statistically by one-way ANOVA. 
All analyses were conducted using SAS 9.2 statistical software (SAS Institute, Cary, NC, 
USA). Differences between treatment means were determined by pair-wise comparisons 
using the least squares means test, with P < 0.05 indicating statistical significance. 
Results are presented as mean values with their standard errors. 
 
4.4. Results  
4.4.1. In vivo study 
4.4.1.1. mRNA expression of PYY and ghrelin in the ileum of obese rats 
  Expression of PYY and ghrelin genes in the ileal tissue of obese rats was 
assessed after a 9 week treatment period with LWDH. Compared to the OP control, the 
ileal gene expression of PYY was unchanged in response to the T1C treatment. Ghrelin 
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mRNA levels were significantly reduced (P = 0.001) by 59% in response to the T1C 
treatment (Figure 4-1). 
 
4.4.1.2. mRNA expression of NPY in the hypothalamus of obese rats 
  The effect of LWDH on NPY gene expression in the hypothalamic tissue 
of obese rats is presented in Figure 4-2. The hypothalamic expression of NPY mRNA 
was unchanged in response to the T1C treatment, compared to the OP control. 
 
4.4.2. In vitro study 
4.4.2.1. Non-toxic concentration range of LWDH ethanol extract in CaCo-2 and  
  SH-SY5Y cells     
  The results of the toxicity assessment of the LWDH ethanol extract in 
CaCo-2 and SH-SY5Y cells is presented in Figure 4-3 and Figure 4-4 a and b, 
respectively. In CaCo-2 cells, cell viability remained relatively stable following treatment 
with LWDH ethanol extract concentrations ranging from 0 to 100 µg/mL, but dropped to 
less than 70% at the concentration of 200 µg/mL. Thus, concentrations of 0, 25, 50, and 
100 µg/mL were chosen for subsequent experiments using this cell line. In SH-SY5Y 
cells, a dramatic drop of cell viability to less than 65% of control was observed at the 
concentration of 50 ug/mL of the LWDH ethanol extract and continued to drop with the 
increase of concentrations. A further optimization was carried out and revealed that cell 
viability remained stable at a concentration range of 0-25 µg/mL. As such, concentrations 
of 0, 5, 10, and 25 µg/mL were chosen for subsequent experiments using this cell line. 
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 F igure 4-1: Effect of LWDH pill on ileal tissue PYY and ghrelin gene expression 
 in obese rats. OP: obese-prone positive control; T1C: 3500 mg/kg BW LWDH-
 treated OP. All animals were fed a high-fat diet (AIN-93G diet modified to 
 contain 60% energy from fat). Data were analyzed d{" uvwfgpvÓu" v-test, with P < 
 0.05 indicating statistical significance. Data are expressed as mean values with 
 their standard errors (n = 12). 
*
Mean value of T1C was significantly different 
 from OP control.  
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F igure 4-2: Effect of LWDH pill on hypothalamic tissue NPY gene expression in 
 obese rats. OP: obese-prone positive control; T1C: 3500 mg/kg BW LWDH-
 treated OP. All animals were fed a high-fat diet (AIN-93G diet modified to 
 contain 60% energy from fat). Data were analyzed d{" uvwfgpvÓu" v-test, with P < 
 0.05 indicating statistical significance. Data are expressed as mean values with 
 their standard errors (n = 12). 
*
Mean value of T1C was significantly different 
 from OP control.  
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 F igure 4-3: Non-toxic concentration determination of LWDH ethanol extract in 
 CaCo-2 cells by MTT assay. 
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 F igure 4-4: Non-toxic concentration determination of LWDH ethanol extract in 
 SH-SY5Y cells by (a) MTT assay and (b) optimized MTT assay.  
 
4.4.2.2. Gene expression of PYY and ghrelin in CaCo-2 cells 
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   The effect of the LWDH ethanol extract on PYY and ghrelin mRNA 
levels in CaCo-2 cells is presented in Figure 4-5 and Figure 4-6, respectively. mRNA 
levels of PYY were increased in response to treatment with the LWDH ethanol extract 
and reached statistical significance (P = 0.02) at the concentration of 100 µg/mL. The 
LWDH ethanol extract did not show any significant effects on mRNA levels of ghrelin.  
 
4.4.2.3. Gene expression of NPY in SH-SY5Y cells 
  The effect of the LWDH ethanol extract on NPY mRNA levels in SH-
SY5Y cells is presented in Figure 4-7. The gene expression of NPY in SH-SY5Y cells 
was unchanged in response to the optimized concentrations of the LWDH ethanol extract, 
compared to control. 
 
 
 
 
 
 
 
 
 
 
113 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 F igure 4-5: Effect of LWDH ethanol extract on PYY gene expression in CaCo-2 
 cells. Data were analyzed by one-way ANOVA. Differences between treatment 
 means were determined by pair-wise comparisons using the least squares means 
 test, with P < 0.05 indicating statistical significance. Data are expressed as mean 
 values with their standard errors (n = 3 independent experiments). 
*
Mean values 
 significantly different from 0 ug/mL control.  
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 F igure 4-6: Effect of LWDH ethanol extract on ghrelin gene expression in CaCo-
 2 cells. Data were analyzed by one-way ANOVA. Differences between treatment 
 means were determined by pair-wise comparisons using the least squares means 
 test, with P < 0.05 indicating statistical significance. Data are expressed as mean 
 values with their standard errors (n = 3 independent experiments).  
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F igure 4-7: Effect of LWDH ethanol extract on NPY gene expression in SH-SY5Y cells. 
Data were analyzed by one-way ANOVA. Differences between  treatment means were 
determined by pair-wise comparisons using the least squares means test, with P < 0.05 
indicating statistical significance. Data are  expressed as mean values with their standard 
errors (n = 3 independent experiments).  
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4.5. Discussion and conclusions  
 Harnessing of the physiological mechanism of appetite regulation has become an 
intensely investigated approach to body weight control and has been reported to involve a 
communication line from the GI tract to the CNS and resident centres of appetite 
regulation therein (Gardiner et al. 2008). The GI tract is the largest endocrine organ in the 
body (Hameed et al. 2009). Endocrine cells synthesize and release various hormones in 
response to nutrient and energy intake (Murphy and Bloom 2004) and it has been 
demonstrated that these hormones strongly influence appetite regulation (Batterham et al. 
2003). In the hypothalamus, the Arc represents the primary CNS region involved in the 
control of food intake (Valassi et al. 2008). Signals from the GI tract cause changes in the 
relative activity of two neuronal subpopulations, resulting in either orexigenic (appetite-
stimulating) or anorexigenic (appetite-suppressing) effects. As such, the line of 
communication between the GI tract and the CNS, referred to as the gut-brain axis, has 
been garnering significant recognition as a key component of a now well established 
model of appetite regulation (Chaudhri et al. 2008).  
 Ghrelin and PYY represent key gut hormones with opposing roles in the 
regulation of appetite and energy homeostasis (Kirchner et al. 2010). Stimulated release 
of PYY and diminished release of ghrelin have been investigated as potential therapeutic 
anti-obesity strategies (Cummings and Overduin 2007). Produced predominantly in the 
stomach (Kojima et al. 1999), ghrelin represents the only known orexigenic gut hormone 
(Hameed et al. 2009). Ghrelin binds to the growth hormone secretagogue (GHS) receptor, 
which is most highly expressed in the hypothalamus (Bailey et al. 2000). Subcutaneous 
injection of ghrelin has been shown to significantly induce appetite and increase food 
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intake (Druce et al. 2006). In obese subjects, fasting ghrelin levels have been shown to be 
lower compared to normal weight controls and to rise following diet-induced weight loss 
(Cummings et al. 2002). In contrast, circulating ghrelin levels have been reported to be 
markedly reduced post-bariatric surgery, thus potentially enhancing the body weight-
lowering efficacy of the procedure (Cummings et al. 2002). Pharmacological blockage of 
ghrelin has been shown to result in decreases in food intake and body weight in rodents 
(Tschop et al. 2000), and GHS-deficient rodents have been shown to be resistant to diet-
induced obesity (Wortley et al. 2005; Zigman et al. 2005). In diet-induced obese mice, 
GHS antagonists have been shown to cause significant reductions in body weight through 
fat loss, attributable to the centrally-mediated anorexigenic effects of GHS blockade 
(Esler et al. 2007). From a therapeutic utility standpoint, PYY has been shown to have 
anorexigenic effects in both normal weight and obese individuals, as inhibition of food 
intake in response to selective agonists and attenuation of this inhibitory effect in 
response to antagonists have both been shown (Lumb et al. 2007). Significant increases 
in circulating PYY levels have also been reported post-bariatric surgery (Korner et al. 
2005), possibly contributing to the initial and long-term sustainment of weight loss 
attributed to the procedure. Development of a PYY nasal spray for thrice daily 
administration has been shown to result in modest weight reductions in humans (Gantz et 
al. 2007), however, side effects including nausea and vomiting were encountered during 
clinical trials. This, in addition to previously reported nausea and conditioned taste 
aversion in mice in response to food intake-lowering dosages (Halatchev and Cone 2005), 
has placed limitations on the utility of  PYY as an anti-obesity agent. 
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 In the present study, ghrelin gene expression in the ileum of obese rats was 
significantly reduced in response to high dose LWDH treatment. Ghrelin is expressed and 
secreted from the ileal region of the small intestine (Date et al. 2000; De Vriese and 
Delporte 2008) and mice with diminished ileal ghrelin expression are significantly leaner 
than controls (Duca et al. 2012). Furthermore, bypass of the ileal region in rats has been 
shown to lead to diminished levels of total ghrelin, with corresponding reductions in food 
intake and weight gain (Yan et al. 2011). Expression and secretion of ghrelin have, 
however, been shown to occur predominantly in the stomach (Kojima et al. 1999; Lim et 
al. 2011). At the time of sacrifice, the subsequent experimental plan had included 
investigation of circulating ghrelin levels from the serum. Unfortunately, the short half-
life of endogenous ghrelin (Wynne et al. 2005) rendered expression levels undetectable. 
In addition, stomach tissue was not collected at the time of sacrifice for further 
biochemical or molecular analyses. As a result, although detectable, ghrelin expression 
levels in the ileal tissue may not have been sufficiently representative of the actual effect 
of LWDH on ghrelin gene expression. The intestinal CaCo-2 cell line has previously 
been used for investigating ghrelin and PYY gene expression levels (Sonoyama et al. 
2000; Yeung et al. 2006).  Thus, in the present study, CaCo-2 cells were used for in vitro 
investigation of the appetite-regulating efficacy of the ethanol extract of LWDH. Ileal 
tissue is also a well recognized site for investigating PYY gene expression (Bilchik et al. 
1995; Duca et al. 2012). Ileal tissue gene expression levels of PYY in the present study 
were unaffected by LWDH treatment, and significantly increased in response to the 100 
µg/mL dose of the LWDH ethanol extract. Nonetheless, the efficacy of LWDH and its 
ethanol extract on PYY gene expression under the current experimental conditions do not 
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appear to represent a potential body weight-lowering mechanism of action of the product. 
Development of more potent analogues, different administration routes or dosing 
regiments, or novel combinatorial approaches with other gut hormones may help unlock 
the future potential of PYY as an anti-obesity therapy. 
 The analyses of gene targets along the gut-brain axis in the present study were 
compared only between OP (positive control) and T1C (high dose LWDH-treated) rats. 
As a result, evaluation of the effect of obesity itself on ghrelin gene expression was not 
possible. Despite the beneficial ghrelin-lowering effects of high dose LWDH treatment in 
the ileal tissue of obese rats, ghrelin gene expression was unaffected in response to 
treatment with the ethanol extract of LWDH in CaCo-2 cells. Although as with PYY, 
alterations in ghrelin gene expression do not appear to represent a potential body weight-
lowering mechanism of action of the product, further investigation into the ghrelin- or 
GHS-modulating effects of LWDH and its ethanol extract in obese rats, and especially in 
humans, may be warranted.  
 In the CNS, the hypothalamus is the key region involved in the regulation of 
appetite (Murphy and Bloom 2004). Gut hormone receptors are located on neuronal 
populations within the hypothalamic Arc (Small and Bloom 2004), which is also partially 
accessible to circulating appetite modulators due to its incomplete isolation from the 
blood-brain barrier (BBB) (Murphy and Bloom 2004). The orexigenic neuropeptide NPY 
is expressed in the hypothalamus (Fei et al. 2012) and modulation of NPY signaling has 
been shown to influence energy balance (Chao et al. 2011). Centrally-administered NPY 
has been shown to induce a marked feeding response and to stimulate food intake 
(Williams et al. 2004). Furthermore, chronic administration has been shown to lead to 
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obesity (Zarjevski et al. 1993). Conversely, knockdown of NPY expression has been 
shown to reduce fat deposition and to improve high-fat diet-induced hyperphagia and 
obesity (Chao et al. 2011). Furthermore, inhibition of hyperphagia and decreased intake 
of high-fat diets have been linked to central knockout of NPY (Sindelar et al. 2005). In 
the present study, NPY gene expression in both the hypothalamic tissue of LWDH-
treated obese rats and in LWDH ethanol extract-treated SH-SY5Y cells was unchanged. 
Expression of NPY, however, predominates specifically in the hypothalamic Arc 
(Williams et al. 2001). At the time of sacrifice, the entire hypothalamic region of the 
brain was collected and processed for subsequent analyses. As such, other hypothalamic 
regions expressing NPY, albeit to a lesser degree, may have confounded the specificity of 
the results in the present study. In addition, although the SH-SY5Y cell line employed for 
investigating the efficacy of the LWDH ethanol extract on NPY gene expression is 
representative of the CNS, primary cell cultures using the specific Arc region of the 
hypothalamus may prove useful for more specific elucidation of the true effects in future 
investigations.  
 In contrast to some of the currently employed, relatively non-specific drug 
therapies, gut hormones act specifically on systems responsible for appetite control 
(Murphy et al. 2006). In addition, due to their natural physiological regulation of appetite, 
gut hormone-based therapies are reportedly less likely to cause adverse side effects 
compared to some of the currently approved drugs (Chaudhri et al. 2008). As such, gut 
hormone-based treatment approaches potentially offer a safer, more attractive alternative 
to combat the obesity epidemic. Although the gut-brain axis and a variety of hormone 
signalling pathways have been emerging as potentially viable anti-obesity targets, the 
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short half-life of many of the endogenous gut hormones must also be considered (Wynne 
et al. 2005; Murphy et al. 2006). Receptor agonists and alternative delivery routes have 
both been postulated to allow for circumvention of this unfortunate characteristic and to 
aid in the future development of gut hormone-based anti-obesity therapies (Chaudhri et al. 
2008).   
 In conclusion, the present study has shed light on the therapeutic body weight-
lowering utility of LWDH (decreased ghrelin gene expression) and its ethanol extract 
(increased PYY gene expression). However, concluding that appetite regulation 
represents a viable body weight-lowering mechanism of action of LWDH, or its ethanol 
extract, requires further investigation. Continued research into the potential to 
pharmacologically exploit endogenously occurring appetite-modulating gut hormones in 
an effort to regulate energy homeostasis is required. Nonetheless, there is strong evidence 
that obesity research and the development of weight loss or weight management products 
should, in large part, focus on the release and function of gut hormones, in connection to 
their association with neuropeptides and receptors in the CNS, in particular the 
hypothalamic Arc. Overall, the future development of safe and effective anti-obesity 
treatments through appetite modulation, in an effort to combat the rampant global rise in 
obesity, continues to have promising potential.  
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C H APT E R 5: E F F I C A C Y O F L IU W E I DI H U A N G PI L L A ND E X T R A C T O N 
F A T T Y A C ID O X ID A T I O N A ND SY N T H ESIS IN VIVO A ND IN VITRO 
 
5.1 Abstract 
 The present study investigated the efficacy of Liuwei Dihuang (LWDH) on fatty 
acid oxidation and synthesis as a potential body weight-lowering mechanism of action of 
the product. In the liver, the high-fat diet-mediated down-regulation of acetyl-CoA 
carboxylase (ACC) and carnitine palmitoyltransferase-1 (CPT1) mRNA levels were not 
significantly reversed in response to treatment with the high dose of LWDH. In contrast, 
the high-fat diet-mediated up-regulation in the mRNA level of fatty acid synthase (FAS) 
was significantly reversed in response to the same treatment. Similar results were seen in 
the muscle, but the effects on CPT1 mRNA levels were statistically significant. The 
protein expression levels of phosphorylated ACC (pACC) and FAS in the liver were 
reversed in response to LWDH treatment, but the effects were not statistically significant. 
In the muscle, protein expression levels of phosphorylated AMP-activated protein kinase 
(pAMPK), pACC, CPT1, and FAS were significantly reversed. In HepG2 cells, no 
significant effects on target mRNA levels were observed in response to treatment with 
the ethanol extract of LWDH. In fatty acid (FA)-treated L6 myotubes, the mRNA level of 
AMPK was increased by the LWDH ethanol extract at the concentration of 100 µg/mL, 
while the mRNA level of FAS was decreased in response to the concentrations of 50 and 
200 µg/mL. Significant increases in expression of pAMPK protein at 100 µg/mL, pACC 
protein at 200 µg/mL, and CPT1 protein at 100 and 200 µg/mL extract concentrations 
were observed. A significant decrease in FAS protein expression was seen in response to 
treatment with the 100 µg/mL LWDH ethanol extract concentration
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regulated fatty acid oxidation and/or down-regulated fatty acid synthesis appear to be 
responsible, at least in part, for the observed body weight-lowering effect of LWDH.  
 
5.2. Introduction 
 Circulating free fatty acids (FFA), which are interrelated with obesity and are well 
documented as a risk factor for several obesity-associated co-morbidities, are generally 
either oxidized for energy production or re-esterified from the circulation for storage as 
triglycerides (TG) (Teusink et al. 2003). In response to dietary fat intake, oxidation of 
fatty acids increases until its rate matches that of intake, in order to maintain a constant 
body weight (Schrauwen et al. 1997). However, in the absence of a compensatory 
increase in energy expenditure, such as fatty acid oxidation, the result is an increase in fat 
mass (Flatt 1987; Kim et al. 2000). In metabolically-healthy individuals, increased fat 
intake is matched with increased fatty acid oxidation capacity (Bergouignan et al. 2012). 
Furthermore, a reduced capacity to oxidize fatty acids has been shown to predispose to 
weight gain (Zurlo et al. 1990). In addition to alterations in fatty acid oxidation capacity 
in obesity, weight gain is associated with increased lipogenesis, resulting in large part 
from stimulated expression of lipogenic enzymes, such as fatty acid synthase (FAS) 
(Diraison et al. 2002). As such, promotion of fatty acid uptake and oxidation, along with 
decreasing endogenous fatty acid synthesis, have become attractive potential anti-obesity 
strategies (Niu et al. 2012). 
 Investigation into the efficacy and mechanism of action of herbal medicines on 
body weight and composition has been gaining considerable attention (Lenon et al. 2012; 
Sui et al. 2012). For example, the medicinal anti-diarrheic drug Geranium thunbergii has 
been reported to improve high-fat diet-induced obesity by altering adipokine levels and 
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down-regulating the expression of lipogenic enzymes (Sung et al. 2011). Berberine has 
been shown to reduce fat mass by promoting fat oxidation (Lee et al. 2006). Recent 
studies on LWDH (Xue et al. 2006; Qian et al. 2010; Perry et al. 2012) and its ethanol 
extract (unpublished data from the Wang lab) have demonstrated its efficacy on lowering 
body weight and improving body fat composition, as well as lipid, FFA, and various 
adipokine levels. To date, however, no investigation into the potential mechanism of 
action responsible for these effects had been conducted.  
!
 Activation of metabolic pathways which promote the transport of fatty acids 
across the mitochondrial plasma membrane for oxidation have been shown to prevent 
fatty acid accumulation in various tissues (Kahn et al. 2005). It was once believed that 
this process occurred by way of passive diffusion (Kiens and Roepstorff 2003). More 
recent evidence, however, has indicated that this process takes place in a protein-
mediated fashion (Bonen et al. 2007). One such protein cascade that regulates lipid 
homeostasis and fatty acid oxidation is driven by the heterotrimeric enzyme AMP-
activated protein kinase (AMPK) (Niu et al. 2012). When activated, the AMPK cascade 
inhibits anabolic and promotes catabolic pathways of energy metabolism (Carling 2005). 
Activated (phosphorylated) AMPK phosphorylates (and inactivates) the downstream 
target, acetyl-CoA carboxylase (ACC), and thus decreases the production of malonyl-
CoA (Harwood et al. 2003). Malonyl-CoA is an inhibitor of carnitine 
palmitoyltransferase-1 (CPT1), the rate-limiting enzyme responsible for the transport of 
fatty acids into the mitochondrion for beta-oxidation (McGarry 2002). Reduced malonyl-
CoA production results in a release of the inhibitory effect on CPT1, promoting the 
transfer of fatty acids into the mitochondrion for beta-oxidation, as well as in a 
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concomitant suppression of fatty acid synthesis (Kahn et al. 2005). As such, activation of 
the AMPK-mediated fatty acid oxidation cascade has been emerging as a promising anti-
obesity treatment strategy (Kahn et al. 2005; Niu et al. 2012). 
! The aim of the present study was to investigate the efficacy of LWDH and its 
ethanol extract on fatty acid oxidation and synthesis as a potential body weight-lowering 
mechanism of action of the product. Gene and protein expressions of key targets in the 
AMPK-mediated fatty acid oxidation cascade, including AMPK, pAMPK, ACC, pACC, 
and CPT1, and the lipogenic enzyme, FAS, were measured. 
 
5.3. Materials and methods 
5.3.1. In vivo study 
5.3.1.1. Animals and diet  
  The animals and experimental diet used in the present study were as 
described in Chapter 2. Sixty male rats were purchased from Charles River Laboratories 
(Montréal, QC, Canada). Twelve of these animals were of the obesity-resistant strain 
(OR-CD) and 48 were of the obesity-prone strain (OP-CD). All animals were housed 
individually in cages in a temperature-controlled room with a 12 hour light:dark cycle 
and acclimated for 2 weeks with free access to regular rodent chow and water. The OR-
CD rats served as the normal control group (OR) and the OP-CD rats were randomly 
divided into 4 groups (n = 12 each) prior to the commencement of treatment. 
Randomization of the OP-CD rats was accomplished by ordering the rats based on initial 
body weight from lightest to heaviest and assigning rats sequentially to 1 of 4 groups. 
These groups included an obesity control (OP) and  3 treatments (T1A, T1B, and T1C). 
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The T1A, T1B, and T1C groups were treated for 9 weeks by twice-daily oral gavage with 
total daily dosages of 500, 1500, or 3500 mg/kg body weight (BW) of the concentrated 
LWDH pills (Wanxi Pharmaceuticals Co. Ltd., Henan, China) suspended in water and 
referred to respectively as T1A, T1B, and T1C. The OR and OP control groups received 
water via oral gavage as the control vehicle. Treatment administration was performed 
during the light cycle; once in the morning and again 6 hours later. Although rats are 
generally more active and thus exert more energy during the dark period (Zucker 1971), 
unpublished data from the Wang lab shows that LWDH enhances energy expenditure at a 
larger magnitude during the light period. Throughout the treatment period, all rats were 
fed an AIN-93G diet (Research Diets Inc., New Brunswick, NJ, USA), modified to 
contain 60% energy from fat, which was provided in the form of a lard and sunflower oil 
mixture at a ratio of 96 to 4% (w/w). Body weight and food intake were recorded on a 
daily basis. Daily food intake was calculated by subtracting the total food plus dish 
weight from that of the previous day. At the end of the study, all animals were fasted 
overnight and anaesthetized using Isoflurane (Abraxis BioScience, Richmond Hill, ON, 
Canada). Blood samples were collected via left ventricular cardiac puncture, placed on 
ice, and allowed to clot. After centrifugation at 2,500 g at 4ºC for 15 minutes, serum was 
collected, aliquoted, and stored at -80°C until analysis of each biomarker was conducted. 
Liver and muscle tissue samples were excised and rinsed briefly in 1 X PBS (Sigma), 
frozen immediately in liquid nitrogen, and stored at -80°C until analysis. The animal use 
and experimental protocols were approved by the Joint Animal Care and Research Ethics 
Committee of the National Research Council Canada and the University of Prince 
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Edward Island. The study was conducted in accordance with the guidelines of the 
Canadian Council on Animal Care. 
 
 
5.3.1.2. Preparation and dose determination of LWDH pill 
 
  The LWDH concentrated pills used in the present study were 
manufactured by Henan Wanxi Pharmaceuticals Ltd. Co. (Nanyang, Henan, China) using 
the 6 Chinese herbs described in Chapter 2 of this thesis, at a composition of 160 g RRP, 
80 g RD, 80 g FC, 60 g CM, 60 g RA, and 60 g Poria. To ensure homogeneity, the pills 
were produced in accordance with the China Pharmacopoeia standard of quality control 
(Fu et al. 2009). Briefly, following extraction with 95% ethanol, the residue of CM was 
mixed with all RRP, RA, and Poria, and part of FC (27 g), followed by extraction with 
hot water (twice, 2 hours each). The water extract was then concentrated to form a paste, 
followed by mixing with powdered RD, FC (53 g), and the ethanol extract of CM to form 
the final product. Based on the recommended daily dosage of 24 pills (approximately 4.5 
g/day) in humans and the previously reported dosage of 2.4 g/kg/day in rats (Xue et al. 
2005), 3 dosages of 500, 1500, and 3500 mg/kg BW were chosen for the present study. 
The daily stomach gavage capacity of the rats used in the present study was determined 
to be approximately 6 mL (University Veterinarian, personal communication). Thus, 
daily treatments were prepared in a vehicle volume of 6 mL, administered twice-daily 
(approximately 3 mL per gavage session), and adjusted based on daily body weight 
recordings.  
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5.3.1.3. Rat liver and muscle tissue gene expression 
  In vivo expression of genes controlling fatty acid oxidation and synthesis 
was conducted by quantitative real-time polymerase chain reaction (qPCR) using liver 
and muscle tissues of OR and OP control rats and T1C treatment rats.  
 
 5.3.1.3.1. Rat liver and muscle tissue RNA isolation 
      Isolation of RNA from rat liver and muscle tissues was performed by way 
of homogenization using the Trizol method, as previously reported (Rio et al. 2010). In 
brief, 1 mL Trizol reagent (Sigma-Aldrich Ltd., Oakville, ON, Canada) was added per 
100 mg frozen tissue to a 2 mL round-bottom tube (Sigma) and homogenized thoroughly 
using a PowerGen 125 homogenizer (Fisher Scientific, Ottawa, ON, Canada). Once 
homogenized, approximately 200 µL chloroform (Sigma; 1/5 the Trizol reagent volume) 
was added and the tubes were mixed vigorously using a bench top Mini Vortexer 
(Analytical Instruments, Golden Valley, MN, USA). Following incubation at room 
temperature and centrifugation at 10,000 g at 4ºC for 10 minutes using a bench top Mini 
Spin centrifuge (Eppendorf, Mississauga, ON, Canada), the aqueous phase was 
transferred to a clean 1.7 mL tube (Sigma). After addition of 500 µL isopropanol (Sigma; 
1/2 the Trizol reagent volume), vigorous vortexing, incubation at room temperature, and 
centrifugation at 12,000 g at 4ºC for 10 minutes, the isopropanol was removed. The 
remaining RNA pellet was washed with 1 mL 75% EtOH (diluted in 
diethylpyrocarbonate (DEPC) H2O; Merck, Darmstadt, Germany), vortexed briefly, and 
centrifuged at 10,000 g at 4ºC for 10 minutes. After removal of the 75% EtOH, the RNA 
pellet was allowed to dry at room temperature. The dried pellet was then dissolved in 
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DEPC H2O. The samples were stored at -20ºC or processed immediately for the 
measurement of RNA concentration and purity. 
 
5.3.1.3.2. Measurement of rat liver and muscle tissue RNA concentration and purity 
     Concentration and purity of RNA isolated from rat liver and muscle 
tissues were measured using a NanoDrop ND-1000 spectrophotometer (Thermo 
Scientific, Wilmington, DE, USA). An aliquot of 2 µL liver and muscle RNA samples 
dissolved in DEPC H2O was used for the measurement of RNA concentration (ug/mL) 
and purity (A260/A280). The cut-off for RNA purity was 1.8. Blank measurements were 
performed using 2 µL DEPC H2O.  
 
5.3.1.3.3. Synthesis of complementary DNA (cDNA) 
     For the synthesis of cDNA, enough RNA sample to obtain 2 µg cDNA, 4 
µL qScript cDNA SuperMix (Quanta BioSciences Inc., Gaithersburg, MD, USA), and 
enough DEPC H2O to reach a final volume of 20 µL was added to 200 µL reaction tubes 
(Sigma), vortexed, and centrifuged briefly. Reverse transcription to cDNA was 
performed using a thermocycler (Thermo Scientific) and under the following reaction 
conditions: 5 minutes at 25ºC, 30 minutes at 42ºC, 5 minutes at 85ºC, and a hold period at 
4ºC. Following reverse transcription, the samples were diluted using DEPC H2O. If not 
used immediately following reverse transcription and dilution, the samples were stored 
temporarily at -20ºC. 
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5.3.1.3.4. Quantitative real-time polymerase chain reaction (qPCR) 
  Quantitative real-time polymerase chain reaction was performed using 3 
µL diluted cDNA and 12 µL qPCR MasterMix (7.5 µL SYBR Green SuperMix (Quanta 
BioSciences), 2.5 µL DEPC H2O, 1 µL forward primer, and 1 µL reverse primer). The 
MasterMix was vortexed and centrifuged briefly prior to adding to the diluted cDNA 
samples. The qPCR reaction was carried out in strip PCR tubes (Roche Applied Science, 
Indianapolis, IN, USA) using a Corbett Rotor-Gene 6000 real-time rotary analyzer 
(Corbett Life Science, Concorde, NSW, Australia) and under the following conditions, 
slightly modified from those previously reported (Reja et al. 2002): initial denature at 
94ºC for 180 seconds followed by 40 cycles at 94ºC for 15 seconds, 57ºC for 20 seconds, 
and 72ºC for 25 seconds. Fold changes in the expression level of each target gene in 
response to treatment was calculated using the deltadelta CT method, as previously 
reported (Livak and Schmittgen 2001)." cpf"pqtocnk¦gf" vq" vjg" kpvgtpcn"eqpvtqn" *く"cevkp+0"
The primer sequences of the internal control and genes of interest (AMPK, ACC, CPT1, 
and FAS) were obtained from the literature (Kim et al. 2008), blasted to determine the 
sequence homology between species, and purchased from Sigma Genosys (Oakville, ON, 
Canada). The forward and reverse sequences for each primer are presented in 
APPENDIX C. Raw data are presented in APPENDIX E. 
 
5.3.1.4. Rat liver and muscle tissue protein expression  
  In vivo expression of proteins controlling fatty acid oxidation and 
synthesis was conducted by Western blot using liver and muscle tissues of OP control 
and T1C rats. 
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5.3.1.4.1. Rat liver and muscle tissue protein extraction 
         In brief, 1 mL prepared radioimmunoprecipitation assay (RIPA) buffer 
containing protease inhibitor was added per 100 mg frozen tissue to a 2 mL round-bottom 
tube (Sigma) and homogenized thoroughly using a PowerGen 125 homogenizer (Fisher 
Scientific). Once homogenized, the tubes were centrifuged at 13,000 g at 4ºC for 20 
minutes. The supernatant containing the soluble protein was then transferred to clean 1.0 
mL tubes (Sigma).      
 
5.3.1.4.2. Rat liver and muscle tissue protein concentration measurement 
         Protein concentration was measured by bicinchoninic acid (BCA) assay, 
as previously reported (Brooks et al. 1995). In brief, soluble protein samples were added 
at a ratio of 1:20 to BCA working reagent (Thermo Scientific) in a 96-well plate (BD 
Biosciences). Standards and blanks prepared from a stock of bovine serum albumin 
(BSA; Thermo Scientific) and RIPA buffer (Sigma), respectively, were run in parallel 
with the samples. The plate was covered, shaken for 30 seconds, and incubated at 37ºC 
for 30 minutes. The plate was then allowed to cool to room temperature and the 
absorbance was read at 562 nm on a Varioskan Flash multimode reader (Thermo 
Scientific). Standard curves were generated for the calculation of protein concentration of 
each sample and are presented in APPENDIX F. All samples were then standardized 
using prepared RIPA buffer and stored at -20ºC in preparation for Western blot 
experiments.   
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5.3.1.4.3. Western blot 
      Western blotting was performed using standardized protein samples 
diluted 1:1 with sample buffer (2 X Laemmli buffer; Bio-Rad Laboratories, Mississauga, 
ON, Canada) consisting of 50 µL く-mercaptoethanol (Sigma) in 950 µL Laemmli buffer. 
The diluted samples were boiled for 5 minutes using a block heater, cooled on ice, 
vortexed, and centrifuged at 1,200 g at room temperature for approximately 2 minutes. 
Prior to beginning the experiments, polyacrylamide gels (resolving and stacking) were 
prepared using the recipes presented in APPENDIX F. Once polymerized, the gels were 
placed in an electrode assembly tank, filled with 1 X running buffer (diluted from 5 X 
running buffer containing 15 g Tris base, 74 g glycine, 50 mL 10% sodium dodecyl 
sulfate; SDS (all from Sigma), and enough water to reach a final volume of 1 L) and 
monitored for any leakage. The running buffer was adjusted to pH 8.3 prior to loading. 
The gels were run at 75 volts (V) for approximately 30 minutes or until the samples had 
visibly passed through the stacking gel. The voltage was then increased to 150 V and run 
for an additional 60-90 minutes. For larger proteins, the run time was lengthened and 
optimized accordingly. Approximately 15-30 minutes prior to completion of the gel 
electrophoresis, pre-cut pieces of filter paper and nitrocellulose membrane (Life 
Technologies) were equilibrated by soaking in 1 X transfer buffer (3.03 g Tris base, 
15.01 g glycine, 200 mL methanol, and 800 mL water) under conditions of gentle 
shaking on a plate rocker. The proteins were then transferred from the gel to the 
nitrocellulose membrane at 15 V for approximately 60 minutes. To detect the protein of 
interest, membranes were first blocked using 5% milk (powdered) dissolved in tris-
buffered saline with Tween (TBST; Sigma) for 60 minutes at room temperature or 
overnight at 4ºC. The membranes were then rinsed 3 times with TBST for 10 minutes 
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each on a plate rocker and incubated for approximately 60 minutes at room temperature 
with primary (1º) antibody (all from Santa Cruz Biotechnology Inc., Santa Cruz, CA, 
USA) diluted in TBST. Following incubation with 1º antibody, the membranes were 
rinsed 3 times with TBST for 10 minutes each on a plate rocker and incubated for 
approximately 60 minutes at room temperature with horse radish peroxidase (HRP)-
conjugated secondary (2º) antibody (Santa Cruz or Jackson ImmunoResearch Inc., West 
Grove, PA, USA) diluted in TBST. Dilution factors and host sources for the 1º and 2º 
antibodies against the proteins of interest are presented in APPENDIX H. Following 
incubation with 2º antibody, the membranes were rinsed 3 times with TBST for 10 
minutes each on a plate rocker, covered with 1.0 mL detection reagent (Thermo 
Scientific), and incubated for approximately 1 minute at room temperature. The protein 
bands of interest were then visualized using a ChemiDoc XRS system and quantified 
using Bio-Rad Quantity One software. All Western blot materials were purchased from 
Bio-Rad, unless otherwise specified.  
 
5.3.2. In vitro study  
5.3.2.1. Preparation and concentration determination of LWDH ethanol extract  
  The ethanol extract of LWDH used in the present study was prepared from 
the standardized commercial concentrated LWDH pill described and used in vivo 
throughout this thesis, as previously reported (Sangha et al. 2012): dry unpolished pills 
were milled and extracted twice with 95% ethanol (30 minutes each). Removal of the 
solvent under reduced pressure and drying at 70°C yielded the ethanol extract of LWDH 
used in the present study. Chemical profiling of the prepared ethanol extract of LWDH 
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using various analytical techniques has recently been published (Sangha et al. 2012). The 
major compounds elucidated from the extract are presented in APPENDIX D. 
     Concentration determination of the ethanol extract of LWDH in both 
HepG2 cells and L6 myotubes was determined by MTT assay (Life Technologies, Inc.). 
A LWDH ethanol extract stock solution was made by dissolving the dried extract in 
DMSO (Sigma) and treatment concentrations ranging from 0 to 200 µg/mL were 
prepared in the cell type-specific complete medium. The concentration of DMSO in each 
treatment was adjusted to 0.05%. Next, cells were cultured in 96-well plates (BD 
Biosciences, Mississauga, ON, Canada). The media was aspirated and treated with 200 
µL of the prepared LWDH ethanol extract concentrations. After an overnight (24 hours) 
incubation at 37ºC, 20 µL of the MTT stock solution (5 µg/mL) was added to each well 
and incubated for 4 hours at 37ºC. Following incubation, the media was aspirated and 
200 µL DMSO was added. The plate was then covered and shaken for 5 minutes on a 
plate rocker (Thermo Scientific) and the absorbance was read at 570 nm on a Varioskan 
Flash multimode reader (Thermo Scientific). 
 
5.3.2.2. HepG2 cell and L6 myotube gene expression 
  In vitro expression of genes controlling fatty acid oxidation and synthesis 
was conducted by qPCR using HepG2 cells and L6 myotubes. 
 
5.3.2.2.1. Culture of HepG2 cells 
  HepG2 cells were purchased from the American Type Culture Collection 
(ATCC, Manassas, VA, USA). The cells were cultured at 37ºC with 5% CO2 in complete 
itqyvj" ogfkc" eqpukuvkpi" qh" FwndgeeqÓu" Oqfkhkgf" Gcing" Ogfkwo" *FOGO=" Ukioc+"
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supplemented with 10% heat-inactivated FBS (Sigma) and 1% antibiotic 
(Penicillin/Streptomycin; Sigma).! Media was changed every 2-3 days and cells were 
treated upon reaching a confluency of 70-80%.  
 
5.3.2.2.2. Treatment of HepG2 cells with LWDH ethanol extract 
  Cells were grown in 75 cm
2
 flasks (BD Biosciences). Upon reaching 
~80% confluency, the media was removed and the cells were washed with 1 X PBS 
(Sigma). Trypsin (Cellgro, Manassas, VA, USA) was then added to detach the cells. 
When the cells were detached, fresh media was added to inactivate the trypsin. The flask 
contents were then transferred to 50 mL conical tubes (BD Biosciences). Following 
centrifugation at 10,000 g at 4ºC for 5 minutes, the media was removed and the cells 
were re-suspended in fresh media. The cells were counted using a hemocytometer 
(Hausser Scientific, Horsham, PA, USA) and diluted to a density of 4 x 10
5 
cells/mL. An 
aliquot of 2 mL was added to each well to achieve the desired cell density of 8 x 10
5 
cells/mL. The media was changed every 2-3 days. Once confluent, the cells were treated 
overnight (24 hours) at 37ºC with the LWDH ethanol extract at concentrations ranging 
from 0 to 100 µg/mL.  
 
5.3.2.2.3. Culture of L6 myotubes 
  Cells were cultured at 37ºC with 5% CO2 in complete growth media 
consisting of DMEM (Sigma) supplemented with 10% heat-inactivated FBS (Sigma) and 
1% antibiotic (Sigma). Once confluent, the growth media was replaced with 
differentiation media consisting of DMEM (Sigma) supplemented with 2% horse serum 
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(Sigma) and 1% antibiotic (Sigma). Media was changed every 2-3 days and cells were 
treated upon differentiation (7-9 days).  
 
5.3.2.2.4. Treatment of L6 myotubes with LWDH ethanol extract 
  Cell culture conditions and treatment regimes for L6 myotubes were as for 
HepG2 cells, with minor modifications: L6 myotubes were seeded (2.5 x 10
5 
cells/mL) 
and allowed to differentiate prior to treatment. To simulate the effect of a high-fat diet in 
vitro, L6 myotubes were pre-treated with, or without, fatty acid (palmitate; 0.25 mM/L; 
Sigma) in DMEM containing 0.5% (w/v) fatty acid-free BSA (Sigma) prior to treatment 
with the LWDH ethanol extract at a concentration range of 0 to 200 µg/mL.  
 
5.3.2.2.5. HepG2 cell and L6 myotube RNA isolation 
  Isolation of RNA from HepG2 cells and L6 myotubes was performed 
using the Trizol method, as previously reported (Rio et al. 2010). In brief, after aspiration 
of the media, 1 mL Trizol reagent (Sigma) was added to each well and the plates were 
kept at room temperature for 10 minutes. The well contents were transferred to 1.7 mL  
tubes (Sigma), followed by addition of 200 µL chloroform (Sigma). The tubes were 
vortexed vigorously, incubated at room temperature for 10 minutes, and centrifuged at 
12,000 g at 4ºC for 10 minutes. The top aqueous phase was transferred to a new 1.7 mL  
tube (Sigma) and 500 µL isopropanol (Sigma) was added. The tubes were again vortexed 
vigorously, kept at room temperature for 10 minutes, and centrifuged at 12,000 g at 4ºC 
for 10 minutes. Following removal of the isopropanol, the RNA pellet was washed with 1 
mL DEPC H2O-diluted EtOH (75%), vortexed, and centrifuged at 10,000 g at 4ºC for 10 
minutes. After removal of the 75% EtOH, the RNA pellet was allowed to dry at room 
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temperature. The dried pellet was then dissolved in DEPC H2O. The samples were stored 
at -20ºC or processed immediately for measurement of concentration and purity.  
 
5.3.2.2.6. Measurement of HepG2 cell and L6 myotube RNA concentration and 
  purity 
  RNA concentration and purity from HepG2 cells and L6 myotubes was 
determined as previously described for rat liver and muscle tissues. 
 
5.3.2.2.7. Synthesis of complementary DNA (cDNA) 
  Synthesis of cDNA from HepG2 cell and L6 myotube RNA was 
performed as previously described for rat liver and muscle tissues. 
 
5.3.2.2.8. Quantitative real-time polymerase chain reaction (qPCR) 
  Quantitative real-time polymerase chain reactions using HepG2 cell and 
L6 myotube cDNA was performed as previously described for rat liver and muscle 
tissues. 
 
5.3.2.3. HepG2 cell and L6 myotube protein expression  
  In vitro expression of proteins controlling fatty acid oxidation and 
synthesis was conducted by Western blot using HepG2 cells and L6 myotubes. 
 
5.3.2.3.1. HepG2 cell and L6 myotube protein extraction  
  In brief, the media was removed and the plates were washed twice with 
cold 1 X PBS, followed by addition of 100 µL cold 1 X RIPA buffer per well. The cells 
were then scraped and the well contents were transferred to clean 1.7 mL tubes and kept 
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on ice for approximately 5 minutes. The tubes were then sonicated for approximately 2 
minutes, followed by centrifugation at 12,000 g at 4ºC for 10 minutes in order to pellet 
the undesired cellular debris. The supernatant containing the soluble protein was then 
transferred to new tubes, on ice, in preparation for protein concentration measurement 
and standardization.   
 
5.3.2.3.2. HepG2 cell and L6 myotube protein concentration measurement 
  Measurement of protein concentration from HepG2 cells and L6 myotubes 
was performed as previously described for rat liver and muscle tissues. 
 
5.3.2.3.3. Western blot 
  Western blot using HepG2 cell and L6 myotube protein samples was as 
previously described for rat liver and muscle tissues. Dilution factors and host sources for 
the 1º and 2º antibodies against the proteins of interest are presented in APPENDIX H. 
 
5.3.3. Statistical analyses 
 Data analyses were performed by one-way ANOVA using SAS 9.2 statistical 
software (SAS Institute, Cary, NC, USA). Differences between treatment means were 
determined by pair-wise comparisons using the least squares means test, with P < 0.05 
indicating statistical significance. Results are presented as mean values with their 
standard errors. 
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5.4. Results  
5.4.1. In vivo study 
5.4.1.1. Gene expression in liver tissue of obese rats 
 
  The effect of LWDH on fatty acid oxidation and synthesis target gene 
expression in liver tissue of obese rats was assessed after the 9 week treatment period and 
is presented in Figure 5-1. Levels of AMPK mRNA in the liver were significantly 
reduced (P = 0.02) in response to high-fat diet feeding, but the high dose LWDH 
treatment was unable to reverse this effect (P = 0.4). Levels of ACC mRNA in the liver 
were reduced in response to high-fat diet feeding and reversed towards control levels in 
response to high dose LWDH treatment. However, these effects were not statistically 
significant. High-fat diet feeding significantly reduced (P = 0.04) gene expression of 
CPT1 in the liver, which was reversed by high dose LWDH treatment. This effect, 
however, did not reach statistical significance (P = 0.09). Gene expression of FAS in the 
liver was significantly elevated (P = 0.03) in response to high-fat diet feeding and 
reversed (P = 0.04) by high dose LWDH treatment.  
 
5.4.1.2. Gene expression in muscle tissue of obese rats 
 
  The effect of LWDH on fatty acid oxidation and synthesis target gene 
expression in muscle tissue of obese rats is presented in Figure 5-2. Muscle tissue gene 
expression of these targets was similarly affected as found in the liver of obese rats, 
differing only in the effect of high dose LWDH treatment on the gene expression of 
CPT1. Levels of the CPT1 gene were decreased by high-fat diet feeding (P = 0.03) and 
significantly reversed by high dose LWDH treatment (P = 0.02). 
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F igure 5-1: Effect of LWDH pill on fatty acid oxidation and synthesis target gene 
expression in liver tissue of obese rats. OR: normal control; OP: positive control; 
T1C: 3500 mg/kg/day LWDH-treated OP. All animals were fed a high-fat diet 
AIN-93G diet modified to contain 60% energy from fat). Data were analyzed by 
one-way ANOVA. Differences between treatment means were determined by 
pair-wise comparisons using the least squares means test, with P  <0.05 
indicating statistical significance. Data are expressed as mean values with their 
standard errors (n = 6). Means with different superscripts were significantly 
different.  
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 F igure 5-2: Effect of LWDH pill on fatty acid oxidation and synthesis target gene 
 expression in muscle tissue of obese rats. OR: normal control; OP: positive 
 control; T1C: 3500 mg/kg/day LWDH-treated OP. All animals were fed a high-
 fat diet (AIN- 93G diet modified to contain 60% energy from fat). Data were 
 analyzed by one-way ANOVA. Differences between treatment means were 
 determined by pair-wise comparisons using the least squares means test, with P  
 < 0.05 indicating statistical significance. Data are expressed as mean values with 
 their standard errors (n = 6). Means with different superscripts were significantly 
 different.  
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5.4.1.3. Protein expression in liver tissue of obese rats 
  The effect of LWDH on fatty acid oxidation and synthesis target protein 
expression in liver tissue of obese rats was assessed after the 9 week treatment period and 
is presented in Figure 5-3. The protein expression level of AMPK was unaffected by 
either high-fat diet feeding or high dose LWDH treatment. In contrast, the protein 
expression level of pAMPK was significantly reduced (P = 0.001) in response to high-fat 
diet feeding but reversed (P = 0.007) by high dose LWDH treatment. Similar to AMPK, 
protein levels of ACC were unaffected by either high-fat diet feeding or high dose 
LWDH treatment. The protein level of pACC was reduced (P = 0.01) in response to the 
high-fat diet. Reversal of this effect in response to high dose LWDH treatment, however, 
did not reach statistical significance (P = 0.08). The high-fat diet reduced (P = 0.02) the 
liver protein expression of CPT1 but this effect was not significantly reversed by the high 
dose LWDH treatment (P = 0.08). Protein expression of FAS in the liver was increased 
(P = 0.04) by the high-fat diet and marginally reduced (P = 0.08) by the high dose LWDH 
treatment.  
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F igure 5-3: Effect of LWDH pill on fatty acid oxidation and synthesis target protein 
expression in liver tissue of obese rats. OR: normal control; OP: positive control; T1C: 
3500 mg/kg/day LWDH-treated OP. All animals were fed a high-fat diet (AIN-93G diet 
modified to contain 60% energy from fat). Data were analyzed by one-way ANOVA. 
Differences between treatment means were determined by  pair-wise comparisons using 
the least squares means test, with P < 0.05 indicating statistical significance. Data are 
expressed as mean values with their standard errors (n = 6). Means with different 
superscripts were significantly different.  
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5.4.1.4. Protein expression in muscle tissue of obese rats   
  The effect of LWDH on fatty acid oxidation and synthesis target protein 
expression in muscle tissue of obese rats is presented in Figure 5-4. More significant 
treatment effects were seen in muscle than in the liver tissue. In contrast to the protein 
expression levels observed in the liver, a significant down regulation of pAMPK (P = 
0.01), pACC (P = 0.007), and CPT1 (P = 0.004), but up regulation of FAS (P = 0.001) 
protein expression, was observed in response to high-fat diet feeding. Strikingly, all of 
these effects were significantly reversed in response to high dose LWDH treatment 
(pAMPK, P < 0.001; pACC, P = 0.006; CPT, P < 0.001; and FAS, P < 0.001).  
 
5.4.2. In vitro study 
5.4.2.1. Non-toxic concentration determination of LWDH ethanol extract in  
  HepG2 cells and L6 myotubes 
  Concentration determination for the ethanol extract of LWDH in both 
HepG2 cells and L6 myotubes was determined by MTT assay and is presented in Figure 
5-5. In HepG2 cells, cell viability remained stable at the concentration range of 0-100 
µg/mL, but dropped to approximately 80% when the concentration was increased to 200 
µg/mL. As such, concentrations of 0, 25, 50, and 100 µg/mL were chosen for subsequent 
experiments using HepG2 cells. In L6 myotubes, cell viability was not affected at the 
concentrations up to 200 µg/mL. Therefore, concentrations of 0, 50, 100, and 200 µg/mL 
were chosen for subsequent experiments using L6 myotubes. 
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F igure 5-4: Effect of LWDH pill on fatty acid oxidation and synthesis target protein 
expression in muscle tissue of obese rats. OR: normal control; OP:  positive control; T1C: 
3500 mg/kg/day LWDH-treated OP. All animals were fed a high-fat diet (AIN-93G diet 
modified to contain 60% energy from fat). Data were analyzed by one-way ANOVA. 
Differences between treatment means were determined by  pair-wise comparisons using 
the least squares means test, with P < 0.05 indicating statistical significance. Data are 
expressed as mean values with their standard errors (n = 6). Means with different 
superscripts were significantly different. 
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 F igure 5-5: Non-toxic concentration determination of LWDH ethanol extract by 
 MTT assay in (a) HepG2 cells and (b) L6 myotubes. 
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5.4.2.2. Gene expression in HepG2 cells  
  The effect of the ethanol extract of LWDH on fatty acid oxidation and 
synthesis target gene expression in HepG2 cells is presented in Figure 5-6. Compared to 
the control (0 µg/mL), the LWDH ethanol extract did not affect the gene expression 
levels of AMPK, ACC, CPT1, or FAS.  
 
5.4.2.3. Gene expression in L6 myotubes 
  The effect of the ethanol extract of LWDH on fatty acid oxidation and 
synthesis target gene expression in L6 myotubes is presented in Figure 5-7. The control 
cells were treated with fatty acid (0.25 mM/L palmitate) to simulate the condition in 
response to high-fat diet feeding in the muscle tissue of obese subjects. Under this 
experimental condition, treating L6 myotubes with 100 µg/mL of the LWDH ethanol 
extract led to a significant increase (P = 0.01) in AMPK gene expression. Treatment with 
the 50 and 200 µg/mL LWDH ethanol extract concentrations decreased FAS gene 
expression (P = 0.02 and 0.01, respectively). No treatment effects were observed in ACC 
or CPT1 gene expressions. 
 
 
 
 
 
 
148 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F igure 5-6: Effect of the ethanol extract of LWDH on fatty acid oxidation and synthesis 
target gene expression in HepG2 cells. Data were analyzed by one- way ANOVA. 
Differences between treatment means were determined by pair-wise comparisons using 
the least squares means test, with P < 0.05 indicating statistical significance. Data are 
expressed as mean values with their standard errors (n = 3 independent experiments). 
Means with different superscripts were significantly different.  
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F igure 5-7: Effect of the ethanol extract of LWDH on fatty acid oxidation and synthesis 
target gene expression in L6 myotubes. FA: fatty acid (palmitate; 0.25 mM/L). Data were 
analyzed by one-way ANOVA. Differences between treatment means were determined 
by pair-wise comparisons using the least squares means test, with P < 0.05 indicating 
statistical significance. Data are expressed as mean values with their standard errors (n = 
3 independent experiments). Means with different superscripts were significantly 
different.  
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5.4.2.4. Protein expression in HepG2 cells  
  The effect of the ethanol extract of LWDH on fatty acid oxidation and 
synthesis target protein expression in HepG2 cells is presented in Figure 5-8. Compared 
to control (0 µg/mL), treatment with the extract did not significantly affect the protein 
levels of AMPK, ACC, CPT1, or FAS. Treatment with the 50 and 100 µg/mL extract 
concentrations resulted in significant increases in the protein expressions of pAMPK (P = 
0.01 and 0.001, respectively) and pACC (P = 0.01 and 0.007, respectively).  
 
5.4.2.5. Protein expression in L6 myotubes  
 
  The effect of the ethanol extract of LWDH on fatty acid oxidation and 
synthesis target protein expression levels in FA-treated L6 myotubes is presented in 
Figure 5-9. Compared to control (0.25 mM/L palmitate), treatment with the ethanol 
extract of LWDH led to a significant increase in the protein levels of pAMPK (100 
µg/mL; P = 0.03), pACC (200 µg/mL; P = 0.01), and CPT1 (100 µg/mL and 200 µg/mL; 
P = 0.01 and < 0.001, respectively), and a significant decrease in the protein level of FAS 
(100 µg/mL; P = 0.004).  
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F igure 5-8: Effect of the ethanol extract of LWDH on fatty acid oxidation and synthesis 
target protein expression in HepG2 cells. Data were analyzed by one-way ANOVA. 
Differences between treatment means were determined by pair-wise comparisons using 
the least squares means test, with P < 0.05 indicating statistical significance. Data are 
expressed as mean values with their standard errors (n = 3 independent experiments). 
Means with different superscripts were significantly different.  
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F igure 5-9: Effect of the ethanol extract of LWDH on fatty acid oxidation and synthesis 
target protein expression in L6 myotubes. FA: fatty acid (palmitate; 0.25 mM/L). Data 
were analyzed by one-way ANOVA. Differences between treatment means were 
determined by pair-wise comparisons using the least squares means test, with P < 0.05 
indicating statistical significance. Data are expressed as mean values with their standard 
errors (n = 3 independent experiments). Means with different superscripts were 
significantly different.  
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5.5. Discussion and conclusions 
 In obesity, the ability to adjust fat oxidation in response to excessive fat intake is 
impaired, endogenous fatty acid oxidation capacity is reduced, and induction of genes 
associated with oxidative capacity is stunted (Ceddia 2005; Boyle et al. 2011). 
Collectively, these obesity-associated abnormalities in fatty acid oxidation and synthesis 
have been reported to lead to an increase in circulating and accumulated fatty acids, a 
myriad of chronic diseases, a decrease in the general quality of life, and a reduction in 
average life expectancy (Fine et al. 1999; Hu et al. 2001; Mokdad et al. 2003). Fatty acid 
oxidation and synthesis play an important role in regulating energy metabolism and 
homeostasis. Consequently, these mechanisms determine circulating TG and FFA levels, 
fat storage, and ultimately, body weight. Our previous work (Chapter 2) demonstrated 
that LWDH lowered both TG and FFA levels and prevented weight gain in obese rats 
(Perry et al. 2012). The results of the present studies are consistent with the notion that 
LWDH reduces body weight and blood TG levels through increased fatty acid 
oxidation/decreased fatty acid synthesis.  
 Activation of metabolic pathways which promote fatty acid oxidation has been 
shown to prevent fatty acid accumulation in various tissues (Kahn et al. 2005). One  
pathway that has been garnering significant attention as a mediator of this effect is driven 
by the master cellular energy sensor AMPK (Ceddia 2005). As an upstream regulator of 
ACC and CPT1, AMPK is critically involved in fatty acid oxidation and synthesis 
(Hardie 2004). When AMPK is activated through phosphorylation, it phosphorylates and 
inactivates the downstream target ACC, a key enzyme responsible for the conversion of 
acetyl-CoA to malonyl-CoA (Harwood et al. 2003). Malonyl-CoA is an inhibitor of 
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CPT1, the rate-limiting enzyme responsible for the transport of fatty acids into the 
mitochondrion for beta-oxidation (McGarry 2002). Malonyl-EqC"vjwu"cevu"cu"c"ÐuykvejÑ"
between fatty acid synthesis and oxidation. The reduction of malonyl-CoA results not 
only in a release of the inhibitory effect on CPT1, promoting the transfer of fatty acids 
into the mitochondrion for beta-oxidation, but also in a concomitant suppression of fatty 
acid synthesis (Kahn et al. 2005).  
 Further to the documented alterations in fatty acid oxidation in obesity, weight 
gain has been shown to be associated with increased lipogenesis, resulting in large part 
from stimulated expression of the lipogenic enzyme FAS (Diraison et al. 2002). Indeed, 
FAS is well recognized as a key lipogenic enzyme, rendering it an additionally important 
therapeutic target for the treatment of obesity (Lin et al. 2007). In addition to promoting 
fatty acid oxidation, activation of AMPK has been shown to concomitantly inhibit fatty 
acid synthesis, in large part by way of decreasing FAS expression (Guo et al. 2012). With 
the known relationship between obesity and impaired fatty acid oxidation/synthesis, 
beneficial effects on the AMPK-mediated fatty acid oxidation cascade and/or the 
lipogenic enzyme FAS, either independently or though AMPK activation, have emerged 
as promising targets for the treatment of obesity (Lin et al. 2007; Niu et al. 2012).  
 In the present study, LWDH and its ethanol extract were tested in vivo and in vitro, 
respectively, for their effects on the AMPK-mediated fatty acid oxidation cascade, as 
well as the lipogenic enzyme FAS. In liver tissue, the high-fat diet-mediated down 
regulation of ACC and CPT1 gene expression were reversed toward control levels in 
response to high dose LWDH treatment. The up regulation in FAS gene expression was 
significantly reversed back to control levels in response to the same treatment. All other 
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targets were unaffected in response to either high-fat diet feeding or high dose LWDH 
treatment. Similar results were seen in gene expression analyses using muscle tissue, but 
reversal of the high-fat diet-mediated down regulation of CPT1 gene expression in 
response to high dose LWDH treatment was statistically significant. Western blot 
analyses in vivo were used to assess the effect of LWDH on pAMPK and pACC protein 
expression. An attenuation in the phosphorylation of AMPK and ACC has been linked to 
obesity and several of its associated co-morbidities (Tanaka et al. 2005). In its inactive 
form, ACC, through disinhibition of CPT1, has been shown to promote increased 
mitochondrial entry of fatty acids and a resultant increase in fatty acid oxidation potential 
(McGarry 2002). In the liver tissue, pACC and FAS protein expressions were reversed 
toward control levels in response to high dose LWDH treatment, but these effects were 
not statistically significant. In the muscle tissue, protein expression levels of pAMPK, 
pACC, CPT1, and FAS were all significantly reversed back to control levels by high dose 
LWDH treatment. All other targets were unaffected in response either high-fat diet 
feeding or high dose LWDH treatment. 
 Liver and muscle tissue are both recognized as major regulatory sites of whole 
body fatty acid metabolism (Gallagher et al. 1998). Relevant to the differences in 
treatment effects seen in muscle compared to liver tissue in the present study, it has been 
suggested that tissue-directed activation of lipid metabolism is useful for improving 
and/or managing obesity and several of its related complications (Haramizu et al. 2009). 
In mice with increased body weight as a result of high-fat diet feeding, markers of fatty 
acid oxidation have been shown to be more significantly affected in muscle tissue 
compared to in the liver, with a corresponding increase in susceptibility to the 
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development of obesity (Haramizu et al. 2009). Furthermore, fatty acid metabolism in 
muscle tissue has been shown to be more sensitive to increased physical activity and 
weight loss, during which stored fatty acid utilization increases substantially (Frayn et al. 
2006). As such, muscle tissue appears to represent a superior in vivo model to liver tissue 
for investigating treatment modulating effects on key targets of fatty acid 
oxidation/synthesis.  
 For investigating the efficacy of natural product extracts on fatty acid oxidation 
through the AMPK-mediated cascade, HepG2 cells have been used as a representative in 
vitro model of fatty acid metabolism in the liver (Lin et al. 2007; Niu et al. 2012). To 
simulate the condition of obesity-associated increases in circulating levels of FFA in vitro, 
cells are often pre-treated with varying concentrations of long-chain fatty acids (FA) 
(Watt et al. 2006). In the present study, non-FA-treated HepG2 cells were used to test the 
initial efficacy of the ethanol extract of LWDH on key targets of the AMPK-mediated 
fatty acid oxidation cascade, as well as the lipogenic enzyme FAS. If significant 
treatment effects were to have been elucidated, transition to a FA pre-treatment design 
would have been adopted. At the gene level, however, no statistically significant LWDH 
ethanol extract treatment effects were observed. Protein expression experiments in 
HepG2 cells showed significant increases in pAMPK in response to the 100 µg/mL 
LWDH ethanol extract concentration and in pACC in response to the 50 and 100 µg/mL 
concentrations. It was subsequently decided to select a cell line more representative of the 
muscle and to pre-treat with FA for subsequent gene and protein expression experiments 
using the ethanol extract of LWDH.  
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 Similar to HepG2 cells, L6 myotubes have been used as a representative in vitro 
model of fatty acid metabolism in the muscle for investigating the efficacy of natural 
product extracts on fatty acid oxidation through the AMPK cascade (Watt et al. 2006; 
Kelly et al. 2010). Using FA-treated L6 myotubes in the present study, expression of the 
AMPK gene was significantly increased in response to the 100 µg/mL LWDH ethanol 
extract concentration, while expression of the FAS gene was significantly decreased in 
response to the 50 and 200 µg/mL concentrations. Protein expression of pAMPK and 
pACC was significantly increased in response to the 100 and 200 µg/mL concentrations, 
respectively. Furthermore, FAS levels were decreased in response to the 100 µg/mL 
concentration of the LWDH ethanol extract.  
  
 Upstream activators of AMPK commonly used and reported in the literature 
include, but are not limited to, the pharmacological agent 5-aminoimida-zole-4-
carboxamide riboside (AICAR) and the serine/threonine kinase liver kinase B1 (LKB1) 
(Shaw et al. 2004; King et al. 2006). Future studies investigating the efficacy of LWDH 
and/or its ethanol extract on the AMPK cascade using a combination of 
activators/inhibitors of AMPK may help further elucidate the beneficial effects of the 
product through increased fatty acid oxidation/decreased fatty acid synthesis. In addition, 
although the beneficial effects of LWDH and its ethanol extract were seen on several 
components of the AMPK-mediated fatty acid oxidation cascade, as well as the lipogenic 
enzyme FAS, dose-dependent effects of the extract were variable. Although the ethanol 
extract of LWDH was optimized in vitro to concentration ranges showing no toxic effect, 
further optimization in future studies may help limit variations and elucidate more 
significant and consistent treatment effects.  
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 More recently, a significant amount of research has been conducted on several 
transcription factors thought to be involved in the gene regulation of fatty acid 
oxidation/synthesis. Sirtuin-1 (SIRT1) is a nutrient-sensing deacetylase whose levels and 
activity increase in response to calorie restriction, promoting a more efficient use of 
energy (Gillum et al. 2010). SIRT1 has been reported to increase expression of fatty acid 
oxidation genes and decrease expression of lipogenic genes (Gillum et al. 2010). Another 
key regulator of energy homeostasis that has been garnering significant attention is the 
transcription factor peroxisome proliferator-cevkxcvgf" tgegrvqt" け" eq-cevkxcvqt" 3g" *REI-
3g+0" D{" dkpfkpi" vq" cpf" oqfwncving the activity of various other transcription factors, 
PCG-3g" ecp" oqfwncvg" vjg" gzrtguukqp" qh" c" pwodgt" qh" igpgu" kpxqnxgf" kp" hcvv{" cekf"
oxidation and synthesis alike (Canto et al. 2009; Jeninga et al. 2010). Deacetylation is 
required for the activation of PCG-3g." cpf" UKTV3" ku" vjg" qpn{" rtqvgkp" kfgpvkhkgf" vq" dg"
capable of this function (Rodgers and Puigserver 2007). By way of its phosphorylating 
capabilities, AMPK has also been shown to enhance the ability of SIRT1 to deacetylate 
(and activate) PCG-3g" (Canto et al. 2009). AMPK and SIRT1 have been shown to 
display condordant functions, such as increased fatty acid oxidation, particularly in 
muscle tissue (Fulco and Sartorelli 2008). In fact, AMPK and SIRT1 are now known to 
regulate one another and to have several target molecules in common (Ruderman et al. 
2010). 
!
 
 In sum, increased fatty acid oxidation/decreased fatty acid synthesis appears to be 
strongly representative of the body-weight lowering mechanism of action of LWDH and 
its ethanol extract. These effects were seen more consistently in muscle tissue and rat L6 
skeletal muscle myotubes than in liver tissue and human HepG2 hepatocytes. 
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C H APT E R 6: O V E R A L L DISC USSI O N , T E C H NI C A L C O NSID E R A T I O NS, 
A ND C O N C L UDIN G ST A T E M E N T  
 
6.1. Discussion  
  
 Obesity is now commonly referred to as the epidemic of the 21
st
 century and is 
well recognized to confer significant risk for the development of a myriad of associated 
life threatening complications (Greenberg and Obin 2006). Accumulating evidence 
suggests, however, that even modest reductions in body weight of as little as 5-10% are 
sufficient to improve, or even abolish, the majority of obesity-associated health risks 
(Renehan et al. 2008). In line with the increasing demand to develop safe and efficacious 
anti-obesity products, there has been a global trend towards the discovery and 
development of anti-obesity products from natural sources. As a viable 
complementary/alternative anti-obesity treatment approach, TCM has been garnering 
significant attention as it is considered to have enormous potential as an information 
source and starting point for the development of products to reduce obesity (Yin et al. 
2008; Perry et al. 2012). The ancient TCM, LWDH, has been used extensively worldwide 
for general health promotion, but to date, very little investigation into its potential anti-
obesity efficacy had been documented. 
 
 The objective of Chapter 2 of this thesis was to determine the efficacy of LWDH 
on body weight and composition, food intake, blood lipids, and leptin and insulin 
resistance in obese prone rats. Results from this chapter shed light on the potential for the 
development of LWDH as a natural product for the management of obesity. Treatment 
with LWDH led to significant reductions in body weight, which persisted throughout the 
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last 4 weeks of the study, reaching reductions of greater than 8% by the last 2 weeks. In 
addition, significant reductions in visceral fat deposition and circulating blood lipids, and 
improvements in leptin and insulin sensitivity were also elucidated. These parameters are 
all highly related to obesity and an improvement in any one is, in turn, beneficial to 
weight control and the mitigation of obesity-related complications (Yuan et al. 2007). 
Further to the beneficial effects on body weight and several associated parameters, 
LWDH led to significant reductions in food intake. Dietary restriction without 
malnutrition ameliorates a wide array of age-related complications and prolongs life in a 
variety of species, including rats (Colman et al. 2009; Ellers et al. 2011). In the present 
thesis, the possible confounding effect of caloric dilution by LWDH on several 
investigated parameters, including body weight, was raised. However, it is not believed 
that caloric dilution influenced the outcomes presented in this thesis and/or in the data 
published or under consideration for publication in the peer-reviewed literature. Although 
presented as a weekly average in this thesis, food intake was recorded on a daily basis 
throughout the in vivo study. Food intake during the 2 week acclimation period was 
consistent and did not differ between control and treatment animals during the entire first 
week of LWDH treatment by oral gavage. If caloric dilution had influenced body weight 
or any of the post-sacrifice parameters that were subsequently measured, food intake 
would have been reduced during the first week of treatment. Furthermore, the high-fat 
diet that was fed to all experimental animals was administered ad libitum throughout the 
study period, and not restricted to immediately post-gavage. All animals were monitored 
on a daily basis for general well being throughout the study (with the help of Dr. 
Jonathon Spears, University Veterinarian, personal communication), and the rate of 
161 
stomach emptying did not appear to differ between the control and treatment animals. 
Furthermore, post-sacrifice liver function testing revealed no adverse side effects in 
response to LWDH treatment by twice-daily oral gavage. In fact, high-dose LWDH 
treatment was revealed to have improved liver function. Thus, rather than as a result of 
caloric dilution, the LWDH-mediated reductions in body weight were believed to be due 
to one of two potential mechanisms of action, which were investigated in subsequent 
chapters of this thesis. Chapter 4 investigated decreased energy consumption through 
appetite regulation as a potential body weight-lowering mechanism of action, while 
chapter 5 investigated the effects of LWDH and its ethanol extract on key targets of fatty 
acid oxidation/synthesis. 
 
 Prior to investigating the two proposed body weight-lowering mechanisms of 
action of LWDH and its ethanol extract, chapter 3 of this thesis was conducted to 
evaluate the efficacy of LWDH on obesity-associated biomarkers of inflammation, 
oxidative stress, and adiponectin production in obese-prone rats. Obesity is now 
recognized to be strongly associated with chronic inflammation (O'Rourke 2009), 
including elevations in the pro-inflammatory cytokine TNF-g."vjg"ejtqpke"kphncoocvqt{"
biomarkers CRP, and the acute phase pro-inflammatory cytokine IL-6 (Hotamisligil et al. 
1993; Browning et al. 2008). Adipose tissue of obese individuals is also a major source of 
circulating ROS and has suppressed antioxidant enzyme activity (Furukawa et al. 2004). 
Furthermore, obesity is associated with dysregulated production of various adipokines, 
including adiponectin (Yamauchi et al. 2001). Overall, this study demonstrate
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first time, the anti-inflammatory, anti-oxidative stress, and adiponectin-ameliorating 
efficacy of LWDH in OP-CD rats.  
 
 The objective of Chapter 4 of this thesis was to determine the efficacy of LWDH 
and its ethanol extract on appetite regulation by analyzing treatment effects on gut 
hormones and neuropeptides along the gut-brain axis. Both in vivo and in vitro 
experimental designs were employed to test the efficacy of LWDH and its ethanol extract, 
respectively. Recently, there has been increasingly convincing evidence that weight loss 
may be due to alterations in the circulating levels and physiology of various gut 
hormones and neuropeptides (Murphy and Bloom 2004; Cummings and Overduin 2007). 
Gut hormones act specifically on systems responsible for appetite control, and due to 
their inherently natural physiological regulation of appetite (Murphy et al. 2006), gut 
hormone-based therapies are reportedly less likely to cause adverse side effects compared 
to some of the currently approved drugs (Chaudhri et al. 2008). Overall, under the 
experimental conditions described in Chapter 4, LWDH and its ethanol extract did not 
significantly affect key components of the gut-brain axis. Although this was the first 
study to investigate the efficacy of LWDH on appetite regulation through the gut-brain 
axis as a potential body weight-lowering mechanism of action, several points have 
potential to be addressed in future studies. The orexigenic gut hormone, ghrelin, was a 
key target of investigation in Chapter 4 of this thesis. Ghrelin gene expression was 
analyzed in ileal tissue of obese rats. However, ghrelin is predominantly expressed and 
secreted from the stomach!" and to a much lesser degree from the small intestine (Date et 
al. 2000). Unfortunately, stomach tissue was not collected at the time of sacrifice for 
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subsequent biochemical or molecular analyses. Although the intestinal CaCo-2 cell line 
has previously been used as a relevant model for studying ghrelin gene expression 
(Yeung et al. 2006), cultured tissue from the stomach may represent a more 
physiologically relevant site for the study of ghrelin secretion (Zhao et al. 2010). As such, 
the CaCo-2 cell line may not have been sufficiently representative of the actual effect of 
the extract on ghrelin gene expression. In the CNS, the hypothalamic Arc is the key 
region involved in the regulation of appetite (Murphy and Bloom 2004). Furthermore, 
expression of NPY, the most potent activator of appetite in the CNS (Valassi et al. 2008), 
predominates in the Arc region (Williams et al. 2001). At the time of sacrifice, the entire 
hypothalamic region of the brain was collected and subsequently processed for gene 
expression analyses. As such, other hypothalamic regions expressing NPY, albeit to a 
lesser degree, may have confounded the specificity of the results. In addition, although 
the SH-SY5Y cell line employed for investigating the efficacy of the LWDH ethanol 
extract on NPY gene expression is representative of the CNS, primary cell cultures using 
the specific Arc region of the hypothalamus may prove useful for more specific 
elucidation of the true effects in future investigations. Continued research into the 
potential to pharmacologically exploit endogenously occurring appetite-modulating gut 
hormones in an effort to regulate energy homeostasis is required. Nonetheless, there is 
strong evidence in support of further investigation into the release and function of gut 
hormones in association with neuropeptides and receptors in the CNS for the 
development of weight loss or weight maintenance products.  
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 The objective of Chapter 5 of this thesis was to determine the efficacy of LWDH 
and its ethanol extract on key targets of fatty acid oxidation and synthesis. In obesity, the 
ability to adjust fat oxidation in response to excessive dietary fat intake is impaired, 
endogenous fatty acid oxidation capacity is reduced, and induction of genes associated 
with oxidative capacity is stunted (Boyle et al. 2011). Further to the documented 
alterations in fatty acid oxidation in obesity, weight gain is often associated with 
increased lipogenesis (Lewandowski et al. 1998; Strable and Ntambi 2010), resulting in 
large part from stimulated expression of the lipogenic enzyme FAS (Diraison et al. 2002). 
Several other factors involved in the regulation of lipogenesis have been identified 
(Kersten 2001), including nutritional (glycolytic conversion of glucose to acetyl-CoA), 
hormonal (primarily insulin), and transcriptional (primarily sterol regulatory element 
binding protein-1c). Collectively, these obesity-associated abnormalities in fatty acid 
oxidation and synthesis have been shown to lead to increased circulating and 
accumulated fatty acids and a myriad of obesity-associated co-morbidities (Mokdad et al. 
2003). Improvements in leptin and/or insulin sensitivity have been shown to stimulate 
fatty acid oxidation, correspondingly resulting in a reduction in circulating TG and FFA 
levels (Gil-Campos et al. 2004). In addition, activation of metabolic pathways which 
promote fatty acid oxidation has been shown to prevent fatty acid accumulation in 
various tissues. One such pathway which has been garnering significant attention as a 
mediator of this effect is driven by the master cellular energy sensor AMPK (Ceddia 
2005). With the known relationship between obesity and impaired fatty acid 
oxidation/synthesis, beneficial effects on the AMPK-mediated fatty acid oxidation 
cascade and/or the lipogenic enzyme FAS, either independently or though AMPK 
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activation, represent promising anti-obesity targets (Niu et al. 2012).! Overall, increased 
fatty acid oxidation/decreased fatty acid synthesis appeared to have strong potential as a 
body-weight lowering mechanism of action of LWDH and its ethanol extract, especially 
in muscle tissue and FA-treated L6 skeletal muscle myotubes. Nonetheless, several points 
have potential to be addressed in future studies investigating the body weight-lowering 
mechanism of action of LWDH and/or its ethanol extract through regulation of key fatty 
acid oxidation/synthesis! targets. Liver and muscle tissue both represent major regulatory 
sites of whole body fatty acid metabolism (Gallagher et al. 1998). It has also been 
suggested, however, that tissue-directed activation of fatty acid metabolism is useful for 
improving and/or managing obesity (Haramizu et al. 2009). Fatty acid oxidation is more 
significantly affected in muscle compared to in liver tissue (Haramizu et al. 2009). 
Furthermore, fatty acid metabolism in muscle tissue has been shown to be more sensitive 
to physical activity and weight loss (Frayn et al. 2006). As a result, muscle tissue and 
representative muscle cell lines may prove to be more useful models for investigating 
treatment efficacy on key targets of fatty acid oxidation/synthesis in future studies. Future 
studies investigating the efficacy of LWDH and/or its ethanol extract on the AMPK 
cascade using a combination of activators/inhibitors of AMPK may also help to further 
elucidate the beneficial effects of the product in terms of its potential effects on fatty acid 
oxidation and synthesis. 
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6.2. T echnical considerations 
6.2.1. Dosage optimization   
 Treatment with the herbal formula LWDH throughout this thesis was by 
administration of a partially-refined concentrated pill. The high doses chosen for use in 
this thesis have had precedent in the literature in diabetic rat studies (Xue et al. 2005) and 
for general health promotion in humans (Hu et al. 2005). The optimal treatment dosages 
for weight management in rats had, to date, not been investigated and remain to be 
determined in humans. Nonetheless, the treatment dosages used in this thesis had 
potential to be significantly reduced when administered in the form of an extract or 
fraction. As such, an ethanol extract of LWDH was used for further in vitro investigation 
into the potential mechanisms of action of the LWDH-mediated reductions in body 
weight in Chapters 4 and 5. Although non-toxic treatment concentrations were 
determined in all of the in vitro models used, future studies may benefit from further 
dosage optimization in an effort to minimize variations and to elucidate more significant 
and concentration-dependent treatment effects. For instance, as the ethanol extract of 
LWDH contains considerable amounts of sugar monomers, dimers, and trimers, the 
concentration could be further reduced by removing the majority of these saccharides. Of 
the major components elucidated from the LWDH ethanol extract, two in particular may 
warrant further investigation. Paeonoforin has been reported to have anti-obesity 
properties (Rabie 2009) and gallic acid has been reported to suppress weight gain by 
inhibiting pre-adipocyte growth or proliferation (Hsu et al. 2006; Hsu and Yen 2007). 
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6.2.2. Appetite regulation 
 As a body weight-lowering mechanism of action of LWDH and/or its ethanol 
extract, appetite regulation through alterations in key components of the gut-brain axis!
did not appear to show promising potential under the current experimental conditions. 
Future investigations into this potential working mechanism would stand to benefit by 
considering the short half-life of the majority of endogenous gut hormones and selection 
of the most relevant physiological sites of production/secretion of the targeted parameters. 
Overall, however, future development of safe and effective anti-obesity treatments 
through appetite modulation!continues to have promising potential.!!
 
6.2.3. Regulation of fatty acid metabolism 
 Increased fatty acid oxidation/decreased fatty acid synthesis appeared to strongly 
represent a potential body-weight lowering mechanism of action of LWDH and its 
ethanol extract under the current experimental conditions. As AMPK is the master 
regulator of this effect, future studies with further targeted activation/inhibition of AMPK 
may help further elucidate any LWDH- and/or ethanol extract-mediated effects through 
this mechanism. Investigation into treatment effects on novel transcription factors 
involved in the regulation of fatty acid oxidation/synthesis may also be warranted. 
 
6.2.4. Choice of reference gene for qPCR experiments 
 Reference genes typically encode for proteins involved in cell maintenance and 
are constitutively expressed under most experimental conditions (Mehta et al. 2010). The 
commonly employed reference genes generally meet this key criterion, but unstable 
changes in expression may present, depending on the experimental conditions and the 
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tissue or cell type being analyzed (Lundby et al. 2005). This may affect the normalizing 
procedure to correct for mRNA content variations between samples (Whelan et al. 2003). 
Glyceraldehyde 3-rjqurjcvg"fgj{ftqigpcug"*ICRFJ+"cpf"く-actin have been among the 
most commonly used reference genes for qPCR experiments (Radonic et al. 2004; Lin 
and Redies 2012). However, their transcription has been shown to be differentially 
expressed in various tissues (Jemiolo and Trappe 2004) and it is now known that neither 
GAPDH pqt"く-actin mRNA is expressed in all cell or tissue types (Lin and Redies 2012). 
In the present thesis, く-actin was chosen as the reference gene for all qPCR experiments. 
Igpg" gzrtguukqp" qh" く-actin is known to be stably expressed in liver tissue (Sun et al. 
2009). In skeletal muscle tissue, however, GAPDH has been reported to be more stably 
gzrtguugf"vjcp"く-actin (Mahoney et al. 2004). Furthermore, the experimental conditions 
can affect the expression of different reference genes in the same tissue. In human 
skeletal muscle following acute exercise, く-actin is more stably expressed that GAPDH 
following resistance exercise, and vice versa following endurance exercise (Mahoney et 
al. 2004). Future studies would stand to benefit by normalizing against greater than one 
reference gene (Bustin et al. 2009), and furthermore, determining and reporting the 
choice and optimal number of these genes (Vandesompele et al. 2002; Bustin et al. 2009). 
 
6.3. Concluding statement!
 Control of body weight in an effort to improve or reverse the deleterious obesity-
associated effects on the general quality of human life and its enormous economic burden 
on the health care system is a top priority in nutritional and medical research (Stein and 
Colditz 2004; Lakdawalla et al. 2005; Perry et al. 2012). This thesis was the first to 
investigate the efficacy of LWDH against obesity and several of its associated 
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complications. Our results demonstrated the efficacy and safety of this promising anti-
obesity TCM in obese-prone rats. Furthermore, we proposed two potential body weight-
lowering mechanisms of LWDH and designed in vitro experiments to investigate an 
ethanol extract of the product. Future studies are required but highly warranted. The 
technical considerations provided herein may help unlock the full potential of this 
promising future anti-obesity therapeutic.  
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Table A A-1: Composition of mineral mix in AIN-93G diet (per 1 kg) 
 
Ingredient Amount (g) 
Sodium chloride 259.0 
Magnesium oxide 41.9 
203 
Magnesium sulfate 257.6 
Chromium sulfate 1.925 
Cupric carbonate 1.05 
Sodium fluoride 0.2 
Potassium iodate 0.035 
Ferric citrate 21.0 
Manganous carbonate 12.25 
Ammonium molybdate 0.3 
Sodium selenite 0.035 
Zinc carbonate 5.6 
Sucrose 399.1 
 
 
Table A A-2: Composition of vitamin mix in AIN-93G diet (per 1 kg) 
 
Ingredient Amount (g) 
Vitamin A palmitate 0.8 
204 
Vitamin D3 1.0 
Vitamin E acetate 10.0 
Menadione sodium bisulfate 0.08 
Biotin 2.0 
Cyanococobalamin 1.0 
Folic acid 0.2 
Nicotinic acid 3.0 
Calcium pantothenate 1.6 
Pyridoxine-HCl 0.7 
Riboflavin 0.6 
Thiamin HCl 0.6 
Sucrose 978.42 
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T A B L E A B-1: Feed efficiency of obese rats fed a high-fat diet* 
 
G roup W k 0 W k 1 W k 2 W k 3 W k 4 W k 5 W k 6 W k 7 W k 8 W k 9 
206 
O R 0.40 0.53 0.56 0.72 0.69 1.23 1.01 1.04 2.49 2.19 
OP 0.31 0.44 0.42 0.56 0.58 0.81 0.84 0.92 1.80 4.12 
T1A 0.38 0.40 0.40 0.61 0.62 0.78 0.80 0.86 1.67 2.33 
T1B 0.38 0.39 0.38 0.55 0.54 0.68 0.89 0.83 1.97 2.55 
T1C 0.40 0.43 0.41 0.54 0.60 0.77 1.16 1.05 3.53 4.57 
 
          
*Calculated as a ratio of food intake to weight gain. 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPE NDI X C : PRI M E R SE Q U E N C ES USE D F O R Q U A N T I T A T I V E R E A L-
T I M E PO L Y M E R ASE C H A IN R E A C T I O N E XPE RI M E N TS T H R O U G H O U T 
T H E T H ESIS 
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Table A C-1: Primer sequences used for the detection of mRNA expression of appetite 
regulation genes in rat ileal and hypothalamic tissues 
!
Gene Forward Primer Sequence Reverse Primer Sequence 
   
208 
く"cevkp AGCCATGTACGTAGCCATCC 
 
ACCCTCATAGATGGGCACAG 
 
Ghrelin CACCAGAAAGCCCAGCAGAGA 
 
CGAAGGGAGCATTGAACCTGA  
PYY GCGGTATGGGAAAAGAGAAGTCC  GCAAGTGAAGTCGGTGTAGTTAGCA 
 
NPY CCAGACAGAGATATGGCAAG 
 
GTCTTCAAGCCTTGTTCTGG 
 
   
!
!
!
!
!
!
!
!
!
!
!
 
Table A C-2: Primer sequences used for the detection of mRNA expression of appetite 
regulation genes in CaCo-2 and SH-SY5Y cells 
!
Gene Forward Primer Sequence Reverse Primer Sequence 
209 
 
く"cevkp 
 
AGCCATGTACGTAGCCATCC 
 
 
ACCCTCATAGATGGGCACAG 
 
Ghrelin GCAGAGGATGAACTGGAAGTCC  CTCTTCCCAGAGGATGTCCTGA 
 
PYY CGGACACGCTTCTTTCCAAAACG 
 
TGGTTGGCAGATCTCCCAGGAG 
 
NPY GCTGCGACACTACATCAACCTC  TGTGCTTTCTCTCATCAAGAGG 
 
   
!
!
!
!
!
!
!
!
!
!
 
Table A C-3: Primer sequences used for measuring mRNA expression of the genes 
regulating fatty acid oxidation and synthesis in rat liver and muscle tissue 
!
Gene Forward Primer Sequence Reverse Primer Sequence 
210 
 
く"cevkp 
 
AGCCATGTACGTAGCCATCC 
 
 
ACCCTCATAGATGGGCACAG 
 
AMPK AGGAAGAATCCTGTGACAAGCAC 
 
CCGATCTCTGTGGAGTAGCAGT 
 
ACC GACGAGCTGATCTCCATCCTCA 
 
ATGGACTCCACCTGGTTATGCC 
 
CPT1 GATCCTGGACAATACCTCGGAG 
 
CTCCACAGCATCAAGAGACTGC 
 
FAS TTCTACGGATCCACGCTCTTCC 
 
GAAGAGTCTTCGTCAGCCAGGA 
 
!
!
!
!
!
!
!
 
 
Table A C-4: Primer sequences used for the detection of mRNA expression of genes 
controlling fatty acid oxidation and synthesis in HepG2 cells and L6 myotubes 
 
Gene Forward Primer Sequence Reverse Primer Sequence 
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く"cevkp 
 
AGCCATGTACGTAGCCATCC 
 
 
ACCCTCATAGATGGGCACAG 
 
AMPK AGGAAGAATCCTGTGACAAGCAC 
 
CCGATCTCTGTGGAGTAGCAGT 
 
ACC GACGAGCTGATCTCCATCCTCA 
 
ATGGACTCCACCTGGTTATGCC 
 
CPT1 GATCCTGGACAATACCTCGGAG 
 
CTCCACAGCATCAAGAGACTGC 
 
FAS TTCTACGGATCCACGCTCTTCC 
 
GAAGAGTCTTCGTCAGCCAGGA 
 
 
 
 
 
 
 
APPE NDI X D: M AJO R C O MPO UNDS E L U C ID A T E D IN L W D H E T H A N O L 
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Table A D-1: Major compounds in LWDH ethanol extract separated with C18 column 
 
Ions (m/z) M .W . Possible Compound 
213 
Positive ion Negative ion   
- 169[M-H]
-
, 
339[2M-H]
-
 
170 gallic acid 
127[M+H]
+
, 
109[M+H-H2O]
+
 
- 126 5-hydroxymethyl 
furfural 
359[M+H]
+
, 
197[M+H+H2O-glu]
+
 
403[M+HCOO]
-
 358 sweroside 
229[M+H+H2O-glu]
+
, 
413[M+Na]
+
 
435[M+HCOO]
-
 390 loganin 
498[M+NH4]
+
 525[M+HCOO]
-
 480 paeoniforin 
167[M+H]
+
 - 166 paeonol 
 
 
 
 
 
 
 
 
 
 
Table A D-2: Major compounds in LWDH ethanol extract separated with HILIC column 
 
Negative ion (m/z) M .W . Possible Compound 
169[M-H]
-
, 170, loganin and gallic acid 
214 
435[M+HCOO]
-
 390 
mix 
179[M-H]
-
, 
225[M+HCOO]
-
, 
293[M+Cl]
-
, 
367[M+Cl]
-
 
180, 
258, 
332 
mix 
monosaccharide, 5-
hydroxymethyl furfual with 
monosaccharide and gallic 
acid with monsaccharide 
179[M-H]
-
, 
225[M+HCOO]
-
 
180 monosaccharide 
295[M-H]
-
, 
455[M-H]
-
 
296, 
456 
mix 
di- and tri-saccharide 
 
 
 
 
 
 
 
 
 
 
 
APPE NDI X E : R A W Q U A N T I T A T I V E R E A L-T I M E PO L Y M E R ASE C H A IN 
R E A C T I O N D A T A F R O M T H E T H ESIS 
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Table A E-1: Raw data used for detecting mRNA expression of appetite regulation genes 
in rat ileal tissue  
Gene  OP   T1C  
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Table A E-2: Raw data used for the detection of mRNA expression of appetite regulation 
genes in rat hypothalamic tissue 
 
 Run 1 Run 2 Run 3 Run 1 Run 2 Run 3 
PY Y 20.81 20.73 20.74 22.24 22.48 22.37 
 25.51 25.60 25.50 19.30 19.34 19.42 
 18.67 18.68 18.79 18.43 18.49 18.51 
 19.37 19.46 19.40 21.38 21.57 21.52 
 21.81 21.85 22.00 21.74 22.13 21.75 
 19.77 18.6 20.15 18.63 18.74 18.72 
Ghrelin 35.55 29.90 30.26 27.88 28.46 28.57 
 29.31 28.64 29.43 29.40 - 29.67 
 28.60 28.01 28.21 26.57 26.70 26.57 
 30.07 31.07 30.01 28.09 27.71 27.50 
 28.42 29.44 28.63 29.59 29.90 29.52 
 25.32 25.35 25.55 29.62 30.34 29.28 
く"cevkp 16.48 17.01 17.03 16.65 16.76 16.65 
 19.65 19.73 19.85 16.23 16.13 16.13 
 16.13 16.12 16.10 15.13 15.03 15.00 
 16.13 16.11 16.02 14.21 14.15 14.23 
 16.05 15.99 15.98 15.79 15.91 15.78 
 14.27 14.29 14.27 15.81 15.99 15.91 
217 
Gene  OP   T1C  
 Run 1 Run 2 Run 3 Run 1 Run 2 Run 3 
NPY 17.38 17.45 17.42 18.17 18.18 18.18 
 18.76 18.64 18.70 17.17 17.27 17.22 
 17.32 17.2 17.26 18.88 18.92 18.90 
 17.30 17.42 17.36 16.96 17.15 17.06 
 17.83 17.91 17.87 17.42 17.49 17.46 
 17.92 17.97 17.95 17.42 17.54 17.48 
く"cevkp 13.04 13.13 13.09 13.69 13.51 13.60 
 13.36 13.36 13.36 13.24 13.28 13.26 
 12.89 12.84 12.87 13.46 13.51 13.49 
 12.67 12.40 12.54 13.12 12.88 13.00 
 13.18 13.16 13.17 13.28 13.35 13.32 
 13.19 13.23 13.21 13.34 13.36 13.35 
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Table A E-3: Raw data used for measuring mRNA expression of appetite regulation genes in CaCo-2 cells by qPCR 
 
 
 
 
 
 
 
 
 
0, 25, 50, and 100 represent the concentrations of the LWDH ethanol extract in µg/mL. 
 
 
 
 
 
Concentration   PY Y   Ghrelin   く"cevkp  
 Run 1 Run 2 Run 3 Run 1 Run 2 Run 3 Run 1 Run 2 Run 3 
0 27.71 29.21 28.46 28.52 28.25 28.385 14.44 14.87 14.66 
25 28.79 27.33 28.06 28.31 28.35 28.33 14.84 15.03 14.94 
50 27.38 28.23 27.805 28.57 27.97 28.27 15.50 14.85 15.18 
100 28.84 27.81 28.33 27.94 28.32 28.13 14.69 14.98 14.84 
219 
Table A E-4: Raw data used for measuring mRNA expression of appetite regulation 
genes in SH-SY5Y cells by qPCR 
 
Concentration   NPY   く"cevkp  
 Run 1 Run 2 Run 3 Run 1 Run 2 Run 3 
0 19.50 19.78 19.47 12.57 12.70 12.52 
5 19.66 19.63 19.45 12.58 12.54 12.56 
10 19.76 19.70 19.60 12.77 12.59 12.92 
25 19.79 19.79 19.71 12.84 13.36 12.82 
 
0, 5, 10, and 25 represent the concentrations of the LWDH ethanol extract in µg/mL. 
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Table A E-5: Raw data used for the detection of mRNA expression of key targets of fatty 
acid oxidation and synthesis from rat liver tissue cDNA samples by qPCR 
 
Gene  O R   OP   T1C  
 Run 1 Run 2 Run 3 Run 1 Run 2 Run 3 Run 1 Run 2 Run 3 
A MP K 19.82 21.94 20.13 21.45 23.32 19.58 20.73 22.67 19.26 
 20.06 22.35 20.15 20.64 22.72 19.56 21.44 23.45 19.55 
 19.23 21.18 20.33 20.92 23.18 19.90 21.38 23.53 19.97 
 19.14 21.20 20.25 21.54 23.58 19.98 20.24 22.28 20.24 
 19.64 21.57 21.02 19.97 22.11 20.13 20.75 22.68 21.16 
 - 20.87 20.57 20.66 22.59 20.04 - 23.97 21.17 
A C C 22.26 24.31 22.80 15.26 22.77 19.46 11.53 25.43 19.43 
 22.96 36.78 23.15 23.29 23.29 19.04 30.55 26.27 19.37 
 30.86 23.82 23.81 17.38 20.56 19.26 - 24.27 19.43 
 - 22.24 20.97 19.04 22.47 19.09 26.60 24.08 19.14 
 22.6 23.49 19.46 30.46 23.76 19.27 21.40 22.84 19.28 
 22.63 18.58 24.23 12.15 30.40 19.30 13.85 28.57 19.23 
CPT1 20.67 33.74 30.36 36.23 24.92 19.53 29.26 25.16 30.86 
 28.51 34.80 35.41 36.32 26.78 21.39 35.01 14.63 39.98 
 29.28 33.16 28.73 30.65 27.56 32.92 - 17.07 27.83 
 38.25 30.67 14.33 17.68 24.16 26.67 33.49 29.93 30.36 
 - 37.52 29.31 33.68 26.02 36.44 30.27 16.54 35.41 
 30.78 33.52 28.97 16.27 13.65 26.50 13.62 20.44 28.73 
F AS 33.22 31.77 26.06 30.67 32.34 27.25 30.78 26.06 21.92 
 30.27 33.75 32.76 26.76 27.73 25.47 32.08 32.76 20.16 
 34.80 28.54 33.46 30.54 29.03 24.61 33.54 33.46 20.60 
 33.98 30.86 22.88 34.47 28.36 24.56 36.86 22.88 20.59 
221 
 30.82 32.99 36.63 25.68 29.21 25.11 34.27 36.63 20.62 
 31.49 31.72 32.76 29.58 27.63 20.34 31.81 32.76 21.83 
く"cevkp 14.31 13.75 14.80 14.45 14.66 15.38 14.38 14.57 15.87 
 14.4 14.43 15.22 14.33 14.27 15.12 14.41 14.34 15.51 
 13.71 14.42 14.28 14.31 14.34 15.41 14.26 14.3 15.59 
 14.38 14.17 14.52 14.31 14.66 15.45 14.45 14.22 15.02 
 14.41 14.61 15.23 14.4 14.15 15.16 14.33 14.52 15.24 
 14.26 13.82 15.22 13.71 13.6 14.58 14.31 14.56 15.52 
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Table A E-6: Raw data used for detection of mRNA expression of key targets of fatty 
acid oxidation and synthesis from rat muscle tissue cDNA samples by qPCR 
 
Gene O R OP T1C 
 Run 1 Run 2 Run 1 Run 2 Run 1 Run 2 
A MP K 19.53 21.22 25.42 27.36 22.36 24.51 
 24.77 26.93 23.99 25.83 25.11 27.57 
 23.23 27.47 24.04 25.99 25.01 27.17 
 28.06 30.14 27.04 29.07 - 36.67 
A C C 23.15 23.82 36.38 33.93 20.13 19.43 
 23.81 22.24 14.79 36.61 20.04 19.14 
 20.97 24.31 22.80 23.68 21.38 19.28 
 19.46 23.49 18.48 34.38 20.24 19.23 
CPT1 20.92 19.40 23.29 25.53 20.92 22.11 
 21.54 - 20.56 18.04 21.54 22.59 
 19.97 21.18 22.47 24.12 19.97 22.77 
 20.66 20.93 23.76 32.07 20.66 23.29 
F AS 36.15 36.18 18.8 24.61 28.99 38.36 
 32.43 - 21.92 24.56 35.02 38.78 
 34.79 38.85 20.16 25.11 35.07 36.13 
 30.10 38.86 20.60 20.34 31.80 36.15 
く"cevkp 14.8 14.28 15.38 14.27 15.59 15.24 
 15.22 14.52 15.12 14.34 15.02 14.45 
 14.28 15.23 15.41 14.66 15.24 14.33 
 14.52 15.22 15.45 14.15 15.52 15.41 
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Table A E-7: Raw data used for detection of mRNA expression of key targets of fatty 
acid oxidation and synthesis from HepG2 cell cDNA samples by qPCR 
 
Concentration   A MP K   A C C   CPT   
 Run 
1 
Run 
2 
Run 
3 
Run 
1 
Run 
2 
Run 
3 
Run 
1 
Run 
2 
Run 
3 
0 19.11 18.91 17.68 25.13 23.53 25.38 19.29 19.32 20.83 
25 18.90 19.52 16.90 25.32 25.38 28.17 19.23 19.36 21.57 
50 18.94 18.87 17.70 25.22 23.62 26.40 19.25 19.53 21.41 
100 19.51 18.92 18.11 25.93 23.40 26.46 19.78 19.74 21.55 
 
 
Concentration   F AS   く actin  
 Run 1 Run 2 Run 3 Run 1 Run 2 Run 3 
0 22.19 22.24 20.57 13.79 13.47 13.64 
25 22.14 22.42 20.90 13.65 14.28 13.28 
50 22.20 22.23 20.92 13.76 13.99 13.47 
100 22.90 23.00 21.15 14.00 14.24 14.66 
 
 
0, 25, 50, and 100 represent the concentrations of the LWDH ethanol extract in µg/mL. 
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Table A E-8: Raw data used for detection of mRNA expression of key targets of fatty 
acid oxidation and synthesis from L6 myotube cDNA samples by qPCR 
 
 
 
Concentration   F AS   く actin  
 Run 1 Run 2 Run 3 Run 1 Run 2 Run 3 
0 17.38 14.84 16.31 11.91 10.21 11.29 
F A 17.11 16.31 14.43 10.28 11.52 10.85 
50 17 16.65 15.87 11.36 10.02 12.23 
100 15.97 18.46 15.59 11.54 11.47 11.64 
200 15.78 17.32 16.75 10.64 9.87 10.83 
 
 
0, 50, 100, and 200 represent LWDH ethanol extract concentrations in µg/mL. FA: fatty 
acid (palmitate; 0.25 mM/L). 
 
 
Concentration   A MP K   A C C   CPT1  
 Run 
1 
Run 
2 
Run 
3 
Run 
1 
Run 
2 
Run 
3 
Run 
1 
Run 
2 
Run 
3 
0 17.49 16.12 15.49 15.82 12.5 12.33 17.02 17.86 15.09 
F A 20.38 15.87 16.63 18.69 15.19 13.17 18.81 19.25 - 
50 17.85 16.67 15.59 15.82 11.89 12.97 17.02 17.86 15.33 
100 18.8 16.24 16.69 16.96 14.84 12.38 19.04 16.44 15.65 
200 20.14 16.16 15.13 16.16 15.19 11.70 18.06 16.48 16.41 
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APPE NDI X F : B I C IN C H O NINI C A C ID ASSA Y ST A ND A RD C UR V ES F O R T H E 
D E T E R M IN A T I O N O F T O T A L PR O T E IN C O N C E N T R A T I O N T H R O U G H O U T 
T H E T H ESIS  
!
!
!
!
!
!
!
!
!
!
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!
!
!
!
!
!
!
!
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!
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!
!
!
F igure A F-1: BCA assay standard curve for the determination of total protein 
concentration in rat liver. 
!
!
!
!
!
!
!
!
!
!
!
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!
!
!
!
!
F igure A F-2: BCA assay standard curve for the determination of total protein 
concentration in rat muscle. 
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!
F igure A F-3: BCA assay standard curve for the determination of total protein 
concentration in HepG2 cells. 
!
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!
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!
F igure A F-4: BCA assay standard curve for the determination of total protein 
concentration in L6 myotubes. 
!
!
!
!
!
!
!
!
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APPE NDI X G : W EST E RN B L O T R ESO L V IN G A ND ST A C K IN G G E L 
IN G R E DI E N TS USE D T H R O U G H O U T T H E T H ESIS  
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Table A G-1: Western blot (a) resolving gel and (b) stacking gel ingredients̆* 
 
(a) Ingredient (µ L) 7% 10% 
30% acrylamide 2300 3300 
4 X resolving gel buffer 2500 2500 
dH2O 5200 4200 
25% AP 30 30 
TEMED 5 5 
!
(b) Ingredient (µ L) 3% 4% 
30% acrylamide 500 650 
4 X stacking gel buffer 1250 1250 
dH2O 3300 3100 
25% AP 15 15 
TEMED 10 10 
!
Resolving gel buffer (4 X): 9.09 g Tris base, 2 mL 10% sodium dodecyl sulfate (SDS), 
and enough dH2O to reach a final volume of 50 mL (adjusted to pH 8.8). AP: ammonium 
persulfate dissolved to 25% using dH2O; TEMED: tetramethylethylenediamine; stacking 
gel buffer (4 X): 3.03 g Tris base, 2 mL SDS, and enough water to reach a final volume 
of 50 mL (adjusted to pH 6.8). 
̆
Proteins > 100 kDa in size were run on gels comprised of 
10 and 4% resolving and stacking gels, respectively. *Volume per gel.  
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APPE NDI X H : DI L U T I O N F A C T O RS A ND H OST SO UR C ES O F A N T IB O DI ES 
USE D F O R PR O T E IN D E T E C T I O N T H R O U G H O U T T H E T H ESIS  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
233 
Table A H-1: Dilution factors and sources of primary and secondary antibodies used for 
detecting fatty acid oxidation and synthesis target proteins in rat liver and muscle tissues 
 
Protein 1º Ab Source 2º Ab Source 
AMPK 1:2500 Rabbit 1:5000 Anti-rabbit 
pAMPK 1:1000 Rabbit 1:2000 Anti-rabbit 
ACC 1:1000 Goat 1:2000 Anti-goat 
pACC 1:1000 Rabbit 1:2000 Anti-rabbit 
CPT1 1:500 Rabbit 1:1000 Anti-rabbit 
FAS 1:1000 Rabbit 1:2000 Anti-rabbit 
actin 1:2000 Rabbit 1:5000 Anti-rabbit 
!
Antibody vendors and catalogue numbers: AMPK (Santa Cruz; sc-25792), pAMPK 
(Santa Cruz; sc-33524), ACC (Santa Cruz; sc-26822), pACC (Santa Cruz; sc-30446-R), 
CPT1 (Santa Cruz ; sc-98834), FAS (Novus Biologicals; NB400-14), actin (Santa Cruz, 
sc-1616), anti-rabbit 2º Ab (Santa Cruz goat anti-rabbit IgG-HRP, sc-2004), anti-goat 2º 
Ab (Santa Cruz donkey anti-goat IgG HRP, sc-2020). 
!
!
!
!
!
!
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Table A H-2: Dilution factors and sources of primary and secondary antibodies used for 
detecting fatty acid oxidation and synthesis target proteins in HepG2 cells 
!
Protein 1º Ab Source 2º Ab Source 
AMPK 1:2000 Rabbit 1:5000 Anti-rabbit 
pAMPK 1:5000 Rabbit 1:2000 Anti-rabbit 
ACC 1:500 Goat 1:1000 Anti-goat 
pACC 1:500 Rabbit 1:1000 Anti-rabbit 
CPT1 1:500 Rabbit 1:2000 Anti-rabbit 
FAS 1:500 Rabbit 1:2000 Anti-rabbit 
actin 1:2000 Rabbit 1:5000 Anti-rabbit 
!
Antibody vendors and catalogue numbers: AMPK (Santa Cruz; sc-25792), pAMPK 
(Santa Cruz; sc-33524), ACC (Santa Cruz; sc-26822), pACC (Santa Cruz; sc-30446-R), 
CPT1 (Santa Cruz ; sc-98834), FAS (Novus Biologicals; NB400-14), actin (Santa Cruz, 
sc-1616), anti-rabbit 2º Ab (Santa Cruz goat anti-rabbit IgG-HRP, sc-2004), anti-goat 2º 
Ab (Santa Cruz donkey anti-goat IgG HRP, sc-2020). 
!
!
!
 
 
 
235 
Table A H-3: Dilution factors and sources of primary and secondary antibodies used for 
detecting fatty acid oxidation and synthesis target proteins in L6 myotubes 
!
Protein 1º Ab Source 2º Ab Source 
AMPK 1:2500 Rabbit 1:5000 Anti-rabbit 
pAMPK 1:1000 Rabbit 1:2000 Anti-rabbit 
ACC 1:1000 Goat 1:2000 Anti-goat 
pACC 1:1000 Rabbit 1:2000 Anti-rabbit 
CPT1 1:500 Rabbit 1:2000 Anti-rabbit 
FAS 1:2000 Rabbit 1:5000 Anti-rabbit 
actin 1:2000 Rabbit 1:5000 Anti-rabbit 
!
!
Antibody vendors and catalogue numbers: AMPK (Santa Cruz; sc-25792), pAMPK 
(Santa Cruz; sc-33524), ACC (Santa Cruz; sc-26822), pACC (Santa Cruz; sc-30446-R), 
CPT1 (Santa Cruz ; sc-98834), FAS (Novus Biologicals; NB400-14), actin (Santa Cruz, 
sc-1616), anti-rabbit 2º Ab (Santa Cruz goat anti-rabbit IgG-HRP, sc-2004), anti-goat 2º 
Ab (Santa Cruz donkey anti-goat IgG HRP, sc-2020). 
!
